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Abstract 
 
Par14 and Par17 are members of the parvulin family of peptidyl-prolyl cis-trans iso-
merases. Par14 has been shown to be enriched in the nucleus and Par17 was dem-
onstrated to be located in the mitochondrial matrix. It has been suggested that Par14 
plays a role in chromatin remodeling on basis of sequence and structural identities to 
HMGB and HMGN proteins. Both Par14 and Par17 have been shown to bind to 
double-stranded DNA in vitro. However, the cellular functions of both proteins have 
not been characterised, and we aimed in this study to give insights to their function. 
 
By means of biochemical fractionations, we have shown that Par14 is enriched in 
chromatin 3-fold higher than in the nuclear matrix. In the same experiments, we also 
observed that Par14 was released from the chromatin fraction after treatment with 
DNase I indicating its binding to DNA. In the light of this, we performed another bio-
chemical fractionation scheme enriching nucleic acid-binding proteins. Using a phos-
pho-cellulose column, we eluted Par14 at 0.35 and 1 M NaCl from the nucleic acid-
binding fraction. This gave credit to the fact that Par14 was associated with DNA in 
vivo. Following Par14’s association with chromatin, pilot experiments were initiated 
using Chromatin Affinity Purification (ChAP) to search for DNA-binding motifs for 
Par14. 
 
Pin1 is the other member of the parvulin family and it has been characterised as a 
mitotic regulator. As a result, we were interested to investigate the role of 
Par14/Par17 in the cell cycle. Using our established cell cycle synchronisation sys-
tem by serum deprivation, we showed with the aid of qRT-PCR that Par14 and Par17 
were 2- and 3-fold up-regulated respectively during the S-phase at the mRNA level. 
A 3- and 5-fold up-regulation was seen for Par14 and Par17 in the G2/M phase re-
spectively. The transcriptional increase of Par14 in the S and G2/M phases was cor-
related with a 4-fold translational increase as analysed by western blotting. As con-
cerns Par17, we observed that Par17 was 4- and 3-fold up-regulated when cellular 
lysates from the individual cell cycle phases were used. Moreover, there was the oc-
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currence of a 28 kDa variant of Par17 in all the phases of the cell cycle before and 
after the fractionation of the cellular lysates.  
 
As a strategy to elucidate the function of Par14/Par17, we used affinity purification 
coupled with mass spectrometry to find their interaction partners. A Par17 construct 
fused to Strep-tag was transfected in HCT116 cells and the cellular lysates were 
passed over a modified streptavidin (Strep-Tactin) column. Elution was done with 
desthiobiotin and the eluted proteins were sent for tandem mass spectrometry. After 
filtering spurious and non-specific binders, EZR was among the 17 potential interac-
tion partners of both parvulin proteins. EZR plays a role in the cytoskeletal network; 
but it remains to be validated by other techniques whether it is a bona fide 
Par14/Par17 interactor. 
 
We were interested to know if some of the potential interaction partners found were 
up- or down-regulated in the advent of a successful Par14/Par17 knock-down. Our 
protein-protein interaction data paved the way to perform gene knock-down experi-
ments for Par14/Par17 using siRNA technology. HeLa and HCT116 cells were trans-
fected and knock-down was investigated by performing qRT-PCR and western blot 
experiments. No appreciable knock-down of Par14/Par17 mRNAs and their gene 
products was registered. Fluorescence microscopic studies were also done on trans-
fected cells to check for any morphological abnormalities as a result of Par14/Par17 
loss. Still, no visible phenotypic changes were observed. 
 
Taken together, Par14 can be described as a chromatin and DNA-binding protein. 
The transcriptional up-regulation of Par14 and Par17 was directly proportional to their 
translational up-regulation. If EZR is validated as an interaction partner of 
Par14/Par17, this may suggest a role of Par14/Par17 as anchor proteins that link the 
cytoskeletal apparatus to a DNA-related process in the nucleus or in the mitochon-
dria.  
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Zusammenfassung 
 
Bei Par14 und Par17 handeln es sich um Peptidyl-Prolyl cis-trans Isomerasen, die 
zur Familie der Parvuline gehören. Es wurde gezeigt, dass Par14 im Zellkern und 
Par17 in der Mitochondrien-Matrix lokalisiert ist. Es wurde angenommen, dass Par14 
eine Rolle im Chromatin Remodeling spielt, da es sequentielle und strukturelle Ähn-
lichkeiten mit HMGB and HMGN Proteinen aufweist. Sowohl für Par14 als auch für 
Par17 konnte in vitro die Bindung an doppelsträngige DNA nachgewiesen werden. 
Jedoch wurden die Funktionen beider Proteine in der Zelle bis jetzt nicht näher cha-
rakterisiert. Unsere Untersuchungen sollen zu einem besseren Verständnis der 
Funktionen  dieser Proteine beitragen. 
 
Mit biochemischen Fraktionierungen konnten in dieser Arbeit gezeigt werden, dass 
Par14 in Chromatin dreimal stärker angereichert ist, als in der nuklearen Matrix. In 
diesen Experimenten konnten wir außerdem beobachten, dass Par14 sich nach Zu-
gabe von DNase I von der Chromatinfraktion löste, was auf seine Bindung an DNA 
hindeutet. Aufgrund dieser Beobachtungen, haben wir ein biochemisches Fraktionie-
rungsschema genutzt, in welchem nukleinsäurebindende Proteine angereichert wur-
den. Unter der Annahme, dass Par14 in vivo DNA-gebunden vorliegt, wurde Par14 
mit 0,35 M und 1 M NaCl unter Verwendung einer Phospho-Cellulose-Säule aus der 
nukleinsäurebindenden Fraktion eluiert. Da Par14 Chromatin-bindende Eigenschaf-
ten aufweist, wurden mit Hilfe einer Chromatin-Affinitäts-Reinigung (ChAP) Pilotexpe-
rimente durchgeführt, um mögliche DNA-Bindungsmotive für Par14 zu finden. 
 
Pin1 ist ein weiteres Mitglied der Parvulin-Familie. Dieses Protein spielt nachweislich 
bei der Regulation der Mitose eine Rolle. Da Par14 und Par17 ebenfalls der Parvulin-
Familie angehören, wurde die Funktion dieser Proteine im Zellzyklus näher unter-
sucht. Mit Hilfe unseres etablierten Zellzyklus-Synchronisations-Systems und qRT-
PCR konnte gezeigt werden, dass die relative  Menge an mRNA von Par14 und 
Par17 in der S-Phase zwei- bis dreimal so hoch war.  Des Weiteren konnte eine drei- 
bzw. fünffach höhere Expression der Par14- und Par17-Gene in der G2/M-Phase 
beobachtet werden. Wie mit Hilfe von Western-Blots gezeigt werden konnte, war die 
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erhöhte Transkription von Par14 in der S- und G2/M-Phase mit einer vierfach erhöh-
ten Translation von Par14 mRNA korreliert. Eine entsprechende Korrelation konnte 
bei Par17 ebenfalls nachgewiesen werden. Eine erhöhte Transkription von Par17 in 
der S- und G2/M-Phasen wurde in Zelllysaten der einzelnen Phasen eine drei- und 
vierfache höhere Konzentration an Par17 nachgewiesen. Darüber hinaus wurde eine 
28 kDa-Variante von Par17 in allen Phasen des Zellzyklus vor und nach der Fraktio-
nierung beobachtet. 
 
Um die Funktion von Par14/Par17 näher zu untersuchen und jeweilige Interaktions-
partner zu finden, wurde eine Massenspektrometrie-gekoppelte Affinitätschromatog-
raphie angewendet. Hierzu wurde zuerst das Strep-tag-gekoppelte Par17-Konstrukt 
in HCT116-Zellen transfiziert und die Zelllysate wurden über eine modifizierte 
Streptavidin (Strep-Tactin)-Säule gereinigt. Die Elution wurde mit Desthiobiotin 
durchgeführt und die eluierten Proteine wurden massenspektroskopisch analysiert. 
Nach der Entfernung von Verunreinigungen und unspezifisch gebundenen Proteinen, 
konnte EZR unter den 17 potentiellen Bindungsproteinen beider Parvulinproteine, als 
Interaktionspartner nachgewiesen werden. EZR spielt eine Rolle im Netzwerk des 
Cytoskeletts. Es bleibt jedoch in weiteren Experimenten zu klären, ob Par14/Par17 
tatsächlich Interaktionspartner sind. 
 
Mit Hilfe von siRNA-Techniken wurde überprüft, ob einige der gefundenen potentiel-
len Interaktionspartner bei einem erfolgreichen Knock-Down von Par14/Par17 hoch- 
oder Herunterreguliert werden. Hierzu wurden HeLa und HCT116-Zellen mit entspre-
chender siRNA transfiziert und der Knock-Down wurde mit qRT-PCR und Western-
Blots analysiert. Es konnte kein signifikanter Knock-Down von Par14/Par17-mRNA 
und der entsprechenden Genprodukte nachgewiesen werden. Es wurden ebenfalls 
fluoreszenzmikroskopische Untersuchungen mit transfizierten Zellen durchgeführt, 
um diese auf morphologische Veränderungen zu untersuchen, die auf das Fehlen 
von Par14/Par17 zurückzuführen sein könnten. Es konnten keine phänotypischen 
Veränderungen beobachtet werden. 
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Zusammenfassend konnten in dieser Arbeit erstmals Hinweise gefunden werden, die 
darauf hindeuten, dass es sich bei Par14 um ein Chromatin- und DNA-bindendes 
Protein handelt. Jedoch bleibt ungeklärt, warum bei Hochregulierung von Par17-
Transkripten in der S- und G2/M-Phase eine entsprechende Zunahme des Genpro-
dukts ausbleibt und warum dieses eher abzunehmen scheint. Wenn EZR als Interak-
tionspartner von Par14/Par17 bestätigt wird, könnte das auf eine Ankerfunktion von 
Par14/Par17 hindeuten, die den Cytoskelettapparat in einem DNA-abhängigen Pro-
zess an den Zellkern oder die Mitochondrien bindet. 
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1.  Introduction 
Proteins are homologous when they share sequence similarities or identities. Homol-
ogy will imply a conserved structure. A conserved structure is an indication of a con-
served function. However, function is a fussy concept. It can range from same bio-
chemical activity, same identical expression or tissue-specific expression pattern, to 
same cellular localisation et cetera. The catalytic core sequence of peptidyl-prolyl cis-
trans isomerases occurs in all three domains of life, Archaea, Prokarya and Eukarya. 
Implicitly, it has been conserved through the course of evolution and purports a con-
served function. 
1.1 Peptidyl-Prolyl cis-trans Isomerases (PPIases) 
The primary catalytic function of PPIases (EC 5.2.1.8) is to accelerate cis-trans isom-
erisation of Xaa-Pro peptide bonds within polypeptide chains (Fanghanel and 
Fischer, 2004). Hence, a role for PPIases in the folding of newly synthesised proteins 
was inferred and chaperone-like activity has been associated with several PPIases 
(Kruse et al., 1995; Schmid, 1995).  
 
 
Fig 1.1 Cis-trans isomerisation of a peptidyl-prolyl bond (Gothel and Marahiel, 1999) 
 
PPIases are ubiquitous proteins expressed in Eukarya, Prokarya and Archaea. Hith-
erto, they have been classified into three main distinct families according to their 
amino acid sequence homology and structural similarity. These are the cyclophilins 
(Cyps), FK506-binding proteins (FKBPs), and the parvulins. In Prokarya, the perip-
lasmic space of Escherichia coli contains all three classes of PPIases, namely PpiA, 
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a cyclophilin-type PPIase, FkPA, a FK506-binding PPIase, and 2 members of the 
parvulin-family, SurA and PpiD (Hennecke et al., 2005; Stymest and Klappa, 2008; 
Weininger et al., 2009; Weininger et al., 2010). Members of cyclophilins and FKBPs 
have also been identified in Achaea (Maruyama et al., 2004). PinA from the cryophilic 
Cenarchaeum symbiosum (SwissProt: O74049) and NmPin from the mesophilic Ni-
trosopumilus maritimus (Schouten et al., 2008) are parvulin-type PPIases that have 
been identified in Achaea. 
 
The prototypical member of the cyclophilin family, cytosolic cyclophilin 18 (Cyp18) 
also known as cyclophilin A in mammalian cells specifically catalyses cis-trans isom-
erisation of amide peptide bonds (Fischer et al., 1984). FKBP12 is the prototypic hu-
man enzyme of the FKBPs and was identified as a FK506 binding module; the term 
FKBP includes all proteins that share amino acid sequence homology with FKBP12, 
although high-affinity FK506 binding is not a common property of all FKBPs (Harding 
et al., 1989). 
 
The cyclophilins and the FKBPs are sometimes termed the immunophilins. Cyps and 
FKBPs have been implicated in the cellular action of the immunosuppressive drugs 
cyclosporine A (CsA) (Fischer et al., 1989; Takahashi et al., 1989) and FK506 (tac-
rolimus) (Harding et al., 1989; Siekierka et al., 1989) respectively. The immunosup-
pressive actions exerted by CsA and FK506 on T cells and B cells have been dis-
cussed in numerous reviews (Schreiber and Crabtree, 1992; Clardy, 1995; Ho et al,. 
1996). The FKBP-FK506, as well as the cyclophilin-CsA complexes, bind to cal-
cineurin and inhibit its phosphatase activity. Calcineurin, a calcium/calmodulin-
dependent serine-threonine phosphatase, dephosphorylates the nuclear factor of 
activating T cells (NF-AT). In its dephosphorylated form, NF-AT is able to cross the 
nuclear membrane to function as a transcription activator of IL-2/4 (interleukin 2 and 
4), granulocyte-macrophage colony stimulating factor (GM-CSF), and gamma-
interferon expression. As a result, cyclophilins and FKBPs, together with their specific 
immunosuppressive-acting ligands CsA and FK506, respectively, are able to interfere 
with this signal transduction pathway. Thus, it is not their isomerisation property but 
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their peptide binding ability that brings about immunosuppression (Schreiber and 
Crabtree, 1992). 
 
The third family of PPIases, the parvulins (Pin1, Par14 and Par17) does not belong to 
immunophilins because family members do not show affinity to immunosuppressive 
drugs. Protein phosphatase 2A (PP2A) phosphatase activator (PTPA) has been de-
scribed recently as the new family of PPIases (Jordens et al., 2006; Leulliot et al., 
2006). It is an essential and specific activator of PP2A and the PP2A-like enzymes. 
PTPA was shown to induce conformational changes by means of isomerase activity 
similar to cyclophilin A and FKBP12 but similar to the isomerase activity of Pin1. The 
detailed treatment of this new family of PPIases is beyond the scope of this work. 
Two members of the parvulin family (Par14 and Par17) were the focus of this thesis. 
1.2 Parvulins 
In 1994, the PPIase family of parvulins was discovered by characterising the proto-
typical enzyme Par10 from E. coli (Rahfeld et al., 1994b; Rahfeld et al., 1994a). The 
name parvulin originates from the Latin word parvulus, which means tiny or very 
small because of its molecular weight of 10 kDa. This PPIase does not exhibit se-
quence similarity to either cyclophilins or FKBPs. The mature enzyme with its sole 
domain of 92 amino acids is enzymatically active in its monomeric state.  
 
Many multidomain parvulins have since then been characterised in prokaryotes. In 
Gram-positive bacteria such as Staphylococcus aureus and Bacillus subtilis, a parvu-
lin-type PPIase PrsA has been identified and the solution structure characterised 
(Heikkinen et al., 2009; Tossavainen et al., 2006). Par27 in Bordella pertussis was 
identified as a prototype of a new group of parvulins in Gram-negative bacteria (Ho-
dak et al., 2008). The existence of only two genes, PIN1 and PIN4, encoding human 
parvulin proteins have been described, which is a low frequency when compared with 
both Cyp and FKBP sequences (Mueller et al., 2006; Rahfeld et al., 1994a).  
 
Pin1, a parvulin family member, is irreversibly inhibited by juglone (5-hydroxy-1, 4-
naphtoquinon (Hennig et al., 1998). Juglone is a benzoquinone that covalently modi-
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fies thiol groups of cysteine residues in parvulins followed by a subsequent slower 
protein inactivation process, which is thought to be a partial unfolding of the PPIase 
domain (Fila et al., 2008). Juglone can also inhibit other proteins as it was reported to 
interact with RNA polymerase Pol II, which then led to a block in transcription (Chao 
et al., 2001). Derivatives of juglone such as PiB (diethyl-1,3,6,8-tetrahydro-1,3,6,8-
tetraoxobenzo[lmn][3,8] phenanthroline- 2,7-diacetate) where shown to bind to the 
PPIase domain of Pin1 (Uchida et al., 2003). The authors also purported that Pin1 
inhibitors could be used as a novel type anticancer drug that acts by blocking cell 
cycle progression. This line of thinking was verified by Bayer and colleagues where 
they identified Pin1 inhibitors that induced apoptosis in a mammalian Ras trans-
formed cell line. Pepticinnamin E was one such inhibitor that destabilised Pin1 in so-
lution in a juglone-like manner but did not covalently modify the protein (Bayer et al., 
2005). Recently, indole 2-carboxylic acid was demonstrated in a PPIase assay to be 
a potent inhibitor of Pin1’s PPIase activity (Potter et al., 2010). But the authors failed 
to confirm the ligand binding potency by biophysical techniques such as surface 
plasmon resonance and nuclear magnetic resonance. 
1.2.1 Pin1 
Pin1 was discovered in a yeast two-hybrid screen aimed to identify proteins that in-
teract with Never in Mitosis gene A (NIMA), an essential mitotic kinase in Aspergillus 
nidulans (Lu et al., 1996). Pin1 is a 18 kDa protein composed of two functional do-
mains, an amino terminal WW domain (amino acids 1-39) involved in protein-protein 
interaction, and a C-terminal PPIase domain (amino acid 45-163) that functions in 
catalysis (Lu et al., 1996). These two domains are separated by a short flexible linker 
region (Bayer et al., 2003). Pin1 is unique from other parvulin family members be-
cause it recognises phosphorylated Ser/Thr-Pro motifs, and increases the rate of cis 
and trans amide isomer inter-conversion by as much as 1300-fold compared to un-
phosphorylated peptides (Yaffe et al., 1997). The isomerisation of proteins by Pin1 
results in an alteration of protein structure and/or function, which is often coupled to a 
change in protein stabilisation. Ess1/Ptf1 is the Pin1 orthologue in Saccharomyces 
cerevisiae. Gemmill and co-workers provided evidence that fewer than 400 mole-
cules per cell of Ess1 were sufficient for growth although wild type cells contain about 
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200,000 molecules (Gemmill et al., 2005). They demonstrated in vitro and in vivo that 
the isomerase activity of Ess1 on the heptad-repeat (YSPTSPS) on the carboxyl-
terminal domain (CTD), the largest subunit of RNA polymerase II (Pol II) was re-
quired for growth only at diminishing low levels (Gemmill et al., 2005). It will be 
worthwhile to decipher if human Pin1 also shows such tendencies. 
 
The over-expression of Pin1 in yeast prevented the premature chromosome conden-
sation followed by cell death whereas the over-expression of NIMA induced this ef-
fect. Thus, it was suggested that Pin1 might function as a negative regulator of mito-
sis (Lu et al., 1996). Besides, the deletion of Ess1 induced a terminal mitotic arrest 
(Hanes et al., 1989). The addition of Pin1 to Xenopus egg extracts led to the inhibi-
tion of mitotic entry and this gave more weight to the role of Pin1 in mitosis 
(Crenshaw et al., 1998; Shen et al., 1998; Stukenberg and Kirschner, 2001; Winkler 
et al., 2000c).  
 
Dodo is the Pin1 orthologue in Drosophila melanogaster (Maleszka et al., 1996). 
Flies deficient of Dodo had no lethal phenotype. Dodo-deficient flies displayed ab-
normalities in the dorsal-ventral patterning of the egg chamber (Hsu et al., 2001) ow-
ing to an alteration in the fly signalling pathway that is homologous to the mammalian 
epidermal growth factor (EGF)-mediated pathway. A similar scenario was observed 
in Pin1-null mice, which had no lethal phenotype but revealed several defects (Liou 
et al., 2002). Pin1-null mice developed retinal atrophy, decreased body weight, tes-
ticular atrophy, and lack of breast epithelial expansion during pregnancy. These de-
fects resembled those that occurred in cyclin D1-null mice (Liou et al., 2002). Fujimori 
and colleagues found that Pin1-null mouse embryonic fibroblasts (MEFs) developed 
normally but showed slower asynchronous growth than wild-type MEFs and were 
markedly delayed in cell cycle re-entry in response to re-stimulation with serum after 
G0 arrest (Fujimori et al., 1999). Additional studies confirmed these growth defects 
by showing that serum-arrested Pin1-/- MEFs were resistant to cell cycle re-entry in 
response to insulin-like growth factor 1 (IGF1) (You et al., 2002). In addition, in Pin1-
null mice primordial germ cells (PGC) demonstrated a prolonged G1-S phase transi-
tion (Atchison and Means, 2003).  
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Pin1 is over-expressed in some human cancers (colorectal cancer, oral squamous 
cell carcinoma, thyroid tumours) in correlation with cyclin D1 and α -catenin over-
expression (Kim et al., 2005; Li et al., 2006; Miyashita et al., 2003; Nakashima et al., 
2004). Such correlations have led to the idea that Pin1 might be tumour promoting. 
On the contrary, the loss of Pin1 also promotes the stabilisation of two important 
proto-oncogenes, MYC and cyclin E. The germ line deletion of Pin1 promotes rapid 
genomic instability in MEFs in a p53-dependent manner that encourages more ag-
gressive Ras-induced transformation of these Pin1-null cells (Yeh et al., 2004; Yeh et 
al., 2006; Zheng et al., 2002). Therefore, it has been suggested that Pin1 might act 
as a tumour suppressor and as an anti cancer drug target (Xu and Etzkorn, 2009). 
The contradictory experimental observations regarding the function of Pin1 in cancer 
remains enigmatic but raises the possibility that Pin1 can function as either a tumour 
promoter or conditional tumour suppressor. This gives rise to the question, if Pin1 
can be used as a diagnostic marker of cancer or to stage the disease. Perhaps, the 
diagnostic values of quantifying the level of Pin1 will probably only pertain to specific 
cancers. Moreover, to be of use clinically, a sensitive and specific high-throughput 
assay for Pin1 must be developed. Hence, irrespective of how attractive it might be to 
present Pin1 as a therapeutic and prognostic target for cancer, much more work is 
required to understand the functions of Pin1 in the pathogenesis of cancer, and a 
large body of precaution is mandatory to ensure the specificity, selectivity, and safety 
of antagonists awaiting discovery (Yeh and Means, 2007).  
 
Pin1 has also been involved in ubiquitylation and protein degradation. Pin1 was 
shown to control the NF-α B-related Spt23 transcription factor involved in the synthe-
sis of unsaturated fatty acids (Siepe and Jentsch, 2009). Low ubiquitylation of Spt23 
is associated with high Pin1 activity, which then triggers Spt23 precursor processing 
and subsequent transcription activation and vice versa with decreased Pin1 activity 
that leads to the poly-ubiquitylation of Spt23 and proteosomal degradation. Evidence 
has also been provided that the inhibition of Pin1 changes the ubiquitylation status of 
the tumour suppressor gene p53 from oligo-ubiquitylation to poly-ubiquitylation that 
leads to its degradation (Siepe and Jentsch, 2009; Wulf et al., 2002). The oligo-
ubiquitylation of p53 is responsible for nuclear export. 
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Pin1 also regulates the post-transcriptional level of some cytokines, associated with 
asthma that possess 3’ untranslated region AU-rich elements (AREs) via interaction 
with AUF1, the nucleoprotein in the ARE-binding complex (Esnault et al., 2006; Shen 
et al., 2005). Pin1 has also been identified as the molecular partner of tau and amy-
loid precursor protein (APP), the key factors of Alzheimer’s disease (AD) (Neve and 
McPhie, 2006). It interacts with the phosphorylated Thr-231 of tau and regulates its 
activity to bind microtubules. It further interacts with the phosphorylated Thr-668 of 
APP and affects its metabolism (Lu, 2004; Lu et al., 1999; Zhou et al., 2000). Hence, 
Pin1 is probably involved in the pathogenesis of asthma and AD.  
1.2.2 Par14/Par17 (PIN4) 
The second and third members of the parvulin family are Par14 and Par17. For un-
explained reasons, the name PIN4 was assigned to both proteins in public databases 
meaning protein interacting with NIMA kinase 4, although such an interaction has 
never been shown. PIN4 is located on the human genome on chromosome Xq13.1 
that encodes two protein species, Par14 and Par17 (Mueller et al., 2006). There are 
two intron-less parvulin pseudogenes on chromosome 1 and 15 found on the human 
genome but they are truncated at the 5’ end and they posses several point mutations 
and, hence they are not expressed (Mueller et al., 2006). The human parvulin promo-
ter is TATA-less and situated in a CpG island typical of housekeeping genes.  
 
Par14 consists of a 1.0 kilo-base cDNA encoding 131 amino acids and it was first 
cloned as a homologue of human Pin1 and E. coli Par10 (Uchida et al., 1999a) and 
has a molecular weight of 14 kDa. It is also known as Eukaryotic Homologue of Par-
vulins (EHPV) (Thorpe et al., 1999). Par14 has an N-terminal basic domain consist-
ing of amino acids 1 - 35 and a PPIase domain of amino acids 36 – 131 (Sekerina et 
al., 2000; Terada et al., 2001). 
 
Par17 is an elongated isoform of Par14 that resulted by alternative transcription initia-
tion (Mueller et al., 2006). This isoform, Par17, contains a 5’ extension including a 
75 bp extended open reading frame with two coupled SNPs leading to amino acid 
substitutions Q16R (rs6525589) and R18S (rs7058353) (Riva and Kohane, 2002). 
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The gene product of Par17 mRNA contains an extra N-terminal consisting of 25 ami-
no acids in addition to the N-terminal basic domain and PPIase domain of Par14. 
Thus, Par17 has a molecular weight of approximately 16.6 kDa and is made of 156 
amino acids. The names Par14 and Par17 are derived from the nomenclature of 
Par10 (Rahfeld et al., 1994b). The digits 10, 14, and 17 are a reflection of their mo-
lecular weights. 
1.2.3 Structure of Par14/Par17 
The N-terminal region of Par14 contains 35 amino acids and it is unstructured. It is 
rich in lysine, serine, and glycine residues (Sekerina et al., 2000; Terada et al., 
2001). Par17 differs from Par14 within the N-terminus by 25 amino acids. The N-
terminal sequence between Met3 and Ala23 of Par17 is suggested to form an am-
phipatic α -helix as shown by the secondary structure prediction package NPS (Kess-
ler et al., 2007). The coupled SNPs resulting in Q16R and R18S substitutions within 
the predicted α -helix does not compromise its amphipatic character. It has been re-
ported that positively charged amphipatic N-terminal α -helices are typical mitochon-
drial targeting signals (Model et al., 2002). 
 
Using nuclear magnetic resonance spectroscopy (NMR), two groups independently 
solved the solution structure of the PPIase domain of Par14 and Par17 (Sekerina et 
al., 2000; Terada et al., 2001). The fold of residues 36-131 of the C-terminal PPIase 
domain consists of a twisted four-stranded α -sheet wrapping around the C-terminal 
helix and the other three α -helices stacking on the other side of the central α -sheet 
(Fig. 1.2). The three dimensional structure of the PPIase domain of Par14/Par17 
shows a high degree of similarity with the crystal structure of the PPIase domain of 
Pin1 (Sekerina et al., 2000). Par14/Par17 PPIase domain have a 34 % and 39 % se-
quence identity with the PPIase domains of E. coli Par10 and human Pin1, respec-
tively (Mueller and Bayer, 2008). 
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Fig 1.2 NMR solution structure of the PPIase domain of Par14/Par17 (Sekerina et al., 
2000), (PDB ID: 1EQ3) 
 
In comparison to Par10, Par14 contains an N-terminal extension of 35 amino acid 
residues. This extension does not possess a polyproline II helix-binding motif typical 
of eukaryotic Pin1-like parvulins (Mueller and Bayer, 2008). Par14 does not acceler-
ate the cis to trans inter-conversion of oligopeptides with side chain-phosphorylated 
Ser/Thr-Pro moieties as in Pin1. Contrastingly, Par14 and Par10 show preference of 
arginine residues adjacent to N-terminal prolines. With the aid of conventional chy-
motrypsin-coupled assay, the enzymatic activity and substrate specificity for Par14 
(Arg-Pro-Phe-NH-Np) was 3.95/mM/s that was 3-fold lower than that of Par10, 
1.35/mM/s (Uchida et al., 1999a). 
1.2.4 Occurrence of Par14/17 
The core sequence (PPIase domain) of Par14 and Par17 is present in metazoans. 
The expression of Par14 was up-regulated in heart and skeletal muscles but very 
week in brain and lung tissues. This expression patterns were seen after analysing 
Par14 mRNA via northern blot (Thorpe et al., 1999; Uchida et al., 1999a; Uchida et 
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al., 1999b). Besides, the expression of Par14 in placenta, liver, kidney, and pancreas 
was present at moderate levels. 
 
About 1 % of PIN4 mRNA transcribes Par17 as quantified by RT-PCR. Par17 is en-
coded in the human genome but is absent from rodent, bovine and non-mammalian 
genomes (Mueller et al., 2006). Our group reported that Par17 is present only in the 
genomes of great apes (man, chimpanzee, gorilla and orang-utan), but not in those 
of other primates, as shown by parvulin sequences from different primate genomic 
DNA samples (Kessler et al., 2007). Quantitative RT-PCR experiments also revealed 
that Par17 mRNA was transcribed in human tissues such as brain, blood vessels, 
kidney, liver, mammary gland, parotis gland, skeletal muscle, small intestine and 
submandibularis.  
 
 
When an antibody against the N-terminal extension of Par17 was used in HeLa and 
HepG2 cellular lysates, a 17 kDa band was seen together with a band of 28 kDa, a 
putative Par17 variant (Mueller et al., 2006). The 28 kDa band suggests a potential 
posttranslational modification, which warranted further experimental investigation. 
The difference of approximately 10 - 11 kDa provoked the thinking that it was a poss-
ible SUMOylation or ubiquitylation. But western blot analyses using antibodies for 
ubiquitin, SUMO1 and SUMO2/3 failed to justify this assumption (Mueller et al., 
2006).  
1.2.5 Cellular Localisation of Par14/Par17 
1.2.5.1 Par14 Localises to the Nucleus and binds to dsDNA 
From cellular fractionation studies, Par14 showed an uneven distribution pattern be-
tween the cytosol and the nucleus (Surmacz et al., 2002). Par14 was 2-fold higher in 
the nucleus than in the cytoplasm. In confirming this enriched localisation of Par14 to 
the nucleus, Par14 and its deletion mutants were fused to green fluorescent protein 
and expressed in HeLa cells. It was observed that the deletion mutant with sequence 
Ser7-Gly-Ser-Gly-Lys-Ala-Gly-Lys14 found in the N-terminus of Par14 was necessary 
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for the nuclear targeting (Surmacz et al., 2002). DNA-cellulose affinity experiments 
also demonstrated that Par14 could also bind to double-stranded native DNA in vitro.  
Based on homologies and similarities of Par14 to members of the high mobility group 
of proteins, double-stranded DNA constructs were developed and tested for their 
Par14 binding affinity in fluorescence titration assays (Surmacz et al., 2002). Par14 
bound preferentially in a 10 - 50 mM range to bent AT-rich DNA octamers. Experi-
ments with truncated Par14 (amino acids 25-131) showed that the unstructured basic 
N-terminal part with sequence similarity to the chromatin-unfolding domain of HMGN 
proteins was indispensable for high affinity DNA binding. Such bent AT-rich seg-
ments of DNA are supposed to dictate nucleosome positioning (Segal et al., 2006) 
and play a role in transcription initiation. Electromobility shift assays were also em-
ployed to confirm the binding of Par14 to double-stranded DNA (Surmacz et al., 
2002). Par14 induced a band-shift that corresponded to the DNA-protein complex.  
 
Subsequent experiments demonstrated that the phosphorylation of Par14 on Ser19 
regulated its sub-cellular localisation to the nucleus and its ability to bind DNA 
(Reimer et al., 2003). In HeLa cells, Par14 is most likely modified by casein kinase 2 
(CK2) as phosphorylation of Par14 is inhibited in vitro and in vivo by 5, 6-dichloro-1-
α -D-ribofuranosyl benzimidazole (DRB), a specific inhibitor of CK2 activity. Mutation 
of Ser19 to Ala abolishes phosphorylation and alters the sub-cellular localisation of 
Par14 from predominantly nuclear to significantly cytoplasmic. Immunostaining 
showed that a Glu19 mutant of Par14, which mimics the phosphorylated state of 
Ser19, is localised around the nuclear envelope, but does not penetrate into the nu-
cleoplasm. As opposed to wild-type Par14, the in vitro DNA binding affinity of the 
Glu19 mutant was strongly reduced, indicating that only the de-phosphorylated pro-
tein is active in DNA-binding in the cellular nucleus. 
 
In a GST pull-down coupled with mass spectrometry experiment, Par14 associated 
with pre-ribosomal ribonucleoprotein particles (Fujiyama et al., 2002). Intriguingly, in 
the same study, it was shown that the basic domain alone was sufficient for most of 
these interactions. Fujiyama-Nakamura and co-authors reported that Par14 exists in 
both phosphorylated and unphosphorylated forms in the cell and argued that only the 
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unphosphorylated form is associated with pre-40S and pre-60S ribosomal complexes 
(Fujiyama-Nakamura et al., 2009). They used sucrose density gradient ultracentrifu-
gation to fractionate cytoplasmic and nuclear extracts. It was seen that phosphory-
lated Par14 was detected in non-ribosomal fractions while unphosphorylated Par14 
was present in both non-ribosomal fractions as in pre-40S and pre-60S ribosomal 
fractions. In sum, Par14 enrichment in the nucleus suggests a function of a highly 
conserved protein involved in a DNA/RNA-dependent process like chromatin remod-
elling, replication, transcription, translation, or ribosome biogenesis. 
1.2.5.2 Par17 Localises to the Mitochondrial Matrix and binds to dsDNA 
Kessler and co-workers performed cellular fractionation studies in which HeLa cells 
were subdivided to obtain the constituents of the cytosol, nucleus, and mitochondria 
(Kessler et al., 2007). This fractionation procedure was followed by western blot 
analysis using an antibody targeted against the N-terminus of Par17. A 17 kDa band 
was detected for Par17 in the mitochondria. The mitochondrial localisation of Par17 
was confirmed by transfection and fluorescence microscopic studies. Fusion con-
structs of Par17 to EGFP were transfected and MitoTracker, a dye that stains the 
mitochondria, was used for mitochondrial detection.  
 
To check if the N-terminal pre-sequence is solely responsible for targeting the protein 
to the mitochondria, fusion constructs from the pre-sequence coupled to EGFP and 
the entire protein coupled to EGFP were transfected and stained as aforementioned. 
Their EGFP fluorescence overlapped with the MitoTracker signal to a lesser extent 
than the full length Par17 constructs. From this observation, it was deduced that the 
mitochondrial association of Par17 is dependent on the pre-sequence. In addition, 
Kessler and colleagues in the same study demonstrated with the aid of in vitro mito-
chondrial import experiments that Par17 associated with mitochondrial surfaces and 
it was imported to the mitochondrial matrix in a time and membrane potential-
dependent manner (Kessler et al., 2007). 
 
In DNA cellulose binding experiments, Par17 was shown to bind to dsDNA. Par17 
was eluted at physiological salt concentrations as Par14 does (Kessler et al., 2007). 
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Hence, Par17 could be associated with the mitochondrial nucleoid. Par17 is thus a 
Hominid-specific DNA-binding constituent of the mitochondrial matrix and the pre-
peptide (N-terminus) represents the most recently evolved functional mitochondrial 
targeting peptide (Kessler et al., 2007). 
1.2.6 Comparing Par14/Par17 with Pin1 
Par14 partially compensated for Pin1 loss in mammalian cells as its mRNA and pro-
tein levels were up-regulated in Pin1-null mouse endothelial fibroblasts (MEFs) 
(Uchida et al., 2003). In the same study, it was inferred that siRNA knock-down of 
Par14 inhibited growth of Pin1-null MEFs stronger than Pin1-null MEFs re-expressing 
Pin1. In an independent and different experiment, knock-down of Par14 transcript 
using siRNA technology lead to suppressed growth and the appropriate expression 
of Par14 was necessary for normal cell growth in HEK293 cells (Fujiyama-Nakamura 
et al., 2009). Moreover, Par14 has been suggested to complement Pin1 function in 
the context of cell cycle regulation and chromatin remodeling (Reimer et al., 2003). 
Nevertheless, the compensation of the absence of Pin1 was not complete as Par14 
was unable to rescue the deletion of the yeast Ess1 (Metzner et al., 2001). Further-
more, its comparably low activity was not for phosphorylated peptide motifs (Mueller 
and Bayer, 2008). This might suggest divergent, but partially overlapping cellular 
functions for the Par14 and Pin1.  
1.3 Peptidyl-Prolyl cis-trans Isomerases and their Role in DNA-Dependent 
Processes 
Pin1 has been suggested to have overlapping functions with Phosphorylated CTD 
Interacting Factor (PCIF1) in vertebrate cells (Yunokuchi et al., 2009). PCIF1 is a 
human WW domain-containing protein that interacts with the phosphorylated carbox-
yl-terminal domain (CTD) of RNA polymerase II (Pol II). CTD is constituted of up to 
52 tandem repeats of the heptapeptide consensus sequence YSPTSPS. When 
phosphorylated at Ser 2 and Ser 5, it serves as a scaffold to recruit proteins, which 
are pivotal in transcription and RNA processing. Yunokuchi group’s reported that 
Pin1 was significantly up-regulated in PCIF1-deficient chicken DT40 cell lines. How-
ever, the reconstitution of PCIF1 in the mutant cell lines did not abrogate the expres-
sion of Pin1. They reasoned that Pin1 over-expression might suppress defects 
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caused by PCIF1 deficiency in DT40 cells. They compared the functional properties 
of Pin1 and PCIF1 and it was revealed that both proteins had similar substrate speci-
ficity as compared to other CTD-binding WW proteins. PCIF1 and Pin1 had overlap-
ping sub-cellular localisation and showed comparative inhibitory effects on transcrip-
tional activation by Pol II in human cultured cells (Yunokuchi et al., 2009). 
 
Xu et al reported that Pin1 was able to modulate CTD phosphorylation both in vitro 
and in vivo (Shaw, 2007; Xu et al., 2003). They argued that inducible over-expression 
of Pin1 resulted in enhanced Pol II phosphorylation on both Ser 2 and Ser 5, which 
gave rise to the hyper-phosphorylated Pol IIOO isoform. In 2007, they demonstrated 
with the aid of transcription in vitro assays that Pin1 inhibited transcription in nuclear 
extracts as opposed to an inactive mutant that stimulated transcription (Xu and Man-
ley, 2007). An inducible Pin1 cell line showed that Pin1 over-expression was suffi-
cient to release Pol II from chromatin, which accumulated in a hyper-phosphorylated 
form in nuclear speckle-associated structures. Their data is congruent with those of 
Yunokuchi and co-workers mentioned above. From several assays, they inferred that 
inhibition reflected Pin1’s activity during transcription initiation and not elongation. 
Hence, suggesting that Pin1 modulates CTD phosphorylation and Pol II activity dur-
ing an early stage of the transcriptional cycle. 
 
The Xenopus laevis Pin1 orthologue has been found to be required for the DNA rep-
lication check point (Winkler et al., 2000b). Pin1 depleted egg extracts were unable to 
transit the G2 to M phase of the cell cycle in the presence of aphidicolin, an inhibitor 
of DNA replication. The inability to transit the G2 to M boundary was exacerbated 
when an isomerase inactive mutant of Pin1 was added. But upon addition of wild-
type recombinant Pin1, entry from the G2 to the M phase was possible (Winkler et 
al., 2000a). These observations speculate that Pin1 in Xenopus laevis maybe re-
quired for the checkpoint delaying the onset of mitosis in the advent of incomplete 
replication. 
 
Ess1 has been proposed to positively regulate the function of Pol II and to be linked 
to chromatin remodeling complexes (Wu et al., 2000). Work from the laboratory of 
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Wu and co-workers have demonstrated that Ess1 interacts both physically and ge-
netically with CTD of RNA Pol II. They suggested that Ess1 binds to the phosphory-
lated form of CTD of Pol II and thereby catalysing its isomerisation. Ess1 coordinates 
sequential steps of transcription by changing the three-dimensional structure of CTD, 
thus, altering the affinity of protein-CTD interactions. In the light of this, Ess1 might 
act as a regulatory switch for loading proteins required for transcription initiation, 
elongation, termination and mRNA processing (Wu et al., 2000). 
 
Intriguingly, it was demonstrated in both genetic and biochemical approaches that 
cyclophilin A and Ess1 interacted with the Sin3-Rpd3 histone deacetylase complex 
(HDAC) by a mechanism that required prolyl isomerisation (revalo-Rodriguez et al., 
2000) and thus, modulating its silencing activity. HDAC regulates transcriptional re-
pression and gene silencing in yeast and mammalian cells (Struhl, 1998). Sin3 and 
Rpd3 contain multiple Ser-pro or Thr-Pro sites. It was suggested that Ess1 is a direct 
target of Sin3 and acted as a negative regulator to Sin3-Rpd3 HDAC. Cyclophilin A 
on its part targeted Rpd3 and served as positive regulator to Sin3-Rpd3 HDAC. The 
authors proposed a model with their findings that Ess1 and cyclophilin A modulate 
the activity if the Sin3-Rpd3 complex, and that excess histone deacetylation pro-
voked mitotic arrest in Ess1 mutants (revalo-Rodriguez et al., 2000). 
 
As aforementioned, the FKBPs constitute a subfamily of peptidyl-prolyl isomerases. 
Kuzuhara gave evidence to the fact that a nuclear FKBP (SpFkbp39p) from Schizo-
saccharomyces pombe could influence chromatin structure (Kuzuhara and Horikoshi, 
2004). They showed that the endogenous FKBP gene was required for the in vivo 
silencing of gene expression at the rDNA locus and that SpFkbp39p had a histone 
chaperone activity in vitro. Both of these activities depended on the N-terminal non-
PPIase domain of the protein. They further alluded that the C-terminal PPIase do-
main was not essential for the histone chaperone activity in vitro, but was required for 
the regulation of rDNA silencing in vivo (Horikoshi et al., 2004; Kuzuhara and Horiko-
shi, 2004).  
 
 
  Introduction 
 
 
 
 
16 
 
Fpr4, a member of the FKBPs in Saccharomyces cerevisiae was reported by Nelson 
and colleagues how its prolyl isomerisation activity as a non-histone modification 
could regulate transcription and they provided evidence for cross-talk between his-
tone lysine methylation and proline isomerisation (Nelson et al., 2006). Fpr4 binds to 
the amino-terminal tail of both histone H3 and H4 and in doing this it catalyses the 
isomerisation of H3 on proline P30 and P38 in vitro. Nelson and co-authors further 
described that P38 was mandatory for the methylation of K36 and that the isomerisa-
tion of Fpr4 inhibited the ability of Set2 to methylate H3 K36 in vitro. Thus, the con-
formational state of P38 that is controlled by Fpr4 is important for methylation of 
H3K36 by Set2. In vivo, the abrogation of Fpr4 activity resulted in increased levels of 
H3K36 methylation and delayed transcriptional kinetics of specific genes in yeast 
(Nelson et al., 2006). 
 
In a yeast two-hybrid screen, FKB52 was identified as a potential interaction partner 
of IRF-4 (Mamane et al., 2000). The interferon regulatory factors (IRFs) are a family 
of transcriptional factors involved in the early host response to pathogens (Mamane 
et al., 1999). IRF-4 plays a crucial role in immunoregulatory gene expression in B 
and T lymphocytes. The work from Mamane’s laboratory lended circumstantial sup-
port that FKBP52 inhibited IRF-4 DNA binding and and that transactivation functions 
by a posttranslational modification of IRF-4 that was dependent on the PPIase activi-
ty of FKBP52 (Mamane et al., 2000). The proline-rich region of IRF-4 (amino acids 
150-237) and the C-terminal tetratricopeptide repeats were characterised as the do-
mains required for the interaction. While IRF-4 and PU.1 function as a transactivator 
complex, their activity was suppressed due to the association of IRF-4 and FKBP52 
and this effect was dependent on the PPIase activity of FKBP52 (Mamane et al., 
2000). PU.1 is a member of the E-twenty six (Ets) family of transcription factors. Tak-
en together, the authors inferred that FKBP52 induces a conformational change in 
IRF-4 by cis-trans prolyl isomerisation that interfered with the binding of IRF-4 to 
DNA and PU.1 and thus, demonstrating a posttranslational mechanism inducing 
transcription repression. 
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1.4 HMG Proteins in DNA-Dependent Processes 
The high mobility group (HMG) proteins are a superfamily of abundant and ubiquit-
ous nuclear proteins that bind to DNA and nucleosome and induce structural 
changes in the chromatin fiber. They are non-histone architectural proteins, which 
influence multiple DNA-related activities such as chromatin remodeling, transcription, 
replication, recombination, DNA repair and genomic stability (Bustin, 2001; Hock et 
al., 2007; Ueda and Yoshida, 2010). The HMG proteins were originally isolated from 
mammalian cells and named according to their electrophoretic mobility in polyacry-
lamide gels due to a high content of positively and negatively charged amino acid 
residues (Goodwin et al., 1973). The HMGs are divided into 3 families (HMGB, 
HMGA, and HMGN), and each family member has a characteristic functional se-
quence motif but they all share a carboxyl terminus rich in acidic amino acids. The 
names of the genes are named in sequential order for example HMGB1, HMGB2. 
Spice variants are indicated by small letters such as HMGA1a, HMGA1b and 
HMGA1c.  
 
The functional motif of the HMGB (formerly HMG-1/-2) family is called the HMG-box. 
The HMGB proteins can contain up to six HMG boxes in tandem. The boxes are 
formed by three α -helices folded together to an L-shaped structure which can pene-
trate the minor groove of DNA. Binding of HMG-boxes to the DNA minor groove 
causes unwinding and widening of the minor groove accompanied by bending (Stros, 
2010). Mammalian HMG-box containing proteins are usually classified into two major 
groups. The first group consists of HMGB-type non-sequence-specific DNA binding 
proteins with two HMG-box domains and a long highly acidic C-tail. The second 
group is highly diverse and consists of proteins having mostly a single HMG-box and 
no acidic C-tails and they bind DNA specifically. Transcription factors of SRY/Sox 
and TCF/LEF family of proteins belong to this second group of HMG-box proteins. 
The consensus DNA binding motif for SRY proteins is A/TAACAA/ (Stros et al., 
2007). Both types of HMG-box domains bind non-B-type DNA structures (bent, 
kinked and unwound) with high affinity. 
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The HMGA (formerly HMG-I/Y/C) family contains three AT-hooks that serve as the 
functional motif. Through these hooks, HMGAs bind preferably to the minor groove of 
AT-rich stretches in B-form DNA and induce conformational changes that promote 
subsequent recruitment of additional components to the binding sites (Hock et al., 
2007). The HMGN family (formerly HMG-14/-17) is characterised by a positively 
charged region of 30-amino acids residues, the nucleosome binding domain (NBD), 
the chromatin unfolding domain (CHUD), and a bipartite nuclear localisation signal 
(NLS). HMGNs bind in a non-specific manner to the 147-base pair nucleosome core 
particle and alter both the local and the higher order structure of the chromatin fiber 
(Hock et al., 2007). 
 
Proteins containing any of these functional motifs embedded in their sequences are 
known as “HMG motif proteins.” Par14 and Par17 are HMG motif proteins. The N-
terminus of Par14 reveals a 45 % sequence identity with the CHUD and the flanking 
sequences of HMGN2, whose residues are involved in contacts to nucleosome DNA 
(Surmacz et al., 2002). Furthermore, Par14/Par17 shows sequence and structural 
homology to SRY and LEF-1 sequence-specific transcription factors, which both con-
tain a single HMG-box (Mueller and Bayer, 2008; Surmacz et al., 2002). On grounds 
of the sequence and structural homology to HMG proteins it is worthwhile to specu-
late that Par14/Par17 could be involved in a DNA-related event such as transcription, 
chromatin architecture and/or chromatin remodeling. 
1.5 Purpose of the Thesis 
There is considerable data supporting the fact that Par14 is a nuclear protein and 
binds to double stranded DNA in vitro. Besides, Par14 shares sequence and struc-
tural homology to HMG proteins. Par17 an isoform of Par14 has been presented as a 
mitochondrial protein which also binds to double-stranded DNA and was eluted at 
physiological salt concentrations in the same manner as Par14. Above all, Pin1, a 
paralogue to Par14 and Par17, is a nuclear PPIase and it has been reported to be 
involved in the regulation of the cell cycle. In the light of these evidences, it was of 
paramount importance to investigate the function of nuclear Par14 and its mitochon-
drial counterpart Par17. For this reason, we employed the following approaches:  
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• To determine the sub-nuclear localisation of Par14 by means of biochemical 
fractionations; 
• To verify the binding of Par14 to nuclear DNA in vivo and to search for the 
DNA-binding motifs for Par14/Par17; 
• To investigate the regulation of Par14/Par17 within the cell cycle making use 
of cell cycle synchronisation, qRT-PCR and western blotting; 
• To search for novel potential interaction partners of Par14/Par17 by means of 
affinity purification followed by tandem mass spectrometry, and; 
• To perform Par14/Par17 gene knock-down studies with the aid of siRNA-
technology. 
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2.  Materials and Methods 
2.1 Materials 
2.1.1 Laboratory Apparatus 
AGFA Curix 60 Developer   AGFA, Düsseldorf, Germany 
ÄKTApurifier 10/100 UPC-900  GE Healthcare, Munich, Germany 
Beckman Tabletop GS-6R centrifuge Beckman, CA, USA 
Biophotometer    Eppendorf, Hamburg, Germany 
CCD-Camera, Fuji LAS-4000x  Fujifilm, Düsseldorf, Germany 
Cell Culture Bench, (HeraSafe)  Heraeus, Hanau, Germany 
Cell Scraper     Eppendorf, Hamburg, Germany 
Centrifuge 5415 R    Eppendorf, Hamburg, Germany 
Centrifuge 5810 R    Eppendorf, Hamburg, Germany 
Chromatography Column (20 ml)  Bio-Rad, Munich, Germany 
Concentrator 5301    Eppendorf, Hamburg, Germany 
Cover Glas     Menzel-Gläser, Braunschweig, Germany 
Coulter Counter  CASYR, Schärfe System, Reutlingen,  
Germany 
CO2 –Incubator (C200)   Labotect, Göttingen, Germany 
Dry Block Heat Bath   VLM, Bielefeld, Germany 
ESI-QTOF Mass Spectrometer   Bruker Daltonics, Bremen, Germany 
FACSCalibur     Becton Dickson Science, CA, USA 
Fastblot      Biometra, Göttigen, Germany 
Inverted Phase Contrast  
Microscope     Olympus CK2, Hamburg, Germany 
Laminar Flow Hood    Heraeus, Hanau, Germany 
Master Cycler Gradient (PCR)  Eppendorf, Hamburg, Germany 
Microtiter Pipettes    Gilson, Villiers-Le-Bel, France 
Thermomixer Comfort   Eppendorf, Hamburg, Germany 
NanoDrop ND-1000 Spectrometer PeQLab Biotechnologies, Erlangen,  
Germany 
Nanoflow HPLC (Ultimate 3000)   Dionex, Idstein, Germany 
Novex MiniCell Chamber    Invitrogen, Karlsruhe, Germany 
Olympus BX61 Fluorescence  
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Microscope      Olympus, Hamburg, Germany 
Overnight Culture Shaker   INFORS, Bottmingen, Germany 
pH-Meter     Knick, Feldchen, Germany 
Pipettes     Eppendorf, Hamburg, Germany 
Roller Mixer SRT6    Stuart, Asbach, Germany 
Sonicator  Bandelin Sonopuls HD 2200, Berlin,  
Germany  
Vortexer (Vortex-Genie 2)   Scientific Industries, INC, N.Y, USA 
Water Bath     Memmert, Büchenback, Germany 
Weighing Machines    Kern, Balingen, Germany 
2.1.2 Disposable Elements 
Ultra 15 Centrifugal Device   Amicon, MA, USA 
(3000 MWCO) 
Cassettes for SDS-PAGE   Invitrogen, CA, USA 
Cell Culture Dishes, Pipettes  
& Flasks      Greiner, Frickenhausen, Germany 
1.5 & 2 ml Tubes    Eppendorf, Hamburg, Germany 
0.2 & 0.5 PCR Tubes   Brand, Wertheim, Germany 
15 & 50 ml Centrifuge Tubes  Greiner, Neu-Ulm, Germany 
ECL on CL-XPosure Film    Thermo Scientific, Rockford, USA 
Gel Blotting Paper    Schleicher & Schuell, Dassel, Germany 
Glas Round-Bottom Tubes  Greiner, Neu-Ulm, Germany 
Gloves     VWR, Leuven, Thailand 
Nitrocellulose Membrane    Whatman, Dassel, Germany 
Polystyrene Round-Bottom  
Tubes      BD Falcon, MA, USA 
UV Cuvettes     Roth, Karlsruhe, Germany 
2.1.3 Chemical Reagents 
The chemicals used were of analytical grade. 
Albumin, Bovine (BSA)   Sigma, Steinheim, Germany 
CNBr-activated Sepharose 4   GE Healthcare, Munich, Germany 
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Desthiobiotin     IBA BioTAGnology, Göttingen, Germany 
Bromophenol Blue    Sigma-Aldrich, Steinheim, Germany 
DAPI      Roth, Karlsruhe, Germany 
DMEM + GlutaMAX    Gibco™, Invitrogen, Karlsruhe, Germany 
DTT      Roth, Karlsruhe, Germany 
Freezing Medium     Gibco™, Invitrogen, Karlsruhe, Germany 
Ethanol     Roth, Karlsruhe, Germany 
EDTA      Roth, Karlsruhe, Germany 
FCS/FBS     Gibco™, Invitrogen, Karlsruhe, Germany 
Glycine     Roth, Karlsruhe, Germany 
Glycerol     Roth, Karlsruhe, Germany   
Isopropanol     Roth, Karlsruhe, Germany 
MagicMark (Protein Ladder)  Invitrogen, Karlsruhe, Germany 
MEM      Gibco™, Invitrogen, Karlsruhe, Germany 
NaHCO3     Roth, Karlsruhe, Germany 
NaCl      Roth, Karlsruhe, Germany 
Nonidet P40     Roche, Mannheim, Germany 
Opti-MEM® I     Gibco™, Invitrogen, Karlsruhe, Germany 
PBS      Sigma-Aldrich, Steinheim, Germany 
Penicillin/Streptomycin   Gibco™, Invitrogen, Karlsruhe, Germany 
PreScissionPlus (Dual Colour)  Biorad, CA, USA 
Propidium Iodide    Roth, Karlsruhe, Germany 
Rotiphorese Gel 30    Roth, Karlsruhe, Germany 
TransPass D2     New England BioLabs, Frankfurt, Germany 
TEMED     Roth, Karlsruhe, Germany 
Tris-HCl     Roth, Karlsruhe, Germany 
Tryple Express     Gibco™, Invitrogen, Karlsruhe, Germany 
Tween-20     Roth, Karlsruhe, Germany 
Triton X-100     Roth, Karlsruhe, Germany  
2.1.4 Commercial Kits, Columns, and Recombinant Enzymes 
ABsolute QPCR SYBR Green Mix  Thermo Scientific, Bonn, Germany 
DNase I     New England BioLabs, Frankfurt, Germany 
ECL Western Blotting Reagents  Thermo Scientific, Bonn, Germany 
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Qproteome Mitochondria  
Isolation Kit      Qiagen, Hilden, Germany 
Qproteome Nuclear  
Subfractionation Kit    Qiagen, Hilden, Germany 
Micrococal Nuclease   Sigma-Aldrich, Munich, Germany 
NAP 10      Column GE Healthcares, Munich, Germany 
NucleoBondR Xtra Midi kit   Macherey-Nagel, Düren, Germany 
peqGOLD Total RNA Kit    PeqLab, Erlangen, Germany 
Reverse-iT MAX 1st Strand  
Synthesis Kit     Thermo Scientific, Bonn, Germany 
SYBR-RT-Mastermix/RT-Mix   Qiagen, Hilden, Germany 
RNase     Sigma-Aldrich, Munich, Germany 
StrepTrap HP Column    GE Healthcare, Munich, Germany 
2.1.5 Human Cell Lines 
Table 2.1 Human cell lines used in cell culture experiments 
Name Description Culture Medium Reference 
HCT 116 
Cells 
Colorectal Carcinoma D-MEM, 10 % foetal calf serum, 1 % Pen/Strep ATCC, USA  
HeLa Cells  Adenocarcinoma, Cervix D-MEM, 10 % foetal calf serum, 1 % MEM & 
Pen/Strep 
DSMZ, Ger-
many 
HFF Cells Human Foreskin 
Fibroblasts 
D-MEM, 10 % foetal calf serum, 1 % Pen/Strep ATCC, USA  
 
2.1.6 Primers and siRNAs/shRNAs Sequences 
Table 2.2 Sequences of primers of used in qRT-PCR experiments 
Name of Primers Sequence 5´-3´ Reference  
Cyclin B2 forward AAA GTT GGC TCC AAA GGG TCC TT Wasner et al., 2003 
 reverse GAA ACT GGC TGA ACC TGT AAA AAT   
GAPDH forward GCTTGTCATCAATGGAAATCCC EP2108705, 2009 
 reverse AGCCTTCTCCATGGTGG   
Par14 forward 253-TGG GAG TGA CAG TGC TGA CAA Mueller et al., 2006 
 reverse 254- CAT GTT TTT CAC ATA GAA TGT GTC TGA C    
Par17 forward 251- CGG CTT TCA GGC ATT TGT TTA G Mueller et al., 2006 
 reverse 252- GCGGCATCTTGGAAGCTTGTT   
Ribosomal 
Protein L13A  
forward GGTGGTCGTACGCTGTG EP2108705, 2009 
 reverse GGTCCGCCAGAAGATGC   
snRNA U6 forward CTC GCT TCG GCA GCA CA -  
 reverse AAC GCT TCA CGA ATT TGC GT   
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Table 2.3 siRNA and shRNA sequences used for Par14/Par17 knock-down studies 
siRNA/shRNA  Sequence 5´-3´ Manufacturer Comments   
siRNA-1 sense 
strand 
CCCAAAGGTG GTGGCAATGC 
AG 
Dharmacon, Bonn, 
Germany 
all four siRNAs in a 
pool 
 antisense 
strand 
GGGTTTCCAC CACCGTTACG 
TC 
     
siRNA-2 sense 
strand 
GTTAAAGTCT GGGATGAGAT      
 antisense 
strand 
CAATTTCAGA CCCTACTCTA      
siRNA-3 sense 
strand 
GGCCGCACAGTATAGTGAAG 
ATA 
     
 antisense 
strand 
CCGGCGTGTC ATATCACTTC 
TAT 
     
siRNA-4 sense 
strand 
AGCATTTGCC TTGCCTGTAA       
 antisense 
strand 
TCGTAAACGG AACGGACATT       
shRNA-1 sense 
strand 
GAGTGACAGTGCTGACAAGA Genscript, New 
Jersey, USA 
loop sequence 
TTGATATCCG 
 antisense 
strand 
CTCACTGTCACGACTGTTCT      
shRNA-2 sense 
strand 
CGCACAGTATAGTGAAGATAA      
 antisense 
strand 
GCGTGTCATATCACTTCTATT      
shRNA-3 sense 
strand 
TTATTATGGTCGAAGGAAGA      
 antisense 
strand 
AATAATACCAGCTTCCTTCT      
shRNA-
Luc 
sense 
strand 
CTTACGCTGAGTACTTCG      
 antisense 
strand 
GAATGCGACTCATGAAGC      
2.1.7 Antibodies 
Table 2.4 Antibodies used in western blotting analyses 
Antibody MW (kDa) Type Manufacturer Dilution 
Primary Antibodies     
α Par17-Ext 17 Rabbit Polyclonal Eurogentec, Cologne, Germany 1 to 1000 
α PPIase 14/17 Rabbit Polyclonal Eurogentec, Cologne, Germany 1 to 1000 
ß-Actin 42 Rabbit Polyclonal Abgent, San Diego, USA 1 to 5000 
Cyclophilin B 21 Rabbit Polyclonal Abcam, Cambridge, UK 1 to 3000 
Cytochrome C 15 Mouse Monoclonal Abcam, Cambridge, UK 1 to 2000 
GFP 27 Rabbit Polyclonal Abcam, Cambridge, UK 1 to 4000 
Histone H3 15 Rabbit Polyclonal Abcam, Cambridge, UK 1 to 4000 
Lamin B1 68 Rabbit Polyclonal Abcam, Cambridge, UK 1 to 1000 
MEK2 46 Rabbit Polyclonal Abcam, Cambridge, UK 1 to 1000 
Nuclear Matrix Protein p84 84 Mouse Monoclonal Abcam, Cambridge, UK 1 to 1000 
Secondary Antibodies     
Anti-Mouse HRP-linked (from Sheep) Amersham, Freiburg, Germany 1 to 2000 
Anti-Rabbit HRP-linked (from Donkey)  Amersham, Freiburg, Germany 1 to 2000 
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2.1.8 Plasmids and Bacterial Cells 
Escherichia coli strain BL21 (DE3), home-made 
Par17QR-GFP, home-made  
Par17QRStrep-GFP, home-made 
pCR®2.1-TOPO® vector, Invitrogen, Karlsruhe, Germany 
pRNATin-H1.3/Hygro/siFluc vector, GenScript, New Jersey, USA  
pRNATin-H1.2/Hygro vector, GenScript, New Jersey, USA  
2.1.9 Buffers and Solutions 
Binding Buffer  
100 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Coomassie Brilliant Blue R 250  
0.5 mg/l in 40 % methanol and 10 % acetic acid 
Coupling Buffer  
0.1 M NaHC03 pH 8.3, 0.5 M NaCl 
Developing Solution  
6 % sodium carbonate, 0.0185 %, (v/v) 37 % formaldehyde and 0.0005 % sodium 
thiosulfate pentahydrate  
Elution Buffer  
100 mM Tris-HCl, 150 mM NaCl, 2.5 mM desthiobiotin, 1 mM EDTA, pH 8.0 
Extraction Buffer  
1 % Triton X-100, 50 mM HEPES, pH 7.4; 150 mM NaCl, 30 mM Na4P2O7.10H2O, 
10 mM NaF, 1 mM EDTA) containing a cocktail of protease inhibitors (Roche Diag-
nostics) and 100 mM phenylmethylsulfonyl fluoride 
Fixing Solution  
50 % ethanol, 12 % acetic acid and 0.0185 %, (v/v) 37 % formaldehyde 
Low Salt Lysis Buffer  
10 mM HEPES, pH 7.4, 10 mM KCl, 0.1 % Triton X-100 supplemented with a cocktail 
of protease inhibitors (Roche Diagnostics) and 100 mM phenylmethylsulfonyl fluoride 
Resolving Gel Buffer 
1.8 M Tris-HCl, pH 8.8 
Running Buffer for SDS-PAGE 
50 mM Tris-HCl, 380 mM glycine, 0.1 % (w/v) SDS, pH 8.3 
Sample Buffer 
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10 mM Tris-HCl, pH 7.6, 0.5 % (w/v) SDS, 25 mM DTT, 10 % (w/v) glycerol, 
0.018 mg/ml bromophenol blue 
Sensitisation Solution  
0.02 %, sodium thiosulfate pentahydrate  
Silver Nitrate Solution  
0.02775 %, (v/v) 37 % formaldehyde, 0.2 % silver nitrate  
Sonication Buffer 
10 mM HEPES, pH 7.8; 10 mM KCl, 1 % sodium deoxycholate, 0.1 % IGEPAL CA-
630 (NP-40), 1 mM DTT, 50 mM NaF, 40 mM glycerol phosphate, 10 mM Na3VO4, 
5 µg/ml PMSF, protease inhibitor cocktail from Roche Diagnostics, Germany 
Stacking Gel Buffer 
1.25 M Tris-HCl, pH 6.8 
Stopping Solution  
50% methanol and 12 % acetic acid 
Stripping Buffer  
0.05 M Glycine, pH 2.5, 1 % SDS, 1 mM EDTA  
TBST-500 Buffer  
50 mM Tris-HCl, pH8.0, 500 mM NaCl; 0.3 % (v/v) Tween  
TBST-150 Buffer  
50 mM Tris-HCl, pH8.0, 150 mM NaCl; 0.3% (v/v) Tween; 3 % (w/v) 
Transfer Buffer 
25 mM Tris-HCl, pH 8.0 – 8.3, 192 mM Glycine, 20 % Methanol 
Urea Buffer  
8 M urea, 100 mM NaH2PO4, and 10 mM Tris-HCl, pH 8.0 
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2.2 . Methods 
2.2.1 Molecular Biology Methods 
2.2.1.1 RNA Extraction and RT-PCR Analysis 
The RNA extractions and qRT-PCR analyses were done from two different perspec-
tives to answer different questions. The first-fold of the protocol was carried out by Dr 
Levin Böhlig at the Department of Molecular Oncology affiliated to the Universitäts-
frauenklinik in Leipzig, Germany. At that time, they had the expertise in doing cell 
cycle synchronisation per serum deprivation and were in possession of human fore-
skin fibroblasts (HFF), which are suitable for the mentioned kind of synchronisation. 
The transcriptional regulation of Par14 and Par17 in the course of the cell cycle was 
the matter of interest. Their protocol was as follows: 
 
Extraction of total RNA from HFF cells was performed with TRIzol Reagent (Invitro-
gen, Germany) according to the supplier’s instructions. Real-time RT-PCR mRNA-
quantification was done with the LightCycler system (Roche, Germany). Each reac-
tion consisted of: 10 µl 2 × SYBR-RT-Mastermix, 0.2 µl Quanti Tect RT-Mix (Qiagen, 
Germany), and 7.2 µl RNase free aqua dest. This mastermix was added to 1.5 µl to-
tal-RNA (50 ng/µl) respectively. For each RT-PCR reaction 18.4 µl of this solution 
was pipetted into a capillary. Finally, specific primers were added to a final concen-
tration of 2 µM. The following primers were used (5' to 3'): Par14: 253-TGG GAG 
TGA CAG TGC TGA CAA and 254- CAT GTT TTT CAC ATA GAA TGT GTC TGA C  
Par17: 251- CGG CTT TCA GGC ATT TGT TTA G and 252- 
GCGGCATCTTGGAAGCTTGTT (Mueller et al., 2006). The reverse transcriptase 
reaction was performed at 50°C for 20 min. Each cycle of the following PCR included 
15 sec denaturation at 95°C, 20 sec of primer annealing at 60°C, and 15 sec of ex-
tension/synthesis (72°C). Expression of U6 snRNA (GenBank accession number 
NR_004394) was used as an internal control that was believed to remain relatively 
constant during the cell cycle and it was analysed as described above with the follow-
ing primers: forward: CTC GCT TCG GCA GCA CA and reverse: AAC GCT TCA 
CGA ATT TGC GT. As a positive control, expression of the cell cycle regulating pro-
tein Cyclin B2-gene was measured (Wasner et al., 2003). Cyclin B2-mRNA was de-
tected with the following primers: forward: AAA GTT GGC TCC AAA GGG TCC TT, 
reverse: GAA ACT GGC TGA ACC TGT AAA AAT. Relative expression changes 
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were calculated using the 2-α α CT method (Livak and Schmittgen, 2001; Schmittgen 
and Livak, 2008). All PCR-products used in LightCycler mRNA quantifications were 
confirmed by sequencing to check their identity. 
 
The second-fold of our RNA extractions and qRT-PCRs experiments was conducted 
to investigate the level of Par14/Par17 knock-down after treatment with shRNAs spe-
cific to them. After the cultivation and transfection of HCT116 cells with the respective 
shRNA constructs, Tina Stratmann at the Department of Medicinal and Structural 
Biochemistry, Center of Medical Biotechnology, University of Duisburg-Essen, Ger-
many conducted the experimental part of the qRT-PCR analyses. The author of this 
thesis performed the data analysis.  
 
In brief, HCT116 cells were transfected with shRNA-1, shRNA-2, shRNA-3 and 
shRNA-Luc in 12-well plates using the transfection reagent nanofectamin (PAA, 
Germany) according the manufacturer’s manual. shRNA-1, 2, and -3 are short hair-
pins specific to Par14/Par17 while shRNA-Luc is a short hairpin specific to luciferase 
and was used as a negative control. Transfection was done for 72 hrs, and total RNA 
was extracted using peqGOLD Total RNA Kit, (PeqLab, Germany) following the 
manufacturer’s protocol. The RNAs from three independent wells for each construct 
was isolated. The concentrations of the RNAs were measured using NanoDrop pho-
tometer (PeqLab, Germany). The synthesis of cDNAs was conducted with the Re-
verse-iT MAX 1st Strand Synthesis Kit (Thermo Scientific, Bonn, Germany). qRT-
PCR was performed on Rotor-Gene3000 (Corbett Life Science now Qiagen, Ger-
many) using ABsolute QPCR SYBR Green Mix (Thermo Scientific, Germany) accord-
ing to the manufacturer’s instructions. Each reaction consisted of: 12, 5 µl Absolute 
QPCR SYBR Green Mix, 2 µl of respective forward primer, 2 µl of respective reverse 
primer RT-Mix, 8 µl RNase free aqua dest. This was done in a “master mix” manner. 
The Par14/Par17 primers mentioned above in the first-fold of qRT-PCR experiments 
were used and primers for GAPDH and ribosomal protein L13A were employed as 
housekeeping genes (Table 2.2). The reverse transcriptase reaction was activated at 
95 °C for 15 min. PCR amplification was done for 35 cycles at 95 °C for 15 sec, 56 
°C for 30 sec, 72 °C for 30 sec. Relative expression changes were calculated with 
the 2-α α CT method (Livak and Schmittgen, 2001; Schmittgen and Livak, 2008). 
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2.2.2 Cell Biology Methods 
2.2.2.1 Eukaryotic Cell Culture 
HCT 116 cells (ATCC, USA) and HeLa cells (DSMZ, Germany) were cultured in 
growth medium (D-MEM, 1 % MEM, 10 % heat-inactivated foetal calf serum and 1 % 
penicillin/streptomycin; Gibco, Germany) in T-75 cm2 culture flasks (Greiner, Fricken-
hausen) and incubated at 37°C in a 5 % CO2 incubator. Note that the growth medium 
for HCT116 cells was not supplemented with 1 % MEM. HFF cells were also grown 
in the same culture medium like HCT116 cells devoid of 1 % MEM. Besides, HFF 
cells were cultured in T-300 cm2 flasks (TPP, Germany). HFFs are very large fibro-
blastic cells and need much space for proliferation.  
 
Cells were allowed to grow to 80 - 90% confluence and were sub-cultured as follows: 
culture medium was discarded and cells were washed briefly two times with pre-
warmed PBS, pH 7.4. Thereafter, cells were trypsinised with 1 ml Tryple Express per 
flask (Gibco, Germany) and incubated for 3 min at 37°C and 5 % CO2. Cell detach-
ment from the culture flasks with Tryple Express was halted by adding 10 ml of cul-
ture medium and the cell suspension was transferred to a 15 ml centrifuge tube. Cen-
trifugation was done for 5 min at 200 x g and the cell pellet was re-suspended in 3 - 5 
ml culture medium. Cell number from a 50 µl aliquot was determined by using a Coul-
ter counter (CASYR, Schärfe System, Germany) and the settings for the respective 
cell line was maintained as recommended by the manufacturer. The required density 
of cells was re-cultured or cryoconserved. 
 
Routinely, 1 x 105 cells were plated in 10 ml growth medium and 2 x 106 cells were 
cryoconserved in 1 ml of Recovery TM cell culture freezing medium (Gibco, Germany). 
For the latter, the vials were first stored at -80°C overnight before they were trans-
ferred to -196°C until use. For use after cryopreservation, a vial was removed and 
was just allowed to thaw by exposing it to a water bath at 37°C. The cells in the vial 
were immediately transferred to a T-25 cm2 culture flask containing pre-warmed cul-
ture medium. Incubation and sub-cultivation were performed as described as above. 
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2.2.2.2 Transient Transfection 
Plasmid DNAs (Par17QR-GFP and Par17QRStrep-GFP) and shRNAs specific for 
Par14/Par17 in pRNTin-H1.2/Hygro and pRNATin-H1.3/Hygro/siFluc vectors were 
isolated, precipitated sequentially with isopropanol, 100 % and 70 % ethanol, and 
dissolved in 10 mM Tris-HCl (pH 8) using the NucleoBondR Xtra Midi kit (Macherey-
Nagel, Germany). One day before transfection, 1.5 x106 HCT116 or HeLa cells were 
seeded on 15 cm2 petri dishes (Greiner Bio-One, Germany) and incubated over night 
at 37 °C and 5 % CO2. Transfection experiments were carried out using 34 µl 
TransPass D2 (New England BioLabs, Germany) transfection reagent per 12 µg 
plasmid DNA (Par17QR-GFP and Par17QRStrep-GFP). For the transfection of 
shRNAs and siRNAs, nanofectamin (PAA, Germany) and Dharmafect I (Dharmacon, 
Germany) were used respectively. The transfection procedures were performed ac-
cording to the instructions of the suppliers. Transfection from 48 and up to 96 hrs was 
conducted. Transfection efficiency was validated by the use of a fluorescence micro-
scope since our plasmid DNAs and shRNAs constructs carried the coding sequence 
of the GFP reporter gene. The siRNAs were co-transfected with siGLO green, which 
also served as a transfection indicator (Section 2.4). The transfected cells were 
washed twice with pre-warmed PBS, pH 7.4 and either scrapped or trypsinised and 
centrifuged (300 x g, 5 min, RT) for down-flow experiments. 
2.2.2.3 Preparation of Cell Lysates 
Transfected HCT116 cellular lysates of Par17QR-GFP and Par17QRStrep-GFP were 
lysed each in 4 ml sonication buffer (10 mM HEPES, pH 7.8; 10 mM KCl, 1 % sodium 
deoxycholate, 0.1 % IGEPAL CA-630 (NP-40), 1 mM DTT, 50 mM NaF, 40 mM glyc-
erol phosphate, 10 mM Na3VO4, 5 µg/ml PMSF, protease inhibitor cocktail from 
Roche Diagnostics, Germany). The lysates were sonicated with five pulses of 20 sec 
each, with a 30 sec rest on ice between each pulse (Bandelin Sonopuls HD 2200, 
Germany). Centrifugation of the sonicated transfected lysates was done at 12,000 x 
g, 4°C for 10 min to get rid of cellular debris. The supernatants were collected and 
stored at -20°C until use for Strep-tag II pull-down experiments.  
 
The transfected cellular lysates obtained after transfection with shRNAs or siRNAs 
were lysed, sonicated and processed in the same manner as described above. They 
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were later used for SDS-PAGE and western blot analyses to check for knock-down 
efficiency. 
2.2.2.4 Cell Cycle Syncrhonisation 
In the present protocol, we describe a simple, reliable, and reversible procedure to 
synchronise human foreskin fibroblasts (HFF) culture by serum deprivation in which 
the cells were arrested in the G0 phase before re-entry into the cell cycle (Davis et 
al., 2001; Merrill, 1998). 1.5 x 106 HFFs were seeded and allowed to grow to about 
65 % confluence in culture medium (D-MEM 10 % foetal calf serum and 1 % 
Pen/Strep; Gibco, Germany) in a T-300 cm2 culture flask (TPP, Germany) at 37°C 
and 5 % CO2. The medium was aspirated and the cells were thoroughly washed 3 
times with pre-warmed PBS, pH 7.4 to remove any trace of serum. Cells were al-
lowed to starve for 30 - 36 hrs by incubating them in culture medium without foetal 
calf serum. After 30 - 36 hrs of serum deprivation, 4 culture flasks that were labelled 
G0 were taken out of the incubator (Section 2.3.2.1 for sub-cellular fractionation). 
Cells were spun down in an Eppendorf tabletop 5810 R centrifuge at 800 x g and 4°C 
for 5 min. The supernatants were aspirated and the cells were first trypsinised and 
re-suspended in 5 ml PBS to facilitate cell counting. Cell counting was done using a 
Coulter Counter as described above. An aliquot of 1 x 105 cells was kept aside for 
analysis by flow cytometry. The remaining aliquot of cells was spun down as men-
tioned above and the pellet was kept at -20°C until use. 
 
HFF cells in the other culture flasks were re-stimulated to enter the cell cycle by aspi-
rating the old culture medium and giving them new culture medium supplemented 
with 20 % foetal calf serum. Cells in G1, S, and G2/M phases were harvested after 
14, 20, and 24 hrs after re-stimulation respectively. 10 % foetal calf serum is normally 
needed for cells that have not been deprived of growth factors. They were prepared 
and stored as cells gained from the G0 phase and the respective aliquots for flow 
cytometry were kept till further analyses. In general, 1.3 x 107 cells per cell cycle 
phase were harvested for subsequent downstream cellular fractionations. 
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2.2.2.5 Fixation 
Cells gained from the different phases of the cell cycle were permeabilised by fixation 
rendering them fit for intracellular staining. 1 x 105 HFF cells from each phase of the 
cell cycle were re-suspended in 200 µl PBS, pH 7.4. 200 µl of ice-cold 70 % ethanol 
was added dropwise to the cells under gentle agitation (750 rpm) in a thermormixer 
and incubated for 15 – 60 min at 4°C. The cells were pelleted at 750 x g for 4 min at 
RT. Respective pellets were washed with PBS; pH 7.4 supplemented with 1 % foetal 
bovine serum (FBS) and allowed to equilibrate for 20 min at RT while rocking on a 
shaker. Cells were centrifuged in a swing bucket centrifuge at 1800 x g for 5 min. 
From a practical point of view, a fixed-radius centrifuge did not pellet the cells at this 
step even at high centrifugal forces. The pelleted cells were ready for use or were 
stored at -20°C until use. The fixation of HeLa cells for microscopic investigations has 
been described in Section 2.4. 
2.2.2.6 Propidium Iodide Staining and Flow Cytometry Analysis 
In this study, propidium iodide (PI) was used as a DNA-staining dye. PI binds to DNA 
by intercalating between the bases with little or no sequence preference and with a 
stoichiometry of one dye molecule per 4 – 5 base pairs of DNA. PI also binds to 
RNA, necessitating treatment with nucleases to distinguish between RNA and DNA 
staining. Once the dye is bound to nucleic acids, its fluorescence is enhanced from 
20- to 30-fold, the fluorescence excitation maximum is shifted ~30 – 40 nm to the red 
and the fluorescence emission maximum is shifted ~15 nm to the blue. Since the 
fluorescence of cells stained with PI is directly proportional to its DNA content and 
thus reflecting which phase of the cell cycle, this property is exploited to analyse cells 
in the different phases of the cell cycle by a flow cytometer.  
 
Before staining with propidium iodide, the cells (Section 2.2.2.5) were washed once 
with PBS, pH 7.4 and re-suspended in 750 µl PBS in the same buffer. After treatment 
of the cells with 10 µl of 50 µg/ml RNase (Sigma-Aldrich, Germany) for 30 min under 
gentle agitation with a thermomixer at 37°C. 15 µl of 50 µg/ml propidium iodide (Roth, 
Germany) were added to the cells and incubated for 5 min making them ready for 
fluorescence activated cell sorting (FACS) analysis. FACSCalibur flow cytometer 
(Becton Dickson Science, Germany) was used. The PI-stained cells were carried to 
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the laser intercept in a fluid stream. When the cells passed through the laser inter-
cept, they scattered laser light and the PI molecules incorporated in them showed 
fluorescence. The counting of doublets (that is two cells, which might have clogged 
and passed throught the laser together) was circumvented by adjusting the instru-
ment settings for a FL-2A histogram. FL-2A is the peak area that is directly propor-
tional to the DNA content of the cells. G1 doublets have the same DNA content, as 
G2/M cells but need a longer time to go through the laser and will not be considered 
on the histogram. In this way, doublets were excluded and they did not falsify the 
populations of the respective cell cycle phases. The cells were excited with an Argon 
laser (488 nm) and the fluorescence emission was recorded on a FL-2 detector 
(585/42 band pass filter). Data processing was done with the software CellQuestTM 
Pro (Becton Dickson Science, Germany). For each sample, 1 x 104 cells were ana-
lysed.  
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2.3 Protein Biochemistry Methods 
2.3.1 Antibody Production and Purification 
2.3.1.1 Production and Affinity Purification of anti serum against the PPIase 
Domain of Par14/Par17 (α PPIase) 
To generate α PPIase polyclonal antibodies, amino acids 36 - 131/61 - 156 corre-
sponding to the PPIase domain of full length Par14/Par17 was cloned into the ex-
pression vector pET-41 according to standard procedures, which has been modified 
with PreScission protease restriction sites (Grum et al., 2010). Alma Rüppel from the 
Department of Structural and Medicinal Biochemistry, University Duisburg-Essen, 
Germany kindly provided the cloned plasmid. For protein production, the plasmid was 
over-expressed in Escherichia coli strain BL21 (DE3) and purified as a glutathione S-
transferase (GST) fusion protein. After cleavage of the GST moiety with PreScission 
protease (GE Healthcare, Germany), the PPIase domain was further purified on a 
superdex 75 column by gel filtration and used as the antigen. A total of 2 mg of the 
recombinant PPIase was sent for immunisation of a rabbit (Eurogenetec, Belgium) 
and analysis of the test bleeds were conducted. The final antiserum α PPIase was 
purified by affinity chromatography as described below.  
 
CNBr-activated Sepharose 4 fast Flow (GE Healthcare, Germany) was equilibrated 
according to the manufacturer’s protocol in a 20 ml chromatography column (Bio-
Rad, Germany). Before coupling of 10.5 mg (21 mg/ml in 0.5 ml) recombinant PPIase 
on the equilibrated sepharose, it was first re-buffered with coupling buffer 
(0.1 M NaHC03, pH 8.3, 0.5 M NaCl) using a NAP 10 column (GE Healthcare, Ger-
many). Coupling was done for 5 hrs at RT under gentle agitation. Excess PPIase was 
washed off with at least 5 medium volumes of coupling buffer. One medium volume 
corresponded to 1 ml. The PPIase concentration in the washed-off medium volumes 
was determined by Bradford assay to 5 mg/ml (2.5 mg in 0.5 ml). This implied that 
8 mg of PPIase was immobilised to the column. The non-reacted groups on the me-
dium were blocked after coupling by transferring to 0.1 M Tris-HCl buffer, pH 8.0 and 
allowed to stand for 2 hrs. 3 medium volumes of buffers 0.1 M acetate, pH 3 - 4 and 
0.1 M Tris-HCl, pH 8-9 both containing 0.5 M NaCl were used alternately 5 times to 
wash the coupled medium after this incubation procedure. 5 ml of antiserum PPIase-
Par14/Par17 was diluted with 14.5 ml PBS, pH 7.4 and 0.5 ml 5 mM NaN3 and the 
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solution was poured onto the coupled medium and incubated overnight under gentle 
agitation on an end-over-end shaker at 4°C. The bottom cap of the column was 
opened and the unbound serum flew through. The column was washed 3 times with 
20 ml of PBS, pH 7.4. 
 
For elution, 2 ml microcentrifuge tubes were prepared each containing 1 ml 
1 M Tris HCl, pH 8.8. The column was placed on the first tube and 1 ml of elution 
buffer (25 mM glycine, pH 2.2) was given onto it and allowed to flow through into the 
tube underneath. This procedure was repeated for all tubes until no antibody flew 
through. To find this out, the viscosity of the flow-through was visually examined. A 
non-viscous flow-through justified that no antibody was present. The components of 
all the microcentrifuge tubes used to capture the eluates were pooled and concen-
trated to a final volume of 0.2 ml with an Amicon Ultra 15 centrifugal device 
3000 MWCO. The antibody concentration was determined using UV/Vis absorption 
and the formula of Warburg and Christian (Warburg and Christian, 1940). The formu-
lar corrects the contamination and the absorbption of nucleic acids at 260 nm. C is 
the protein concentration and A280 is the absorbance of proteins at 280 nm. 
 
𝐶𝑃𝑟𝑜𝑡𝑒𝑖𝑛 (𝑚𝑔 𝑚𝑙⁄ ) = 1.55𝐴280  − 0.76𝐴260 
 
0.77 mg/ml in 0.2 ml of α PPIase was purified and diluted with 0.2 ml sterile 87 % 
glycerol, making the end concentration of the antibody to be 0.38 mg/ml in 0.4 ml. 
2.3.1.2 Production and Affinity Purification of anti serum against the N-
Terminal Extension of Par17 (α Par17-Ext) 
The antiserum for the N-Terminal extension for Par17 was done at Eurogenetec, 
Belgium and as previously described by Mueller and co-workers (Mueller et al., 
2006). The final antiserum was subjected to affinity purification as elucidated below 
to reduce background and to increase specificity and sensitivity for the detection of 
Par17. 
 
Affinity purification was done in the same manner as described in Section 2.3.1.1 for 
the purification of antiserum PPIase Par14/Par17. A main difference in the procedure 
was the use of the solid phase synthesised 25-amino acid peptide for coupling to the 
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equilibrated CNBr-activated Sepharose 4 fast Flow (GE Healthcare, Germany). Sas-
cha Gentz from the Department of Physical Biochemistry at the Max Planck Institute 
for Molecular Physiology, Dortmund, Germany kindly provided this synthetic peptide. 
The final concentration of α Par17-Ext antibody diluted to a 1:1 ratio in 87 % glycerol 
stood at 1 mg/ml in 0.5 ml.  
2.3.2 Biochemical Fractionations 
2.3.2.1 Sub-cellular Fractionation 
Qproteome mitochondria isolation kit (Qiagen, Germany) was used to separate HFF 
G0, G1, S and G2/M cell populations into cytosolic, nuclear, and mitochondrial frac-
tions. 1.3 x 107 cells were centrifuged at 500 x g 4°C for 10 min and the supernatant 
was aspirated. The pellets were washed in 1 ml 0.9 % NaCl solution and centrifuged 
again at 500 x g, 4°C for 10 min. The pellets were re-suspended in 0.5 ml ice-cold 
lysis buffer (composition of the lysis buffer was not disclosed by the manufacturer) 
supplemented with protease inhibitor solution and an incubation step followed for 
10 min at 4°C on an end-over-end shaker. The cell pellets were centrifuged at 1000 x 
g for 10 min at 4°C and the supernatants were termed S1, which primarily contained 
cytoplasmic proteins (Fig. 2.1). The pellets (P1) were washed 2 times with lysis 
buffer to remove cytosolic contaminants and re-suspended in 1 ml ice-cold disruption 
buffer (composition of the disruption buffer not disclosed by the manufacturer) sup-
plemented with protease inhibitor solution. The supernatants (S2) collected after a 
centrifugation step at 1000 x g, 4°C for 10 min were transferred to 2 ml centrifuge 
tubes. The pellets (P2) which contained nuclei, cell debris, and unbroken cells were 
further extracted with 0.5 ml disruption buffer and the first and second S2s were 
pooled. The resulting P2s (containing nuclei, unbroken cells and cell debris) were 
dissolved in 300 µl disruption buffer and sonication was performed at 3 pulses for 
30 sec with a 30 sec rest on ice between each pulse at 17 - 20 % amplitude (Bande-
lin Sonopuls HD 2200, Germany). Thereafter, the sonicated P2 pellets were clarified 
by centrifugation at 16,000 x g (Eppendorf Centirfuge 5415R), 4°C for 5 min and the 
resulting supernatants (S3) were kept at -20°C until further analysis. The super-
natants S2 from above were centrifuged for 30 min at 12,000 x g (Eppendorf Centir-
fuge 5415R) at 4°C. The resulting supernatants S4 were aspirated and the pellets 
(P4) were believed to contain mitochondria. The mitochondrial pellets were washed 
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with 1 ml mitochondria storage buffer (composition not disclosed by the manufac-
turer) by pipetting up and down and centrifuged at 12,000 x g (Eppendorf Centirfuge 
5415R) for 20 min at 4°C. These pellets were re-suspended in 50 µl of mitochondria 
storage buffer for further analysis. Storage of all the samples was done at -20°C. 
 
 
Fig 2.1 Small scale biochemical cellular fractionation scheme  
Final fractions used for SDS-PAGE and western blot analysis were S1 (cytosolic fraction), P2 
(fraction containing nuclei, cell debris and unbroken cells) and P3 (high purity mitochondria). 
 
Protein determination for S1, P2 and P3 each resulting from the synchronised G0, 
G1, S and G2/M HFF cell populations respectively was achieved by Bradford assay. 
Equal amounts of protein from the respective fractions of the cell cycle were used for 
SDS-PAGE and subsequent immunoblotting procedures. 
2.3.2.2 Sub-nuclear Fractionation 1 
A small-scale biochemical sub-nuclear fractionation scheme was adapted from the 
protocols of (Mendez and Stillman, 2000; Wysocka et al., 2001) in which the nucleus 
was separated from its soluble components leaving behind an insoluble pellet be-
lieved to be enriched in chromatin-nuclear matrix bound material. 4 x 107 HeLa cells 
  Materials and Methods 
 
 
 
    38
were harvested with a cell scraper or by trypsination and centrifuged at 200 x g for 
2 min. The supernatant was discarded and the cell pellet was washed 2 times with 
2 ml PBS and centrifuged like above. The pellet was re-suspended in 1 ml of buffer A 
(10 mM HEPES, pH 7.9; 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10 % glycerol, 
1 mM DTT, 1 mM PMSF and protease inhibitor cocktail from Roche Diagnostic, Ger-
many). Triton X-100 was added to a 0.1 % final concentration. Incubation followed for 
10 min on ice and centrifugation was performed at 1300 x g, 4°C for 5 min. The su-
pernatant S1 was separated from the nuclei pellet P1. S1 was clarified by high-speed 
centrifugation at 20,000 x g for 20 min at 4°C and the supernatant S2 was kept that 
contained cytosolic proteins (Fig. 2.2). The nuclei pellet P1 was washed twice with 
2 ml of buffer A and centrifuged at 1300 x g, 4°C for 5 min. At this stage, P1 was di-
vided in two equal amounts of 0.5 ml (P1+/P1-) in buffer B (3 mM EDTA, 
0.2 mM EGTA, 1 mM DTT, protease inhibitors as described above). P1- was lysed 
for 1 hr at 4°C and spinning was done at 1700 x g for 5 min at 4°C. Soluble nucleo-
plasmic proteins (supernatant, S3-) were separated from the pellet P3- that consisted 
of insoluble chromatin-nuclear matrix bound proteins.  
 
 
Fig 2.2 Scheme of biochemical sub-nuclear fractionation 1 
Final fractions used for SDS-PAGE and western blot analysis were S1 (soluble cytosolic pro-
teins), S3- (soluble nucleoplasmic proteins), S3+ (solubilised nuclear proteins with micrococal 
nuclease), P3- (chromatin-nuclear matrix bound proteins) and P3+ (solubilised chromatin-nuclear 
matrix bound proteins with micrococal nuclease). NM stands for nuclear matrix. 
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To release chromatin and nuclear matrix bound proteins, P1+ as separated above 
was first centrifuged at 1300 x g for 5 min at 4°C. The supernatant was discarded 
and the pellet was treated in 0.5 ml buffer A supplemented with 10 U of micrococal 
nuclease (MNase) and 0.05 M CaCl2 solution for 1 hr at 28°C. MNase treatment was 
stopped by adding 1mM EGTA. P1+ was spun at 1700 x g, 4°C for 5 min and the 
supernatant S3+ believed to consist of solubilised nuclear proteins was separated 
from the pellet P3+ containing solubilised chromatin-nuclear matrix bound proteins. 
Protein determination of the isolated fractions S2, S3+, S3-, P2, P3+, and P3- was 
done by the Bradford method. SDS-PAGE and western blot analysis were carried out 
with equal amounts of the isolated fractions.  
2.3.2.3 Sub-nuclear Fractionation 2 
Procedures for permeabilsation and sequential small-scale biochemical sub-nuclear 
fractionation were adapted from the method of (Qiao et al., 2001). These procedures 
differed from the sub-nuclear fractionation I described above by separately enriching 
chromatin and the nuclear matrix. This distinction was not that clear-cut in the sub-
nuclear fractionation 1 protocol. 
 
In summary, 4 x 107 HeLa cells were harvested by using a cell scraper and spun at 
200 x g for 2 min and the supernatant was discarded. The pellet was washed two 
times with PBS, pH 7.4 and spun down at 200 x g for 2 min. The re-suspension and 
permeabilsation of the pellet was done in 5 ml low salt lysis buffer (10 mM HEPES, 
pH 7.4, 10 mM KCl, 0.1 % Triton X-100) supplemented with a cocktail of protease 
inhibitors (Roche Diagnostics, Germany) and 1 mM PMSF for 15 min at 4°C. The 
permeabilised nuclei pellet (P1) was recovered at 200 x g, 5 min at 4°C and the su-
pernatant collected was termed the cytosolic fraction, S1 (Fig. 2.3). P1 was washed 
again three times with low salt lysis buffer to remove any cytoplasmic contaminants 
and centrifugation was done like above. The nuclei pellet was re-suspended in 800 µl 
lysis buffer and separated in two equal volumes of 400 µl and termed P1- and P1+ 
respectively. Incubation of P1- on ice was done for 1 hr. At the same time, P1+ was 
treated with 30 U DNase I (RNase free, New England BioLabs, Germany) and incu-
bated for 15 min at RT and later for an extra 15 min at 37°C. DNase I in P1+ was in-
activated for 10 min at 75°C. Chromatin proteins were extracted from P1- and P1+ by 
adding 500 µl of extraction buffer (1 % Triton X-100, 50 mM HEPES, pH 7.4; 
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150 mM NaCl, 30 mM Na4P2O7·10H2O, 10 mM NaF, 1 mM EDTA) containing a cock-
tail of protease inhibitors (Roche Diagnostics, Germany) and 1 mM PMSF, for 15 min 
at 4°C respectively.  
 
 
Fig 2.3 Scheme of biochemical sub-nuclear fractionation 2 
Final fractions used for SDS-PAGE and western blot analysis were S1 (soluble cytosolic pro-
teins), S2+/- (chromatin fraction treated with and without DNase I), S3+/- (nuclear matrix fraction 
treated with and without DNase I).  
 
Both P1-/P1+ were centrifuged at 14,000 x g for 10 min at 4°C and the respective 
supernatants S2-/S2+ were collected and named chromatin fractions. The resulting 
pellets P2-/P2+ were solubilised in 250 µl urea buffer (8 M urea, 100 mM NaH2PO4, 
and 10 mM Tris-HCl, pH 8.0) and clarified by centrifugation at high-speed in a micro-
centrifuge for 10 min at 4°C. The supernatants S3- and S3+ collected respectively 
were called nuclear matrix fractions. Protein determination was performed by Brad-
ford assay and equal amounts of S1, S2-/+ and S3-/S3+ were loaded on an SDS-
PAGE gel for subsequent immunoblot analysis. 
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2.3.2.4 Fractionation of Nuclear and Nucleic Acid Binding Proteins 
Qproteome nuclear subfractionation kit (Qiagen, Germany) was used for the frac-
tionation procedure and the extraction of nucleic acid binding proteins. 4 x 107 HeLa 
cells were harvested using a cell scraper. They were washed two times with 5 ml of 
ice-cold PBS and centrifuged at 450 x g, 4°C for 5 min. The lysis of the pelleted cells 
was achieved by re-suspending them in 1 ml lysis buffer (components not disclosed 
by the manufacturer) supplemented with 10 µl protease inhibitor solution and 5 µl of 
0.1 M DTT followed by a 15 min incubation on ice. Thereafter, 50 µl of detergent so-
lution were added to the cell suspension and vortexed at maximum speed. The cell 
suspension was centrifuged for 5 min at 10,000 x g in a microcentrifuge (Eppendorf 
Centirfuge 5415R) pre-cooled to 4°C. The supernatant collected was termed cytoso-
lic fraction (S1). The pellet (P1) that contained cell nuclei was re-suspended in 
0.5 ml lysis buffer supplemented with 5 µl protease inhibitor solution and 2.5 µl of 
0.1 M DTT by vortexing at maximum speed. Centrifugation of the nuclear pellet was 
done for 5 min at 10,000 x g in a pre-cooled microcentrifuge at 4°C. This step was 
repeated twice to remove cytosolic contaminants. The supernatants (S2) were dis-
carded and the nuclear pellet (P2) was re-suspended in 100 µl extraction buffer sup-
plemented with 1 µl protease inhibitor solution and incubated for 30 min with gentle 
agitation (750 rpm in a thermomixer) at 4°C. The nuclei suspension was centrifuged 
for 10 min at 12,000 x g in a microcentrifuge pre-cooled (Eppendorf Centirfuge 
5415R) to 4°C. The supernatant (S3) that was believed to contain nucleic acid-
binding proteins was transferred into a microcentrifuge tube. 0.3 ml of dilution buffer 
supplemented with 3 µl protease inhibitor solution and 6 µl of 0.1 M DTT was added 
to 0.1 ml of the nucleic-acid binding protein supernatant S3 (Fig. 2.4).  
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Fig 2.4 Scheme of biochemical fractionation of nuclear and nucleic acid binding  
proteins 
Final fractions used for SDS-PAGE and western blot analysis were S1 (soluble cytosolic pro-
teins), E1-E3 (eluted nucleic acid-binding proteins with 0.1, 0.35 and 1 M NaCl), and S4+ (solubi-
lised nuclear proteins). 
 
The remaining pellet (P3) was re-suspended in 0.1 ml extraction buffer that has been 
supplemented with benzonase, 1 µl protease inhibitor solution and the suspension 
was incubated by gentle agitation for 1 h (750 rpm in a Thermomixer) at 4°C. The 
pellet suspension (P3) was centrifuged for 10 min at 12,000 x g in a pre-cooled mi-
crocentrifuge (Eppendorf Centirfuge 5415R) at 4°C. The supernatant S4+ (solubilised 
nuclear proteins) obtained was stored. In order to obtain nucleic acid-binding pro-
teins, a phospho-cellulose fractionation column was prepared by adding the re-
suspended nuclear protein fractionation resin (0.4 ml) to the column and allowing it to 
settle. The resin was a component of the kit and it was ready for use. 0.4 ml elution 
buffer NE1 containing 5 µl protease inhibitor solution and 1.5 µ of 1 M DTT was 
added to the nuclear protein fractionation column and allowed to flow through the 
column by gravity. The now diluted 0.4 ml nucleic acid binding protein solution (S3) 
from above was poured onto the equilibrated phosphor-cellulose fractionation col-
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umn. The first 0.4 ml that flew through was discarded. After this procedure, another 
0.5 ml of elution buffer NE1 was given onto the equilibrated phosphor-cellulose col-
umn and the flow-through E1 was captured and stored. 0.4 ml of elution buffer NE2 
also supplemented with 5 µl protease inhibitor solution and 5 µl of 1 M DTT was 
poured onto the column and the flow-through E2 was captured and stored as well. 
The last elution step was done by adding elution buffer NE3 to the column and the 
eluate E3 was also collected and stored. The eluates E1, E2 and E3 were concen-
trated and desalted by chloroform/methanol precipitation (Wessel and Flugge, 1984). 
Bradford assay was used to determine the concentrations of S1, E1, E2, E3 and S4+ 
and equal amount of protein from each of them was loaded for electrophoresis and 
subsequent western blotting analysis. 
2.3.3 Preparation of Polytene Chromosome Squashes 
Polytene chromosomes were also used as a measure to test the association of 
Par14 with chromatin. Polytene chromosome squashes from Drosophila 
melanogaster were prepared and kindly provided to us by Dr Corinna Schirling from 
the Department of Genetics at the Center of Medical Biotechnology affiliated to the 
University of Duisburg-Essen, Germany. For further reading on how polytene chro-
mosomes are prepared, please refer to (Schirling et al., 2010) and Drosophila Proto-
cols, eds. W. Sullivan, M. Ashburner, R. Scott Hawley, Cold Spring Harbour Press, 
New York, 2000. 
2.3.4 Chromatin Affinity Purification (ChAP) 
In order to search for the DNA-binding motifs of Par17/Par14, we employed a mod-
ified form of Chromatin Immunoprecipitation (ChIP) experiment that we termed 
Chromatin Affinity purification (ChAP). Here, a Par17 construct fused to Strep-tag II 
and GFP (Par17QRStrep-GFP) was transfected into HCT116 cells. A Par17 con-
struct without the Strep-tag II but fused to GFP (Par17QR-GFP) was used as nega-
tive control. A quick overview on Strep-tag II has been elucidated in Section 2.3.5.1. 
This modified version of conventional ChIP experiments was a measure to circum-
vent large amounts of highly purified, specific and sensitive antibodies normally 
needed. 
 
  Materials and Methods 
 
 
 
    44
HCT116 cells were grown to 70 – 80 % confluency in 10 cm2 culture dishes and tran-
siently transfected as described in Section 2.2.2.2. After 2 – 3 days of transfection, 
the medium was aspirated and the cells were washed 2 times with pre-warmed 1x 
PBS. 10 ml of 1 % formaldehyde was added to the culture dishes. Incubation in 1 % 
formaldehyde was done at RT on a shaker for 10 and 30 min respectively. Formal-
dehyde was used as a cross-linking reagent. The formaldehyde solution was aspi-
rated and cells were washed 2 times with pre-warmed 1x PBS. 1 ml of 0.125 M gly-
cine was added to each plate and gently swirled to mix for 5 min at RT. This step 
served to stop the cross-linking reaction. The glycine solution was decanted and cells 
were washed again 2 times with pre-warmed 1x PBS. Thereafter, the cells were 
scrapped from the dishes using RIPA buffer (50 mM Tris-HCl, pH 8; 150 mM NaCl, 
2 mM EDTA, pH 8; 1 % NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS, protease 
inhibitor cocktail from Roche Diagnostics, Germany) and pooled in two 15 ml canoni-
cal tubes i.e. for cells transfected with Par17QRStrep-GFP and Par17QR-GFP con-
structs respectively. The cells were pelleted for 5 min at 200 x g, 4°C. The superna-
tants were discarded leaving behind the pellet, which could be stored at -80°C until 
further use. A total of 8 culture dishes were used, 4 being for the negative control. 
 
The pellets (total cell extract) were re-suspended in RIPA buffer and incubated for 
10 – 30 mins on ice. Before chromatin shearing was done, we first performed pilot 
experiments with untransfected cellular lysates to optimise the appropriate sonication 
conditions (Fig. 3.6). The final sonication was done at 8 pulses for 15 sec with a 
30 sec rest on ice between each pulse at 17 - 20 % amplitude (Bandelin Sonopuls 
HD 2200, Germany). The sheared chromatin samples were centrifuged at 12000 x g 
at 4°C for 10 min. The supernatants were transferred to 2 ml tubes while avoiding 
any pelleted material and stored either at -80°C or directly used. The reversal of the 
cross-linking was done by adding 4 µl 5 M NaCl and 2 µl RNase A (0.5 mg/ml) to 
100 µl of each the sheared chromatin samples. They were vortexed and incubated 
for 4 hrs or overnight at 65°C. After this incubation procedure, the samples were 
briefly centrifuged for 15 sec to collect the liquid from the sides of the tube and al-
lowed to return to RT. 5 µl of the Proteinase K (20 mg/ml) solution and 0.5 % SDS 
were added to each tube and incubated at 52°C for 2.5 hours. Proteinase K works at 
an optimum temperature of 50 – 60°C; 0.5 -1 % SDS. Proteinase K cleaves peptide 
bonds adjacent to the carboxylic group of aliphatic and aromatic amino acids. The 
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chromatin samples were ran on a 1 % agarose gel to determine the sizes of the 
sheared DNA. We loaded varying amounts of each sample (10 and 20 µl) to avoid 
overloading. The sheared chromatin samples were pre-cleared on a 1 ml engineered 
streptavidin (Strep-Tactin) hand column (IBA, Germany). The elution was done with 
2.5 mM desthiobiotin. The eluates for the samples that were treated with 
Par17QRStrep-GFP and Par17Q-GFP constructs were further purified with Nucleo-
Spin® Extract II (Macherey-Nagel, Germany) to obtain DNA free from proteins or any 
other contaminants. DNA concentrations were measured using NanoDrop ND-1000 
Spectrometer (PeqLab, Germany). The respective DNA samples were cloned in to a 
pCR®2.1-TOPO® vector according to the manufacturer’s instructions (Invitrogen, 
Germany). 
2.3.5 Protein-Protein Interaction Studies 
2.3.5.1 Background to in vivo Protein-Protein Interaction Analysis 
In living cells, protein-protein interactions are indispensible for virtually every process. 
The study of protein-protein interactions has become a formidable challenge in mod-
ern day biological sciences to understand the principles underpinning the concerted 
action of proteins in time and space that elicit cellular functions. The interactions of 
proteins could be transient or stable in which they form a complex. A protein may be 
a carrier of other proteins as it is the case of importins, which translocate between 
the nucleus und the cytoplasm. Another form of interaction is the case in which 
kinases or phosphotases add or remove phosphate groups from proteins thus modi-
fying them. These modifications usually lead to change in their interaction patterns 
with other proteins and thus elicit different signal transduction pathways. For these 
reasons, the interactome can be a very dynamic network of protein complexes with 
changing compositions strictly depending on the given physiological state (One-
STrEP-tag and Strep-tag® comprehensive manual, Version PR27-0001; IBA Bio-
Tagnology, Germany). 
 
In our quest for interaction partners of Par14/Par17, we made use of the Strep-tag 
II/Strep-Tactin system. The Strep-tag II is a short peptide of 8 amino acid residues 
(Trp-Ser-His-Pro-Gln-Phe-Glu-Lys) with a molecular weight of approximately 1 kDa 
that binds to an engineered streptavidin called Strep-Tactin. We used StrepTrap HP 
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that is a ready to use 1 ml column pre-packed with Strep-Tactin sepharose (GE-
Healthcare, Germany). The binding between Strep-Tactin and Strep-tag II is reversi-
ble and elution of our strep-tagged II protein was enabled by competitive binding with 
desthiobiotin, a derivative of biotin, which is the natural occurring binder to strepta-
vidin (Schmidt and Skerra, 2007). One of the strengths of strep-tag II lies in its small 
size making it not to hamper protein folding and thus not interfering with the function 
of the protein in question. Strep-tag II is also biochemical inert, hence rendering the 
use of buffers at physiological condition possible. Strep-tag II has been successfully 
applied in the identification of protein interaction partners, (Junttila et al., 2005; Witte 
et al., 2004) and this gave us the credibility to use it for the search of binding partners 
of Par14/Par17.  
2.3.5.2 Search of Interaction Partners of Par14/17 using the Strep-Tag II/Strep-
Tactin System 
This protocol describes the approach used to search for potential binding partners of 
Par14/Par17 in the cell. Strep-tag II and His-tag were fused to Par17QR in a vector 
carrying the coding sequence of the GFP reporter gene. The construct was defined 
as Par17QRStrep-GFP. As a negative control, Par17QR in the GFP vector was used 
devoid of tags (Par17QR-GFP). Both constructs were transfected in HCT116 cells, 
and the gene products were expressed at least for 48 hrs and up to 72 hrs. The cellu-
lar lysates were prepared as described in Section 2.2.2.3. Before loading the trans-
fected HCT116 lysates on the 1 ml StrepTrap HP column, the lysates were concen-
trated to a volume of 1 ml each using a 15 ml Amicon® 3,000 MWCO Ultra-15 cen-
trifugal device (Millipore, Germany). The 1 ml from each lysate was diluted to an end 
volume of 2 ml with 1 ml of binding buffer (100 mM Tris-HCl, 1 mM EDTA, pH 8.0).  
For the remaining part of the affinity purification procedure and regeneration of the 
1 ml column, ÄKTApurifier 10/100 UPC-900 (GE Healthcare, Germany) was used. 
The column was mounted as recommended in the manufacturer’s handbook. The 
column was equilibrated with 10 column volume (1 column volume = I ml) of binding 
buffer (100 mM Tris-HCl, 1 mM EDTA, pH 8.0) at 1 ml/min. The lysate of 
Par17QRStrepGFP was applied on the column using a syringe fitted to luer adapter. 
The column was washed with 20 column volumes until no material appeared in the 
effluent. A step gradient elution with 50, 150, and 500 mM NaCl was done. This was 
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a measure applied to investigate if the protein-protein interactions were electrostatic 
in nature. When the salt elution was done, the column was washed again with 
10 column volumes of binding buffer which was salt free. Elution with 2.5 mM dest-
hiobiotin in elution buffer (100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0) was 
performed with 20 column volumes. The column was regenerated with 10 column 
volumes of double distilled water followed by 10 column volumes of 0.5 M NaOH and 
again with 10 column volumes of double distilled water. Salt and desthiobiotin elu-
tions and the regeneration step were done at 1ml/min at 4°C. Before use, the column 
was first flushed again with binding buffer and the lysate of Par17QR-GFP was 
loaded upon, and the purification cycle was repeated as described above. 2 ml of 
flow-through, wash-through, salt and desthiobiotin-eluted fractions for both lysate 
types were collected and stored at -20°C until the analyses with SDS-PAGE and sil-
ver staining were conducted. 
2.3.6 SDS-PAGE and Immunoblotting 
SDS-PAGE and immunoblotting were carried out according to standard protocols 
with the following notations. After determining the protein concentrations by the Brad-
ford method using a BioPhotometer (Eppendorf, Germany), 30 µg protein per lane 
except otherwise stated and 3 µl of Prescision Plus Protein Standards Dual Colour 
protein ladder (Bio-Rad, USA) were separated by SDS-PAGE (Laemmli, 1970). The 
protein samples were re-suppended in sample buffer consisting of 10 mM Tris-
HCl, pH 7.6; 0.5 % (w/v) sodium dodecylsulphate (SDS), 25 mM dithiothreitol (DTT), 
10 % (w/v) glycerol, 0.018 mg/ml bromophenol blue and boiled at 95°C for 5 min. 
Electrophoretic separation was carried out for about 2 hrs at 125 V in a Novex 
MiniCell Chamber (Invitrogen, Germany). Thereafter, the protein samples were re-
solved on 12.5 or 15 % SDS-PAGE gels. Blotting was done on a nitrocellulose mem-
brane (Invitrogen, Germany) in transfer buffer (25 mM Tris-HCl, pH 8.0 – 8.3, 192 
mM glycine, 20 % methanol) at 30 V for 1 hr using the semi-dry Fastblot apparatus 
(Biometra, Germany). The gel left after transfer was subsequently stained with 
Coomassie Brilliant Blue R 250 (0.5 mg/l in 40 % methanol and 10 % acetic acid) for 
30 min under gentle agitation. The gels were de-stained overnight under agitation 
with 40 % methanol and 10 % acetic acid and scanned. Images were stored in TIFF 
format at a resolution of 300 dpi. 
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Blocking of the membrane to minimise non-specific binding of the antibody was done 
for 1 hr in TBST-150 buffer [(50 mM Tris-HCl pH8.0, 150 mM NaCl; 0.3 % (v/v) 
Tween; 3 % (w/v) milk powder (Instant-Magermilchpulver, Granovita, Germany)] at 
4°C and incubated with the respective antibody overnight at 4°C on a end-over-end 
roller. Washing of the membranes after incubation with the primary antibody was first 
done in 5 ml TBST-500 buffer (50 mM Tris-HCl pH8.0, 500 mM NaCl; 0.3 % (v/v) 
Tween) for 5 min and later in 5 ml TBST-150 buffer like above with the exception of 
milk powder. The latter washing step was repeated for a second time. The washings 
took place at 4°C on a shaker and they served as a measure to wash off excess un-
bounded primary antibody. Anti-rabbit horseradish conjugated secondary antibody 
from donkey or anti-goat horseradish conjugated secondary antibody from sheep 
(Amersham Biosciences, UK) were used at a 1:2000 dilution in TBST-150 buffer in 
3 % powdered milk and incubated for 2 hrs at 4°C. The membrane was washed 
again 3 times for 5 min in 5 ml TBST-150 buffer in the absence of 3 % powdered 
milk. Immunoreactions were visualised with use of an enhanced chemiluminescence 
(ECL western blot reagents) kit followed by exposure on CL-XPosure Film (Thermo 
Scientific, Germany). Protein bands on the film were developed using the AGFA 
Curix 60 developer (AGFA, Germany). The films were scanned and stored. The im-
ages were saved in TIFF format at a resolution of 300 dpi.  
 
Used membranes were stripped-off of antibodies when necessary with stripping 
buffer (0.05 M glycine, pH 2.5, 1 % SDS, 1 mM EDTA) for 30 mins at RT under gen-
tle agitation on a shaker. They were washed 2 times with 2 ml TBST-150 buffer for 
2 mins and were ready for use. 
2.3.7 Silver Staining 
Silver staining is about 10 – 100 times more sensitive than various staining tech-
niques like coomassie blue stain. It is a staining technique with a detection level 
down to 0.3 – 10 ng (Switzer, III et al., 1979). The basic mechanism behind this 
method is that silver ions will react with the carboxyl and sulfhydryl groups of proteins 
and can be visualised after a reduction step with chemical reagents. The location of 
the proteins bands are visualised as bands where the reduction occured. 
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The silver staining protocol described here was adapted from Mortz and colleagues 
(Mortz et al., 2001). 15 µl of each eluate obtained from the Strep-tag II pull-down as-
says mixed with sample buffer were ran on 12.5 or 15 % SDS-PAGE gels and the 
conditions for protein electrophoresis were the same as described in Section 2.3.6. 
At the end of each run, the gels were removed from the glass plates and washed in 
deionised water for 5 min. Each gel was soaked overnight in 100 ml l fixing solution 
(50 % ethanol, 12 % acetic acid and 0.0185 %, (v/v) 37 % formaldehyde) with gentle 
agitation on a shaker. The fixing solution was discarded and the gel was washed 
3 times with 100 ml of 50 % ethanol for 20 min. The gel was pre-treated in 50 ml 
sensitisation solution (0.02 %, sodium thiosulfate pentahydrate) for 1 min. Washing 
was done 3 times with deionised water for 20 sec and this was followed by impreg-
nating the gel with 50 ml silver nitrate solution (0.02775 %, (v/v) 37 % formaldehyde, 
0.2 % silver nitrate) for 30 min with shaking to avoid unequal background. The silver 
nitrate solution was discarded and the gel was washed with deionised water 3 times 
for 20 sec. After washing with deionised water, the protein bands on the gel were 
developed by soaking the gel in 50 ml developing solution (6 % sodium carbonate, 
0.0185 %, (v/v) 37 % formaldehyde and 0.0005 % sodium thiosulfate pentahydrate) 
for approximately 2 - 5 min until staining was sufficient. The developing solution was 
decanted and the reaction was quickly stopped by soaking the gel for 10 min in 50 ml 
stopping solution (50 % methanol and 12 % acetic acid). The gel was washed again 
in deionised water for 10 min and it was ready for scanning and stored in TIFF format 
at a resolution of 300 dpi. 
 
Emphasis was made on the following:  
1) All solutions were prepared fresh before use in clean glasswares using deion-
ised water. 
2) The protocol described above was used for the silver staining as depicted in 
Fig. 3.13 and Fig. 3.14. This protocol differed with the silver staining that was 
compatible for mass spectrometry analyses. Under the supervision of Dr Bar-
bara Sitek at Medizinisches Proteom-Center affiliated to the Ruhr University of 
Bochum, Germany, mass spectrometry compatible silver staining experiments 
were performed (Fig. 3.15). 
3) Our protocols differed with that from the Medizinisches Proteom-Center in the 
composition of some of the solutions. For the differences refer to Table 2.5. 
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The chemicals that they used were of analytical grade and the gels were han-
dled with powder-free gloves. These measures were done to minimise con-
tamination with keratin since they could lead to false positives in protein identi-
fication by tandem mass spectrometry. 
 
Table 2.5 Comparison of our in-house protocol with mass spectrometry compatible 
protocol used for identification of Par14/Par17 interaction partners 
Solutions In-House Protocol Mass Spectrometry 
Compatible 
   
Fixing solution 50 % ethanol, 12 % acetic acid, 
0.0185 %, (v/v) 37 % formalde-
hyde 
50 % Ethanol, 10 % acetic acid    
Sentisation Solution 0.02 %, sodium thiosulfate 30 % ethanol, 500 mM sodium 
acetate, 8 mm sodium thiosulfate 
 
Silver Nitrate Solution 0.02775 %, (v/v) 37 % formalde-
hyde, 0.2 % silver nitrate 
0.01 % (v/v) 37 % formaldehy-
de, 6 mM silver nitrate 
  
Developing Solution 6 % sodium carbonate, 0.0185 %, 
(v/v) 37 % formaldehyde and 
0.0005 % sodium thiosulfate 
236 mM sodium carbonate,  
0.01 % (v/v) 37 % formaldehyde 
 
Stopping Solution 50 % methanol and 12 % acetic 
acid 
50 mM EDTA, pH 8.0    
2.3.8 Tandem Mass Spectrometry Analysis 
As already mentioned, mass spectrometric analyses were done at the Medizinisches 
Proteom-Center affiliated to the Ruhr University of Bochum, Germany under the di-
rection of Dr Barbara Sitek and she provided us the following protocol.  
 
Bands of interest were manually cut out of the preparative silver stained gels. The 
bands were digested with trypsin (Promega, Germany) in-gel, and later extracted 
from the gel. Protein-derived peptides were analysed by LC-MS/MS in an ESI-QTOF 
mass spectrometer (micrOTOF Q, Bruker Daltonics, Germany) connected online with 
a nanoflow HPLC (Ultimate 3000, Dionex, Germany). The reversed phase columns 
(75 µm ID, 150 mm length; Acclaim C18 PepMap Material) were ran at a flow rate of 
300 nl/min after flow splitting. In order to improve reproducibility after 10 min pre-
concentration on a 2 cm pre-column (same specifications as analytical column ex-
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cept 100 µm ID) gradient elution was applied from 12 % B to 85 % C (C=35 % ACN, 
0.1 % FA) in 120 min followed by a ramp to 90 % B (B=84 % ACN, 0.1 % FA) over 
25 min followed by column re-equilibration for 30 min. 
 
The mass spectra were acquired in the 100-2000 m/z range with an online 
nanospray-source set to 1400 V capillary voltage and nitrogen dry gas flow to 
6.0 l/min at 140°C. Each MS-scan was followed by MS/MS-experiments of the three 
most intense ions under varying collision RF values from 800 to 250 Vpp during 
fragmentation, with overall duty cycle times between 3.6 and 5.4 s depending on pre-
cursor ion intensity.  
 
For protein identification, un-interpreted ESI-MS/MS-spectra were correlated with the 
IPI-protein sequence human sub-database (v3.41 Human, 72155 proteins) applying 
the Mascot (v.2.2.0) algorithm (Perkins et al., 1999). Proteins were considered as 
identified when either two peptides were explained by the spectra, with a Mascot 
Score higher than 22.5 or 1 peptide was explained by the spectra, with a Mascot 
Score higher than 70.  
2.4 Par14/Par17 Gene Knock-Down Experiments 
Over the last decade, RNA interference (RNAi) has been used as a powerful tool to 
study gene function. It is a phenomenon that small double-stranded RNA also known 
as small interfering RNA (siRNA) can post-transcriptionally prevent the expression of 
a gene product. Here, one of the double-stranded siRNAs is complementary to the 
target gene mRNA. Concomitant with the other cellular-based processes, the com-
plementary strand will bind to the cognate mRNA that will lead to its cleavage and 
destruction, thus initiating a temporary knock-down of the gene and its cognate pro-
tein will not be expressed. Several authors have reviewed the mechanism of siRNAs 
and other small interfering RNA molecules, which can also initiate gene knock-down 
(Grimm, 2009; Scherr and Eder, 2007; Shabalina and Koonin, 2008). 
 
We used two variations of the siRNA technology to induce gene knock-down of 
Par14/Par17. The first variation was the use of synthetic double-stranded siRNAs. 
We ordered four double-stranded synthetic siRNAs in a pool that were Par14/Par17-
specific (Dharmacon, Germany). Their sequences can be seen on Table 2.3 (siRNA-
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1, siRNA-2, siRNA-3 and siRNA-4). A negative control non-targeting siRNA was also 
ordered. The sequence of the negative control siRNA was scrambled so that it had 
no homology to any human gene. Also ordered was a transfection indicator referred 
as siGLO green. It is a fluorophore with an absorption maximum at 488 nm and 
emission maximum at 518 nm. The siRNAs were re-suspended according to the pro-
tocol of the manufacturer and aliquots were stored at -80°C until use. For best re-
sults, we limited freeze thawing for each aliquot to five events and gloves were worn 
to maintain a nuclease-free working condition. Synthetic siRNAs are susceptible to 
enzymatic degradation by nucleases. 
 
HeLa cells were grown and cultured as described in Section 2.2.21. They were co-
transfected with the pool of Par14/Par17-specific siRNAs and the siGLO transfection 
indicator. They were transfected at a 1:1 ratio to a final concentration of 100 µM in 
12-well plates. This was the highest concentration recommended by the manufac-
turer. Sterile cover slips (15 x 15 mm or 18 x 18 mm; Menzel-Gläser, Germany) were 
first placed on the wells before growth and transfection of HeLa cells. DharmaFECT 
siRNA transfection reagent (Dharmacon, Germany) was used for lipid-mediated de-
livery and the instructions of the manufacturer were followed. The duration of trans-
fection lasted for 24 to 96 days. After transfection stop, the cells were washed 2 
times with 1 ml of pre-warmed PBS, pH 7.4.  
 
In order to check transfection efficiency and to visualise any morphological aberra-
tions that cells might have incurred in the event of a Par14/Par17 knock-down, they 
were stained either with propidium iodide (PI) or DAPI as dyes that stain nuclear 
DNA. Stock solutions of either dye were made to 5 mg/ml and diluted with culture 
medium to a working solution of 200 nM. 300 µl of the pre-warmed DAPI or PI work-
ing solution was given to the each well and incubated for 1- 5 min at RT. Thereafter, 
the cells were washed 3 times with 1 ml of pre-warmed PBS, pH 7.4. Fixation was 
done with 0.5 ml PBS, pH 7.4 containing 3 % paraformaldehyde for 5 – 10 min at RT. 
Cells were washed again 3 times with PBS, pH 7.4. The cover slips-containing cells 
were semi-dried by exposing them in the air. They were carefully removed from the 
wells and embedded on a microscope slide on which 20 µl of mowiol (polyvinylalco-
hol) (Sigma, Germany) had been placed on. At this stage, the cover slips were 
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sealed to the microscope slides with nail polish and stored in darkness at 4 °C. Mi-
croscopic observations were done with an Olympus BX61 Fluorescence Microscope. 
Vector-based siRNA technology was the second variation of RNAi that we employed 
to elicit Par14/Par17 gene knock-down. Here, we designed 3 small DNA inserts 
which encoded short hairpin RNAs (shRNA) targeting Par14/Par17. The DNA inserts 
each of 76 bp were cloned into pRNTin-H1.2/Hygro vector with an inducible H1 pro-
moter containing a tetracycline operator (TetO1). The cloning was done by Gen-
Script, USA. The sequences of the shRNAs used have been listed on Table 2.3 
(shRNA-1, shRNA-2 and shRNA-3). A shRNA for luciferase was cloned into the vec-
tor pRNATin-H1.3/Hygro/siFluc and was used as non-targeting negative control. Both 
vectors embodied the GFP gene, whose gene product was used to test for transfec-
tion efficiency. The luciferase construct was referred to as shRNA-Luc. The se-
quence of siRNA-3 from the pool of the double-stranded siRNA overlapped with the 
sequence of shRNA-2. One of the advantages of using vector-based siRNA technol-
ogy is that a stable cell line can be established and long-term effects of RNAi can be 
studied (Brummelkamp et al., 2002; Sui et al., 2002). 
 
HeLa cells were grown and cultured as described in Section 2.2.21. The short hair-
pin constructs were propagated using NucleoBondR Xtra Midi kit (Macherey-Nagel, 
Germany) and subsequently transfected using the transfection reagent, nanofecta-
min (PAA, Germany). The instructions of the manufacturers were strictly adhered too. 
Transfection was done in 12-well plates containing sterile cover slips. Transfection 
was stopped after 24 to 96 hrs. Before microscopic analyses, the cells were stained, 
fixed with 3 % paraformaldehyde and embedded in mowiol in the same way as was 
with the case with cells treated with Par14/Par17-specific synthetic siRNAs. 
 
Par14/Par17 gene knock-down effects were not only verified on the basis of morpho-
logical phenotypes but also at the protein level. Transfected HeLa cellular lysates 
from both Par14/Par17-synthetic siRNAs and from Par14/Par17-short hair pins were 
processed for SDS-PAGE and western blot procedures in the same manner as de-
scribed in Section 2.3.6. An antibody against the PPIase domain for Par14/Par17 
(α PPIase) was used to detect the extent of knock-down of both proteins. 
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Also to investigate the level of knock-down, qRT-PCR was used. In this instance only 
the Par14/Par17-shRNAs were used and transfection was performed as described 
before in HCT116 cells. 12-wells plates were used and transfection was done for trip-
licates per shRNA. Duplicates of the Ct values were performed for each well. Quan-
titative RT-PCR could not be performed using the pool of Par14/Par17-synthetic 
double-stranded siRNAs because they ran out of stock and cost was a limiting factor 
for re-purchasing. The qRT-PCR procedure carried out has been elucidated in Sec-
tion 2.2.1.1.  
 
Calculation of the percentage knock-down (KD) for example for Par14 was done by 
comparing the expression of Par14 in the wells transfected with one of the shRNAs 
(e.g. shRNA-1) with the expression of Par14 in untreated cells after normalisation 
with the expression of the housekeeping genes (HKG) in both of the cells transfected 
with shRNA-1 and in untreated cells to account for any difference in cell number and 
transfection efficiency between the wells. The following formula was used: 
 % 𝐾𝐷 𝑃𝑎𝑟14 𝑠ℎ𝑅𝑁𝐴1 = [1 − (𝐴𝑣 𝑜𝑓 𝐴𝑣 𝐶𝑡 𝑃𝑎𝑟14 𝑠ℎ𝑅𝑁𝐴 − 1)/(𝐴𝑣 𝑜𝑓 𝐴𝑣 𝐻𝐾𝐺𝑠 𝑠ℎ𝑅𝑁𝐴1 ) ×(𝐴𝑣 𝑜𝑓 𝐴𝑣 𝐶𝑡 𝐻𝐾𝐺𝑠 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑)/(𝐴𝑣 𝑜𝑓 𝐴𝑣 𝐶𝑡 𝑃𝑎𝑟14 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑)] ∗ 100 
 
Av of Av Ct Par14 shRNA-1: average of the average of the average of duplicate Ct 
values of the expression of Par14 from triplicates treated with shRNA-1 
Av of Av HKGs shRNA-1: average of the average of the average of duplicate Ct val-
ues of the expression of GADPH and ribosomal protein L13A from triplicates treated 
with shRNA-1 
Av of Av Ct HKGs untreated: average of the average of the average of duplicates Ct 
values of the expression of GAPDH and ribosomal protein L13A from untreated tripli-
cates 
Av of Ct Par14 untreated: average of the average of the average of duplicates Ct 
values of the expression of Par14 from untreated triplicates 
 
The % KD for Par17 with the different shRNAs was calculated using the same formu-
la and logic. 
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2.5 Microscopy Techniques 
2.5.1 Immunostaining- and fluorescence of Polytene Chromosome Squashes 
Slides on which polytene chromosomes have been embedded upon were taken out 
of 80 % ethanol and placed in 40 % ethanol for 10 min. Following this, the slides 
were immersed in 5 % anti-goat serum in buffer A (150 mM Tris-HCl, pH 7.4; 
600 mM KCl, 150 mM NaCl, 5 mM Spermidin, 1.5 mM Spermin) for blocking pur-
poses for a duration of 1 hr. The slides were then removed and immersed again 2 
times in buffer A for 10 min. This step served as a washing procedure. Dilutions of 
1:3000 (30 µl) of 5 % anti-goat serum in buffer A for preimmune serum of the PPIase 
domain of Par14/Par17, affinity chromatography purified final immune serum of α P-
PIase and α Histone H3 (Abcam, UK) were given to each slide respectively and incu-
bated overnight at 4°C. Washing of the respective slides was done twice in buffer A 
after incubating them for 10 min. The slides were then labelled with 30 µl of anti-
rabbit, Alexa Fluor 514 at 1:3000 (A31558 Invitrogen, Germany) using the same pro-
cedure as for the primary antibody labelling for 3 hrs at RT. This was followed by 
washing the slides twice for 10 min in buffer A. The slides were removed and im-
mersed in 0.25 ml buffer A containing 0.1 µg/ml DAPI as a DNA counter stain for 5 -
10 min. Before embedding the slides in 87 % glycerol and 2 % propyl gallate, they 
were briefly washed in Buffer A again. Each slide was sealed with a cover slip using 
nail varnish before microscopic examination or storage at -20°C. 
2.5.2 Indirect Immunofluorescence of Polytene Chromosome Squashes 
The evaluation of the polytene chromosome squashes was carried out using Olym-
pus BX61 fluorescence microscope having a F-View II camera and the Cell^P soft-
ware (Olympus, Hamburg), a UPlanSApo 100x objective and a U-M41002b filter (ex-
citation 545 +/- 30 nm, emission 610 +/- 35 nm for AlexaFluor 514 (PI) and excitation 
480 +/- 10 nm, emission 520 +/- 20 nm for DAPI). The exposure time for AlexaFluor 
was 50-60 ms and 500-600 ms for DAPI.  
2.5.3 Fluorescence of siRNA and shRNA treated HeLa Cells 
The same Olympus microscope was used as in Section 2.5.2 for the visualisation of 
siRNAs and shRNAs transfected HeLa and HCT116 cells. UPLAFL N 60x objective 
was used and the excitation and emission wavelengths for PI and DAPI were the 
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same as in Section 2.5.2. For GFP, we used an excitation of 480 nm and an emis-
sion of 510 nm. 
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3.  Results 
Here, the findings of the affinity purification of α PPIase and α Par17-Ext antisera will 
be presented. Also, the outcomes of the various biochemical fractionations, Chroma-
tin Affinity Purification (ChAP) and indirect immunofluorescencence of polytene 
chromosomes experiments performed will be put into perspective. Furthermore, a 
critical look will be taken at the transcriptional/translational regulation of Par14/Par17 
in the course of the cell cycle, and the data obtained from the search of potential in-
teractors of Par14/Par17 by means of affinity purification coupled with mass spec-
trometry. Above all, an appraisal of the data generated from the Par14/Par17 knock-
down experiments by means of siRNA-technology will be done. 
3.1 Affinity Purification of Antibodies α PPIase and α Par17-Ext 
In preparation of the cellular and sub-nuclear biochemical fractions, it was advisable 
to work with highly sensitive and specific antibodies for Par14 and Par17. After the 
production of the antisera of the PPIase domain of Par14/Par17 and the N-terminal 
extension of Par17, we affinity purified both antisera as described in Materials and 
Methods (Section 2.3.1). Western blot analyses were done to validate the efficiency 
of the purification (Fig. 3.1). Affinity-purified α PPIase was used on total cell extract 
(TCE) and recombinant Par14 (rhPar14) for immunoblotting (Fig 3.1A). For α Par17-
Ext, we used TCE and the lysate from recombinant Par17 E. coli expressing cells 
(Fig. 3.1B).  
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Fig 3.1 Affinity-purified α PPIase and α Par17-Ext  
A) Recombinant Par14 (rhPar14) and total cell extract (TCE) from HeLa cells were used to de-
termine the specificity of affinity-purified α PPIase. B) Cell lysate from E. coli expressing recombi-
nant Par17 (Par17 E. coli Lysate) and total cell extract (TCE) from HeLa cells and were used to 
determine the specificity of affinity-purified α Par17-Ext 20 µg of TCE, 300 ng of Par17 E. coli ly-
sate and 100 ng of rhPar14 were used respectively. Both affinity-purified antibodies were used at 
a 1:1000 dilution. 
 
Affinity-purified α PPIase and α Par17-Ext were used at a final concentration of 1.74 
ng/µl and 3 ng/µl respectively (1:1000 dilution). We acknowledged the presence of 14 
and 17 kDa bands that corresponded to the molecular weights of Par14 and Par17 
upon use with the α PPIase (Fig. 3.1A). The band underneath rhPar14 was justified 
by proteolytic degradation suffered by the recombinant protein. We also saw a band 
of 17 kDa that reflected the molecular weight of Par17 when α Par17-Ext was used 
(Fig. 3.1B). From the western blots using both affinity-purified antibodies, we saw 
only the signals of the proteins (Par14 and Par17 respectively) that they detected. 
This implied that the problem of unrelated proteins being detected was addressed. 
 
In this work, we used the affinity-purified α PPIase antibody for western blot analyses 
for the fractions obtained from the sub-nuclear fractionation 2 (Section 3.2.2), the 
fractionation of nuclear and nucleic acid-binding proteins (Section 3.2.3) and lysates 
from the phases of the cell cycle for the detection of Par14 (Section 3.3.2). The im-
munostainings of polytene chromosome squashes (Section 3.2.4) were also done 
with the purified α PPIase. The analyses of cell cycle phases lysates and the subse-
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quent cellular fractionation of the respective phases of the cell cycle were performed 
with the purified α Par17-Ext for the detection of Par17 (Section 3.3.3). 
3.2 Par14, Chromatin and DNA-Binding in vivo 
3.2.1 Sub-Nuclear Localisation 1 of Par14 
One of the aims of this thesis was to characterise the sub-nuclear localisation of 
Par14. HeLa cells were employed for the biochemical fractionation procedures ex-
plained in Materials and Methods (Section 2.3.2). Our first strategy was to fraction-
ate the nucleus in a manner in which chromatin-nuclear matrix bound proteins will be 
isolated. For this goal, we adapted two nuclear fractionation protocols that served to 
address this question (Mendez and Stillman, 2000; Wysocka et al., 2001) as de-
scribed in Section 2.3.2.2. 
 
Fractions S2 (soluble cytosolic proteins), S3- (soluble nucleoplasmic proteins), S3+ 
(solubilised nuclear proteins with MNase), P3- (chromatin-nuclear matrix bound pro-
teins) and P3+ (solubilised chromatin-nuclear matrix bound proteins with MNase) 
together with total cell extract (TCE) and recombinant Par14 (rhPar14) were ran on a 
12.5 % SDS-PAGE gel (Fig. 3.2A). TCE and rhPar14 were used as endogenous and 
exogenous positive controls for Par14. For fraction S3+, almost no nuclear proteins 
were retrieved when treated with MNase. This can be due to the fact that the treat-
ment with MNase yielded no effect to release nuclear proteins. The gel also revealed 
that the loading was more or less constant although there was a slight discrepancy in 
the amount of protein found in P3+ as in P3- (Fig. 3.2A). The samples analysed 
showed to an extent a non-homogenous protein separation pattern. We argue this on 
the grounds that these fractions contained proteins obtained from different cellular 
locations, thus the heterogeneity of the separation pattern. The lane for rhPar14 was 
virtually empty because only 50 ng was loaded but it was sufficient for the detection 
with the α PPIase antibody by western blotting. 
 
When the SDS-PAGE was over, the gel was transferred to a nitrocelluse membrane 
for immunoblotting. We saw a Par14 signal for the recombinant Par14 sample. This 
is the upper band and not the lower band (Fig. 3.2B). The upper band should be 
linearly viewed from right to left until we arrive at the band of the TCE as llustrated by 
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the red horizontal line. This is the convention we shall use in this section to determine 
whether or not Par14 band signals were present in the various isolated and analysed 
fractions. The lower band resulted from proteolytic degradation (Fig. 3.1A). 
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Fig 3.2 Par14 is present in chromatin-nuclear matrix bound fractions.  
A) An asynchronous culture of HeLa cells was subjected to biochemical fractionation (Section 
2.3.2.2). After cell lysis, S2 (soluble cytosolic proteins) was obtained by centrifugation. The nuclei 
were divided in two equal aliquots. One of them was incubated for 1 hr at 28°C with 10 U of mi-
crococcal nuclease (MNase), and the other one was incubated without MNase. After this treat-
ment, nuclei were lysed and the following fractions were obtained S3- (soluble nucleoplasmic 
proteins), S3+ (solubilised nuclear proteins with MNase), P3- (chromatin-nuclear matrix bound 
proteins) and P3+ (solubilised chromatin-nuclear matrix bound proteins with MNase). Total cell 
extract (TCE) and recombinant Par14 (rhPar14) were used as endogenous and exogenous posi-
tive controls for Par14. Protein-equivalent amounts (30 µg) of the final fractions apart from frac-
tion S3+ that contained virtually no protein were ran on a 12.5 % SDS-PAGE gel. 50 ng of 
rhPar14 was loaded B) After electrophoresis, the gel was transferred to a nitrocellulose mem-
brane for immunoblotting with α PPIase, α MEK2, α Lamin B1 and α Histone H3 antisera. Antibo-
dies were used at a 1:1000 dilution. MEK2, lamin B1 and histone H3 were used to benchmark the 
different fractions. C) α PPIase was used for an analytical blot where TCE, MNase and rhPar14 
had been probed on the membrane. 
 
A western blot signal in fraction S2 containing soluble cytosolic proteins was seen for 
Par14 (Fig. 3.2B). This confirmed the cytosolic localisation of Par14 as previously 
reported (Surmacz et al., 2002). The nuclei were divided in two equal amounts after 
the cytosolic fraction was isolated. P3- was the fraction that resulted after no treat-
ment with MNase and P3+ was the fraction that resulted after MNase treatment. S3- 
and S3+ are the supernatants that were collected after centrifugation of P3- and P3+. 
The aim was to release with and without MNase soluble and solubilised chromatin-
nuclear matrix bound proteins. S3- was believed to contain soluble nucleoplasmic 
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proteins and P3- was the chromatin-nuclear bound proteins fraction. The Par14 sig-
nal for the S3- fraction was weaker than the signal in the P3- fraction. Thus, we saw 
a trend that Par14 is associated with chromatin-nuclear matrix bound proteins.  
 
S3+ and P3+ were referred to as solubilised nuclear proteins and solubilised chroma-
tin-nuclear matrix bound proteins respectively. Taking a critical look at Fig. 3.2B, we 
saw no Par14 signals for both fractions. Instead, we saw a very strong protein band 
signals slightly above where a Par14 signal was expected for S3+ and P3+ respec-
tively. We were interested in these bands and conducted western blot experiments 
using TCE, MNase, and rhPar14 as samples and applying the α PPIase antibody at a 
1:1000 dilution. We saw that this antibody detected MNase (Fig. 3.2C). Therefore, 
the question of the occurrence of the bands was addressed. Another striking revela-
tion was a protein signal above the Par14 signal in fraction S2. This band was also 
seen in the different biochemical fractionation schemes so far described in the Mate-
rials and Methods. We will refer to them where necessary in the course of this result 
section. The fidelity of the sub-nuclear fractionation was confirmed by the use of anti-
bodies against MEK2 for the cytosolic fraction, lamin B1 as a marker for the nuclear 
matrix fraction and histone H3, which characterised the chromatin fraction. We must 
also say that histone H3 was also found in the other fractions. This is because his-
tones are abundantly highly expressend proteins and are ubiquitously present in 
various compartments of the cell. But it is a known fact that histones form an integral 
part of the chromatin structure.  
3.2.2 Sub-Nuclear Localisation 2 of Par14 
The sub-nuclear localisation 1 described above was ambiguous to characterise 
Par14 to chromatin or the nuclear matrix. For this reason, we adapted a sub-nuclear 
fractionation protocol used by Qiao and colleagues that could highly enrich chromatin 
and nuclear matrix proteins (Qiao et al., 2001). A small-scale biochemical fractiona-
tion procedure of an asynchronous culture of HeLa cells was performed as described 
in Section 2.3.2.3. From the scheme, we isolated cytosolic, chromatin and nuclear 
matrix proteins. Fractions S1 (soluble cytosolic proteins), S2+/S2- (chromatin pro-
teins with and without DNase I), S3+/S3- (nuclear matrix proteins with and without 
DNase I), together with TCE and rhPar14 were ran on a 12.5 % SDS-PAGE gel 
(Fig. 3.3A). TCE and rhPar14 were used as endogenous and exogenous positive 
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controls for Par14. We saw that an almost equal amount of protein was loaded for all 
the fractions. The samples analysed showed to an extent a non-homogenous protein 
separation pattern. The hetorogeneity of the separation patterns obtained is due to 
the fact that these were proteins obtained from different cellular localisations in the 
cell. 100 ng of rhPar14 was loaded and we could see a weak band of it on Fig. 3.3B. 
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Fig 3.3 Par14 localises more to chromatin than to nuclear matrix  
A) An asynchronous culture of HeLa cells was subjected to biochemical fractionation. Par14 was 
solubilised in the chromatin and nuclear matrix enriched fractions S2+ and S3+ respectively by 
treatment with DNase I as described in materials and methods (Section 2.3.2.3). The distribu-
tions of different proteins in the TCE, S3+/- nuclear matrix fractions, S2+/- chromatin fractions and 
rhPar14 (as positive control for Par14) are shown. Protein-equivalent amounts (30 µg) of the final 
fractions were used for SDS-PAGE analysis. 100 ng of rhPar14 was laoded. B) After electropho-
resis the gel was transferred to a nitrocellulose membrane for immunoblotting with α PPIase, 
α MEK2, α Lamin B1 and α Histone H3 antisera. Antibodies were used at a 1:1000 dilution. MEK2, 
lamin B1 and histone H3 were used to benchmark the different fractions. C) Spatial distribution of 
Par14 in the various fractions quantified by densitometric analyses. The area of the band signals 
were measured and subtracted from the background signal on the blots. Multi Gauge densitome-
try software version 3.1 was used.  
 
Comparing the western blot conducted and the densitogramm as shown on 
Fig. 3.3B/C, it was seen that the band area signals for Par14 in the chromatin frac-
tions S2+ and S2- were 3- and 2-fold higher respectively  than those of the nuclear 
matrix fractions S3+ and S3- respectively. The densitogramm shows the spatial dis-
tribution of Par14 in the various fractions (Fig. 3.3C). The band signal areas were 
measured and corrected with the background signal on the blots using the Multi-
guage densitometry software. S2+ and S3+ were fractions that were solubilised with 
DNase I, while S2-/S3- did not undergo any nuclease treatment. Hence, we saw an 
appreciable enrichment of Par14 in the chromatin fractions than the nuclear matrix 
fractions.  
 
To determine whether Par14 is bound to DNA, permeabilised HeLa cells were 
treated with DNase I for 1 hr. The first 30 mins of incubation was done at RT and the 
last 30 mins was conducted at 37°C. Par14 was 1.4-fold released from chromatin 
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when treated with DNase I as deduced from the Par14 band signal in S2+ on 
Fig. 3.3B/C as opposed to S2-. No appreciable difference of the release of Par14 
could be inferred for the nuclear matrix fraction S3+ that underwent treatment with 
DNase I. These results indicated that Par14 was potentially chromatin-bound and 
was differentially released after DNase I treatment, suggesting an intimate associa-
tion with DNA. Par14 has been shown to be present in the cytosol (Surmacz et al., 
2002) and this we saw in S1 that reflected the proteome of the cytosol. TCE and 
rhPar14 were loaded to serve as endogenous and exogenous positive controls re-
spectively for the detection of Par14 in the various fractions. The fidelity of the sub-
nuclear fractionation was confirmed by the use of antibodies against MEK2 for the 
cytosolic fraction, lamin B1 as a marker for the nuclear matrix fraction and histone H3 
that characterised the chromatin fraction. Histone H3 behaved in a similar way by 
occurring not only in the chromatin fractions as in Fig. 3.2B. To mention is also the 
fact that we saw protein band signals above the weak Par14 band signal in the nu-
clear matrix fractions S3+/S3-. This band was similar to what we saw in the Par14 
signal in the S2 fraction in Fig. 3.2B. 
3.2.3 Par14 binds to DNA in vivo 
From DNA-cellulose binding assays and EMSA studies, it was demonstrated that 
Par14 bound to DNA in vitro (Kessler et al., 2007; Surmacz et al., 2002). In concert 
with our Par14 enrichment with chromatin and its release after treatment with DNase 
I as described in Section 3.2.2, it was mandatory to verify the in vivo binding of 
Par14 to DNA using a different biochemical fractionation approach. The Qproteome 
nuclear subfractionation kit from Qiagen, Germany was used whereby nuclear pro-
teins are separated to allow for the enrichment detection of low-abundance proteins 
such as transcription factors. A small-scale biochemical fractionation procedure of 
HeLa cells was performed as described in Section 2.3.2.4.  
 
From the fractionation scheme, we isolated cytosolic, nucleic-acid binding proteins 
and solublised nuclei. Fractions S1 (soluble cytosolic proteins), E1 - E3 (nucleic-acid 
binding proteins eluted with 0.1, 035 and 1 M NaCl), S4+ (nuclei solublised with be-
zonase) together with TCE and rhPar14 were ran on a 12.5 % SDS-PAGE gel 
(Fig. 3.4A). TCE and rhPar14 were used as endogenous and exogenous positive 
controls for Par14. We saw a very little amount of proteins were eluted with 
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0.1 M NaCl. The band patterns of the protein samples obtained showed some de-
screpancies. For example, the bands on which the red lines are placed upon were a 
testimony of proteins that were conspicuously enriched in the S4+ fraction as op-
posed to the other fractions. No band was seen on the lane of rhPar14 because only 
50 ng was loaded and this amount was sufficient for detection via immunoblotting. 
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Fig 3.4 Par14 binds to DNA in vivo and elutes with increasing salt concentration 
A) An asynchronous culture of HeLa cells was subjected to biochemical fractionation (Section 
2.3.2.4). The electrophorectic distributions of different proteins in the TCE, E1 - E3, nucleic acid- 
binding fractions; S4+, nuclei solubilised with benzonase and rhPar14 (as positive control for 
Par14) are shown. Protein-equivalent amounts (30 µg) of the final fractions were used for analy-
sis. B) After SDS-PAGE, the gel was transferred to a nitrocellulose membrane for immunoblotting 
with the affinity-purified α PPIase, MEK2, and nuclear matrix protein p84 antisera. Antibodies were 
used at a 1:1000 dilution. MEK2 and nuclear matrix protein p84 were used as markers for the 
different fractions. 
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The nuclear and nucleic acid-binding protein fractionation scheme employed and the 
resulting fractions have been described in Section 2.3.2.4. Fraction S3 contained 
nucleic acid-binding proteins (Fig. 2.4) that was later bound on a phospho-cellulose 
column and eluates were collected using increasing salt concentrations (0.1, 0.35, 
and 1 M). Analysis of the eluates on an immunoblot showed that at 0.35 M (E2) and 
1 M (E3) salt concentrations Par14 was eluted (Fig. 3.4B). The red line is below of all 
Par14 band signals. This finding indicated that Par14 was part of the fraction termed 
nucleic acid-binding. Thus, Par14 bound to physiological DNA. S4+ was the super-
natant of the nuclei pellet P4+ that was treated with benzonase, and it was referred to 
as the solubilised nuclei fraction. The presence of Par14 in S1 (cytosol) and S4+ 
(solubilised nuclei) went to validate previously published data that assigned Par14 to 
these compartments (Reimer et al., 2003). We also used an antibody against the 
transcription factor p84 as a marker to verify the fidelity of the eluates E1, E2 and E3 
that resulted from S3, the nucleic acid-binding fraction. Transcription factors bind to 
DNA and this justified our use of p84, a transcription factor to characterise these elu-
ates. We saw bands at E1 and E2 when the antiserum for p84 was probed on the 
membrane, although a band signal was also seen in the S1 fraction. TCE and 
rhPar14 were used as endogenous and exogenous positive controls for the identifi-
cation of Par14. The protein band signal above the Par14 band signal reported in the 
S3+/S3- nuclear matrix fractions in Fig 3.2B and in the S2 cytosolic fraction 
(Fig 3.3B) was also recurrent in this fractionation procedure for the S4+ fraction 
(Fig 3.4B). 
3.2.4 Par14 and Polytene Chromosomes 
We have shown with a certain body of evidence that Par14 is a chromatin protein 
and it binds to DNA in vivo. The next approach to validate this finding was to investi-
gate if Par14 in Drosophila melanogaster is associated with polytene chromosomes. 
Human Par14, CCDS14417 shares 72.5 % sequence identity with its orthologue in 
Drosophila melanogaster, CG11858-RA (Wheeler et al., 2007). Within their PPIase 
domains, they share 81 % sequence identity (Fig. 3.5A). Based on this fact, we de-
cided to perform indirect immnolabeling on polytene chromosomes using the affinity-
purified α PPIase to visualise polytene chromosomes. As mentioned earlier, Dr 
Corinna Schirling provided out of courtesy the polytene chromosome squashes. Al-
exa Fluor 514-conjugated goat anti-rabbit was used as a secondary antibody. Hence, 
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the orange colour we saw in Fig 3.5B. As a positive staining control for a chromatin 
protein, antiserum for histone H3 was also given onto the polytene chromosome 
squashes. The chromosomes were also stained with the preimmune serum for the 
α PPIase, which served as a negative staining control. Fig. 3.5B shows the detection 
of bands and interbands when the histone H3 antibody was used for staining. The 
detection of bands and interbands is also observed when the preimmune serum and 
the affinity-purified PPIase were applied. The pattern of staining was the same and to 
this effect, it reduced the credibility to acknowledge the fact that Par14 in Drosophila 
melanogaster was associated with polytene chromosomes.  
 
 
Fig 3.5 No clear-cut co-localisation of Par14 to either puffs or interbands on polytene 
chromosomes in Drosophila melanogaster  
A) Sequence alignment of Par14 in humans and in Drosophila melanogaster. Identical residues 
are shown in blue. Multiple sequence alignment with the Clustal series of programs was used 
(Chenna et al., 2003). B) Immunodetection and distribution of Par14 on wild type polytene chro-
mosomes. The left panel shows indirect immunofluorescence using antibodies against the 
PPIase domain of Par14/Par17, histone H3 and preimmune serum of PPIase domain of 
Par14/Par17 stained concomitantly with DAPI (blue, first column), Alexa Fluor 514 (orange, 
second column) and merged (third column). The right panel shows cutouts of the merged col-
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umns on the left panel. C) Immunoblots of nuclear extracts from Drosophila melanogaster Kc 
cells. Left Lane: preimmune serum of PPIase domain of Par14/Par17; right Lane: affinity-purified 
serum of PPIase domain of Par14/Par17. A band of 14 kDa is observed on lane 2 and not on 
lane 1 corresponded to the molecular weight of Par14 in both organisms. 
 
Western blots were carried out using the nuclear extracts of Kc cells from Drosophila 
melanogaster. A protein band of 14 kDa was detected when the α PPIase was used 
and this band was absent when the preimmune antiserum of α PPIase was applied 
(Fig. 3.5C). 14 kDa is the molecular mass of Par14 in Drosophila melanogaster and 
in humans.  
3.2.5 Chromatin Affinity Purification (ChAP) 
From our sub-nuclear fractionation experiments, we observed the relatively enrich-
ment of Par14 with chromatin than with the nuclear matrix. Besides, we saw the elu-
tion of Par14 at 0.35 and 1 M NaCl when nucleic acid-binding proteins were bound 
on a phospho-cellulose column. This knowledge paved the way for the search of po-
tential DNA-binding motifs for not only Par14 but also for Par17. Par17 has been 
shown to bind to DNA in vitro (Kessler et al., 2007). We employed our home-made 
Chromatin Affinity Purification (ChAP) assay, which is a deviation from the conven-
tional Chromatin Immunoprecipitation assay (ChIP), where large amounts of very 
specific and sensitive antibodies are required. 
 
Before the transfection of HCT116 cells with Par17QR-Strep-GFP and Par17QR-
GFP constructs, we first performed preliminary experiments to optimise the chromatin 
shearing efficiency. Sonification of untransfected cellular lysates previously fixed with 
1 % formaldehyde at RT for 10 min was done at 4, 8, and 12 pulses with a 30 sec 
rest on ice at each pulse for lanes 2, 3 and 4 respectively (Fig. 3.6). This was to 
avoid emulsification and overheating. An aliquot of un-sheared cellular lysate was 
also loaded on the 1 % agarose gel for comparison purposes. 100 bp ladder from 
New England Biolabs, Germany was used. DNA fragments of 200 – 1500 bp are de-
sired for follow-up experiments (Chromatin Immunoprecipitation and Shearing Kits, 
Version E1, Active Motif, Belgium).  
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Fig 3.6 Analysis of DNA sheared 
HCT116 cells were fixed for 10 mins with 1 % formaldehyde at RT and chromatin was prepared 
as described in Materials and Methods. Chromatin was sheared with 4, 8 and 12 pulses at 15 sec 
with a 30 sec rest on ice between each pulse at 17 - 20 % amplitude Bandelin Sonopuls HD 
2200. The sheared and un-sheared chromatin samples were subjected to cross-link reversal, 
treated with 5 M NaCl, Proteinase K and purified with NucleoSpin® Extract II (Macherey-Nagel, 
Germany). Samples were separated by electrophoresis on a 1 % agarose gel. 
 
Following the optimisation of shearing conditions, Par17QR-Strep-GFP and 
Par17QR-GFP constructs were transfected for 2 – 3 days in HCT116 cells. As de-
scribed in Materials and Methods (Section 2.3.4), the respective cellular lysates 
were fixed in formaldehyde, sheared, reversed cross-linked and pre-cleared. After 
DNA concentration measurement, the eluates obtained from Par17QR-Strep-GFP 
and Par17QR-GFP were sub-cloned into the HindIII and XhoI restriction sites on the 
pCR®2.1-TOPO® vector and transformed in E. coli. 
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Fig 3.7 Blue and white colonies after cloning and transformation of DNA-fragments 
from Par17QR-Strep-GFP and Par17-GFP using pCR®2.1-TOPO® vector  
A) Blue and white colonies from Par17-GFP construct and B) Blue and white colonies from 
Par17QR-Strep-GFP construct. 
 
Blue and white colonies are seen on Fig. 3.7. The pCR®2.1-TOPO® vector contained 
the lacZ gene coding for α -galactosidase responsible for the hydrolysis of galactose. 
The presence of the LacZ gene on the vector allowed for blue/white screening after 
transformation. Fig. 3.7A showed colonies from DNA-fragments from Par17QR-GFP 
and Fig. 3.7B displayed colonies obtained after transformation with DNA-fragments 
from Par17QR-Strep-GFP.  
 
9 and 3 white clones obtained from constructs Par17QR-Strep-GFP and Par17-GFP 
were picked respectively. Minipreps were made using NucleoSpin Plasmid Kit (Ma-
cherey-Nagel, Germany) and the the plasmids containing the DNA fragments were 
digested with HindIII and XhoI restriction enzymes. For unknown reasons, the restric-
tion digestions did not work fully despite several repetitive attempts. Our goal was to 
verify the sizes of the inserted DNA fragments on a 1 % agarose gel. But since we 
were blocked by an unsuccessful restriction of the plasmids, we did not go further 
with sequencing. 
3.3 Transcriptional and Translational Regulation of Par14/Par17 and the Cell 
Cycle 
As stated in the Section 1 of this work, we aimed to study the transcriptional and 
translational regulation of Par14/Par17 in the course of the cell cycle. Pin1, a 
paralogue to Par14/Par17 has been reported to play a role in cell cycle regulation. 
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Therefore, it was interesting to investigate the roles of Par14/Par17 within the cell 
cycle. For a brief overview of Pin1 refer to Section 1.2.1.  
 
The transcriptional regulation experiments were conducted at the Department of Mo-
lecular Oncology affiliated to the Frauenklinik at the University of Leipzig by Dr Levin 
Böhlig. The working group of Dr Böhlig uses an established cell cycle synchronisa-
tion system by means of serum deprivation using human foreskin fibroblasts (HFF). 
We did not have this system in our laboratory at that time. In consequence, we came 
to the consensus that transcriptional experiments should first be carried out in Leipzig 
and if the outcome looks encouraging, the author of this work will go to their labora-
tory to learn this technique. 
 
The findings of the transcriptional regulation experiments will be explained shortly in 
the coming paragraphs. These findings opened more questions and the author of this 
thesis made a 2-day research stay at the laboratory in Leipzig to learn cell cycle syn-
chronisation by serum deprivation. During this time, the first translational regulation 
experiments were also carried out. 
3.3.1 Transcriptional Regulation of Par14 and Par17 across the Cell Cycle 
The transcriptional regulation of Par14 and Par17 across the cell cycle was studied 
with the aid of qRT-PCR technology (Section 2.2.1.1). Human foreskin fibroblasts 
(HFF) were suitable for cell cycle synchronisation by serum deprivation as described 
in Materials and Methods. 
 
After 30 - 36 hrs of starvation by depriving cultured HFFs from FCS, an aliquot of 
1.3 x 107 cells was obtained and termed G0 cells at t = 0. The rest of the cells were 
further cultured in medium containing 20 % FCS to re-stimulate them to enter the cell 
cycle. Normally, 10 % FCS in the culture medium of cells that have not been de-
prived from growth factors is sufficient. Aliquotes of 1.3 x 107 cells were collected 
within 14, 20, and 24 hrs after growth re-stimulation for G1, S and G2/M cells respec-
tively (Tschop et al., 2006).  
 
The determination of the cell cycle phases of harvested cells was determined by 
DNA staining and fluorescence-activated cell sorting (FACS) analysis. The distribu-
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tion of the cells relative to their location during the cell cycle was represented with the 
help of a histogram (Fig. 3.8A). The actual number of cells in the various cell cycle 
phases is shown on Fig. 3.8B. No cell cycle synchronisation method is known to 
date, which achieves a 100 % distribution of cells into the respective phases. 
 
 
Fig 3.8 Cell cycle distribution of synchronised human foreskin fibroblasts (HFF) 
A) Histogram of the percentage of cells present in corresponding cell cycle phases. Cell cycle 
arrest at the respective phases was confirmed by flow cytometric analysis of cellular DNA content 
– FACSCalibur flow cytometer (BD) was used. B) The percentage of cells present in correspond-
ing cell cycle phases is shown. The arithmetic X-Mean is a measure of the fluorescence intensity 
and a value of X-Mean = 200 +/- is a good indication how the fluorochrome (propidium iodide) 
bound to DNA. 
 
Quantitative RT-PCR analyses were done using primers for Par14 and Par17 as pre-
viously described (Mueller et al., 2006). U6 splisosomal RNA (U6 snRNA) was used 
as an internal control since it is abundantly transcribed and highly conserved across 
species (Brow and Guthrie, 1988). Primers for cyclin B2 were employed and the 
transcription of cyclin B2 served as a marker gene for the G2/M phase (Wasner et 
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al., 2003). Transcriptional expression profiles for Par14, Par17, and cyclin B2 were 
normalised against the expression profile for snRNA U6. It was taken that cells in G0 
are quiescent and the percentage mRNA expression was set at 100 for G0 cells har-
vested after serum deprivation. The percentage mRNA expression of Par14, Par17 
and cyclin B2 at G1 was computed by calculating the difference of the exponential 
between the normalised Ct values of the respective genes at G0 and G1 and multi-
plying by 100: 
 % 𝑚𝑅𝑁𝐴 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2^(𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐶𝑡 𝑓𝑜𝑟 𝑔𝑒𝑛𝑒 𝐴 𝑎𝑡 𝐺0 − 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐶𝑡 𝑓𝑜𝑟 𝑔𝑒𝑛𝑒 𝐴 𝑎𝑡 𝐺1) × 100 
 
The same calculation and logic were used to obtain the percentage mRNA expres-
sions at S and G2/M phases for Par14, Par17, and cyclin B2.  
 
 
Fig 3.9 Slight but significant transcriptional up-regulation of Par17 than Par14 in the S 
and G2/M phases of the cell cycle 
qRT-PCR analysis of Par14/Par17 across the cell cycle with synchronised human foreskin fibrob-
lasts (HFF). Synchronisation was achieved by serum deprivation. After 30-36 hrs of serum depri-
vation, cells in G0 were arrested at t = 0 h. HFF cells were re-stimulated with 20 % FCS. G1 cells 
were harvested after t = 14 h; S phase cells harvested after t = 20 h and G2/M cells harvested 
after t = 24 hrs. mRNA levels of Par14/Par17 were normalised using snRNA U6. Cyclin B2 was 
used as a positive control for a gene highly expressed in the G2/M phase. One-way ANOVA was 
performed using R: A language and environment for statistical computing, R Development Core 
Team (2008). The bars are means (+/- SD) from five independent experiments. G0 = Gap 0 
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(quiescent), G1 = Gap 1, S = Synthesis, G2/M = Transition of Gap 2 and Mitosis; * = p α  0.05, ** 
= p α  0.01. 
 
The white and grey columns represent the percentage mRNA expression for Par14 
and Par17 across the cell cycle respectively. The dark blue column shows the per-
centage mRNA expression of cyclin B2 used as marker gene for the G2/M phase. 
The bars are an indication of the standard deviation between five independent ex-
periments conducted. The asterisks on the bars are an indication of the statistical 
significance expressed in p-values. The probability of the observed event occurring 
by chance is less than one in one hundred (** = p α  0.01) or is less than one in 20 (* 
= p α  0.05). One-way analysis of variance (One-way ANOVA) was performed using R 
(A language and environment for statistical computing, R Development Core Team 
(2008), R Foundation for Statistical Computing, Vienna, Austria, and ISBN 3-900051-
07-0). The semi-quantitative RT-PCR analyses were carried out for five independent 
experiments. One-way ANOVA compares the means of two more samples. The re-
sults showed that Par14 and Par17 are slightly up-regulated with expression of Par17 
stronger than that of Par14 in the S and G2/M phases of the cell cycle. 
3.3.2 Translational Regulation of Par14 and Par17 across the Cell Cycle 
The slight but statistically significant transcriptional up-regulation of Par 14 and Par17 
during the S and G2/M phases of the cell cycle warranted the investigation of the 
translational expression of both proteins. Cell cycle synchronisation, FACS and 
western blotting analyses were done as described in Materials and Methods during 
the 2-day research period in Leipzig by the author in collaboration with Dr Levin 
Böhlig. The distribution of the cells in the various phases of the cell cycle was the 
same to that used for the qRT-PCR experiments (Fig. 3.8B). We used the lysates 
from the same cells from which the total RNA had been extracted for the transcrip-
tional investigation experiments. For western blot analyses, the affinity-purified anti-
bodies directed against the PPIase domain of Par14/Par17 and the N-terminal exten-
sion of Par17 were used to detect endogenous Par14 and Par17 respectively (Sec-
tion 3.1). An antibody for α -actin was applied to identify the cognate protein, which 
served as an internal loading control after stripping the membranes from the corres-
ponding Par14 and Par17 antibodies.  
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Fig 3.10 Translational up-regulation of Par14 in the course of the cell cycle  
A) HFF cell lysates were prepared from the indicated cell cycle phases and processed for west-
ern blot analysis using α PPIase (1:1000) and α - actin (1:5000) antisera. 30 µg of protein for each 
cell lysate from the respective phase of the cell cycle was loaded. B) Densitometric analysis of 
Par14 band signals normalised with α - actin band signals in the respective phase of the cell 
cycle. Multi Gauge densitometry software version 3.1 was used.  
 
We saw an up-regulation in the translational expression of Par14 in the course of the 
cell cycle (Fig. 3.10). There was a ~3-fold up-regulation of Par14 in G1 and a ~4-fold 
increase in both S and G2/M phases respectively (Fig. 3.10B). Normalisation of 
Par14 expression was done with α -actin. Firstly, the expression of α -actin at G0 was 
obtained by dividing the value of its band signal area by its self and a factor of 1 was 
obtained. This was done because we considered cells at G0 to be resting and thus 
no relative expression changes. Secondly, the relative expression of α -actin at G1, S 
and G2/M phases was calculated with respect to its expression at G0. This was done 
by dividing the values of the respective band signal areas at G1, S and G2/M by the 
value of the band signal area at G0. This can be explained by the following equation 
for the relative expression at G1: 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺1 =  (𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑎𝑡 𝐺1 –𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙)(𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑎𝑡 𝐺0 –𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙)  
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Thirdly, the normalisation of Par14 expression in the various phases of the cell cycle 
was computed by dividing the value of the band signal area of Par14 at the phase in 
question by the relative expression of α -actin during this phase. The equation below 
elucidates how the normalised expression of Par14 during G1 was obtained. 
 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑃𝑎𝑟14 𝑎𝑡 𝐺1 =  (𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑃𝑎𝑟14 𝑎𝑡 𝐺1 − 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙) 𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺1   
 
Fourthly and lastly, the fold changes of Par14 at G1, S and G2/M were done by divid-
ing the normalised value of Par14 at the respective phase by its normalised value at 
G0. The equation below gives a visualisation of this calculation with respect to G1. 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝑃𝑎𝑟14 𝑎𝑡 𝐺1 =  𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑃𝑎𝑟14 𝑎𝑡 𝐺1
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝑃𝑎𝑟14 𝑎𝑡 𝐺0 
 
After doing all these calculations, it was acknowledged that Par14 was translationally 
up-regulated in the course of the cell cycle and its expression in the S and G2/M was 
~ 4-fold constant.  
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The translational regulation of Par17 within the cell cycle was also studied by western 
blotting. The densitometric analyses of the 17, 24 and 28 kDa bands were done in 
the same manner as described above for Par14. 
 
 
Fig 3.11 Translational down-regulation of Par17 at the S and G2/M phases of the cell 
cycle 
A) HFF cell lysates were prepared from the indicated cell cycle phases and processed for west-
ern blot analysis using α Par17-Ext (1:1000) and anti α -actin (1:5000). α -actin was used as an 
internal loading control. 30 µg of protein for each cell lysate from the respective phase of the cell 
cycle was loaded. B) Densitometric analyses were done for the 17, 24, and 28 kDa bands. Multi 
Gauge densitometry software version 3.1 was used and α -actin was used for normalisation (in-
ternal control). 
 
We saw three protein band signals (17, 24, and 28 kDa) after the use of α Par17-Ext 
on the cellular lysates from the different phases of the cell cycle (Fig. 3.11A). Of in-
terest was the presence of the 28 kDa band that had been previously observed when 
the same antibody was used (Mueller et al., 2006). Besides, the signal of the 28 kDa 
band was very strong as against the 17 kDa signal for Par17 at the G0 phase, which 
was almost absent. We performed densitometric analyses for all of the three bands 
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with the Multi Gauge densitometry software version 3.1 after normalising them with α -
actin as an internal control. The grey columns stood for the quantitation of the relative 
fold changes for the 17, 24 and 28 kDa bands. Par17 was down-regulated at ~ 4 and 
3.5-fold in the S and G2/M phases respectively while the fold changes of the 24 and 
28 kDa bands were more or less constant throughout the cell cycle (Fig. 3.11B). 
3.3.3 Cellular Localisation - Translational Regulation Par17 across the Cell 
Cycle 
This part of the study was carried out entirely in our laboratory after the successful 
establishment of the synchronisation of HFFs cells within the cell cycle by serum de-
privation coupled with FACS analyses for verification. The expression of a 28 kDa 
Par17 variant when unfractionated cellular lysates were used pushed for the investi-
gation of the expression this Par17 protein variant expression in different cellular 
compartments.  
 
The percentage of cells found in the various phases of the cell cycle was determined 
by flow cytometry (Fig. 3.12A). 
 
 
 
 
 
 
A 
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Fig 3.12 Translational down-regulation of Par17 during the S and G2/M phases of the 
cell cycle in the mitochondria 
A) Percentage of cells present in corresponding cell cycle phases is shown. B) FACS and west-
ern blot analyses. The histograms above show the confirmation of cell cycle arrest at the respec-
tive phases by flow cytometric analysis of cellular DNA content of HFF cells. Synchronous cul-
tures of G0, G1, S and G2/M HFF cells were subjected to biochemical cellular fractionation and 
equivalent amounts (30 µg) of the final fractions from each compartment in the respective cell 
cycle phase were used for analyses and probed by immunoblotting with α N-Terminal Par17 
(1:1000), α Cytochrome C (1:2000), α p84 (1:2000), α Cyclophilin B (1:3000) and α -actin (1:5000). 
Antibodies against cytochrome C, cyclophilin B and p84 were used to benchmark the mitochon-
drial, cytosolic and nuclear fractions respectively. C) Densitometric analyses of the 17 and 28 kDa 
B 
C 
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bands using the Multi Gauge densitometry software version 3.1. α -actin was used as an internal 
control for normalisation. 
 
Sub-cellular biochemical fractionation was done with the aid of Qproteome mitochon-
dria isolation kit (Qiagen, Germany). The kit allows the separation of the cell into its 
cytosolic, mitochondrial, and nuclear constituents. In order to be sure that the iso-
lated fractions for the respective cellular compartments where typical for the physio-
logical state, different proteins specific for these compartments were used to charac-
terise these fractions. An antibody against cytochrome C was used to benchmark the 
mitochondrial fraction. Antibodies against cyclophilin B and nuclear matrix protein 
p84 were used for the characterisation of the cytosolic and nuclear fractions respec-
tively. α -actin was used as an internal control for equal loading and its constant ex-
pression in the respective compartments for each cell cycle phase is shown 
(Fig. 3.12B). 
 
We performed densitometric analyses with the Multi Gauge software version 3.1 to 
determine the relative expression of Par17 and the 28 kDa variant across the cell 
cycle in the respective cellular compartments (Fig. 3.12C). The expressions of Par17 
and the 28 kDa variant were normalised with respect to the expression of α -actin 
whose expression at G0 was kept constant. The equation underneath sheds light on 
how this was done for the expression of Par17 during the G2/M in the mitochondria: 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑜𝑓 𝑃𝑎𝑟17  𝑎𝑡 𝐺2𝑀 𝑖𝑛 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎 =  (𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑃𝑎𝑟17 𝑎𝑡 𝐺2𝑀 𝑖𝑛 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎 –𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙)
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺2𝑀 𝑖𝑛 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎× 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺0 𝑖𝑛 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎(𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑃𝑎𝑟17 𝑎𝑡 𝐺0 𝑖𝑛 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎 − 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙) 
 
The normalised value of α -actin at G2/M in the mitochondria was done as follows: 
 
𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝑣𝑎𝑙𝑢𝑒 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺2𝑀 𝑖𝑛 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎 =  (𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺2𝑀 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎 –𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙)(𝐵𝑎𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑟𝑒𝑎 𝑜𝑓 𝛽 − 𝑎𝑐𝑡𝑖𝑛 𝑎𝑡 𝐺0 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎 –𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙)  
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To obtain the relative expression of Par17 and its 28 kDa variant at G0, G1 and S 
phases in the different celluar fractions, the equations above were adapted and used 
respectively. The dark blue columns revealed the relative expression of the 28 kDa 
variant across the cell cycle in the cytosol. The grey columns showed the relative ex-
pression of Par17 and the 28 kDa variant in the course of the cell cycle in the nu-
cleus. The relative expression of Par17 and its 28 kDa variant within the cell cycle 
are shown by columns in black in the mitochondria. It is seen that Par17 was sub-
stantially down-regulated in the S and G2/M phases in the mitochondria (Fig. 3.12B). 
The band signal for Par17 was almost absent in the S phase and it was extremely 
weak in the G2/M phase (~ 3-fold decrease) in the mitochondria (Fig. 3.12C). 
 
After studying the transcriptional and translational expression of Par14/Par17 with 
respect to the cell cycle phases, we decided to search for potential interaction part-
ners of both proteins. We were also interested to know if any of the potential interac-
tion partners are cell cycle related proteins. 
3.4 Protein-Protein Interactions of Par14/Par17 
In our search of possible interaction partners for Par14/Par17, we used a 
Par17QRStrep-GFP construct, which had both Strep and His tags. We know that 
Par17 is the elongated isoform of Par14 since the only difference between both pro-
teins is in the N-terminal 25-amino acid extension of Par17 (Kessler et al., 2007; 
Mueller et al., 2006). As a result, we reasoned that the potential binding partners for 
Par17 that we shall identify could as well be interaction partners for Par14. In the 
course of the results and discussion sections, we will make particular references if 
one of the potential binding partners found suits for Par14 or Par17 or for both. 
3.4.1 Silver Staining of Strep-tag II Affinity Purified Par17 Fusion Protein 
The transfection efficiency of HCT116 cells with constructs Par17QRStrep-GFP and 
Par17QR-GFP was evaluated by cell counting using a fluorescence microscope to be 
more than 60 %. The cellular lysates obtained after the transfection in HCT116 cells 
with Par17QRStrep-GFP and Par17QR-GFP constructs were ran on a 1 ml Strep-
Trap HP column pre-packed with Strep-Tactin sepharose attached to an ÄKTApuri-
fier 10/100 UPC-900 (GE Healthcare, Germany). The UV-absorption chromatogram 
at 280 nm on Fig. 3.13A depicts the run. UV-absoprtion was measured in milli-
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absorbance-units (mAU) shown on the y-axis and the wash and eluted fractions (F) 
are shown as a measurement in volumes (ml) on the x-axis. Protein signals were 
seen as a measure of the peak area given by the absorption in mAU multiplied by the 
volume in ml. The chromatogram shows sub-peak areas of proteins eluted with 50, 
150 and 500 mM NaCl and with 2.5 mM desthiobiotin. This was done with the aid of 
the Unicorn software (GE-Healthcare, Germany) that was part of the ÄKTApurifier 
10/100 UPC-900 system. The aliquots of fractions in which we saw protein signals 
were collected and ran on a 12.5 % SDS-PAGE followed by silver staining. 2 ml of 
fractions of interest were collected and 15 µl for each were used for silver staining 
(Fig. 3.13B). 
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Fig 3.13 Chromatogram and Silver-stained Gel of Proteins pulled-down with 
Par17QRStrep-GFP construct 
A) UV-absorption chromatogram at 280 nm. X-axis shows fractions (F) of wash and elution steps 
after the application of HCT116 cellular lysates transfected with Par17QRStrep-GFP on a Strep-
Tactin column attached to an ÄKTApurifier 10/100 UPC-900. Y-axis shows the UV-absorption in 
milli-absorbance-units (mAU). B) Silver stain of the wash and eluted fractions. F1-F10: flow-
through; F11: wash-through; F17 and F18: proteins eluted with 50 mM NaCl; F26 and F27: pro-
teins eluted with 150 mM NaCl; F37 and F38 proteins eluted with 500 mM NaCl, F48-F55: wash-
through with 0 mM NaCl and F56, F57 and F61-F72 pooled fractions of proteins eluted with 
2.5 mM desthiobiotin. 
 
Fraction F1-F10 contained unbound proteins that flew through the column 
(Fig. 3.13B). The column was washed with binding buffer and fraction F11 was col-
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lected. A sharp difference in the amount of proteins present could be seen between 
the flow-through F1-F10 and wash-through F11 indicating a substantial amount of 
unspecific proteins flew through and were washed away during these steps. The first 
elution procedure that followed was done using an increasing salt gradient from 50, 
150, to 500 nM NaCl since we reasoned that interactions between Par14/Par17 and 
its binding partners might be under electrostatic influence. Fraction F17 and fraction 
F18 showed samples that were obtained after elution with 50 mM NaCl, whereas 
fractions F26 and F27 were eluted with 150 mM NaCl. Fractions F37 and F38 
(Fig. 3.13B) were samples obtained after the elution with 500 mM NaCl. Fig. 3.13B 
shows that no substantial amounts of proteins were pulled-down as a result from the 
salt gradient elutions. 
 
The second elution procedure was performed with 2.5 mM desthiobiotin. Desthiobio-
tin binds to Strep-Tactin and elution with desthiobiotin served as a competitor to push 
away Strep-tag II bound proteins from the column. Before elution with desthiobiotin, 
the column was washed again with binding buffer, which was devoid of salt. Frac-
tions F48-F55 were pooled from this washing step. Fractions F56, F57, and F61-F72 
were pulled-down with 2.5 mM desthiobiotin. Fractions F61-F72 were pooled. The 
bands at about molecular weights of 75-85 kDa appeared to be procedural artefacts. 
They were redundant at the elution steps with NaCl, wash step with 0 NaCl and for 
fractions F56 and F57. A high density of proteins pulled-down in the fractions F61-
F72 could be seen, which suggested that these were proteins that interacted with the 
heterologously expressed Par17 fusion protein.  
 
The procedure explained in Fig. 3.13A and B was repeated for the control construct 
Par17QR-GFP, which was devoid of the Strep-tag II (Fig. 3.14A and B). The num-
bering of the fractions were different as in Fig. 3.13 but the logic was the same. Pro-
teins were also eluted using 2.5 mM desthiobiotin with the pooled fraction F51-F67 of 
the control construct. 
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Fig 3.14 Chromatogram and Silver-stained Gel of Proteins pulled-down with Par17QR-
GFP construct 
A) UV-absorption chromatogram at 280 nm. X-axis shows fractions (F) of wash and elution steps 
after the application of HCT116 cellular lysates transfected with Par17QR-GFP on a Strep-Tactin 
column mounted to an ÄKTApurifier 10/100 UPC-900. Y-axis shows the UV-absorption in milli-
absorbance-units (mAU). B) Silver stain of the wash and eluted fractions. F1-F4: flow-through; 
F5: wash-through; F13 and F15: proteins eluted with 50 mM NaCl; F21 and F22: proteins eluted 
with 150 mM NaCl; F28 and F29 proteins eluted with 500 mM NaCl; F43-F50: wash-through with 
0 mM NaCl and F51-F67 pooled fraction of proteins eluted with 2.5 mM desthiobiotin. 
Visual inspection acknowledged the fact that more proteins were eluted with the 
Par17QRStrep-GFP construct for fractions F61-F72 (Fig 3.13B) in comparison to the 
proteins obtained from the control construct Par17QR-GFP for fractions F51-F67 
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(Fig 3.14B). This acknowledgement edged us to identify proteins that were eluted in 
both pooled fractions by tandem mass spectrometry. Aliquots of eluted fractions F61-
F72 and F51-F67 with 2.5 mM desthiobiotin were sent to the Medizinisches Proteom-
Center affiliated to the Ruhr University of Bochum, Germany. Dr Barbara Sitek and 
her team performed an analytical silver gel as shown in Fig. 3.15 that also repro-
duced our silver stainings in terms of the amount of the pulled-down proteins seen in 
the respective fractions. After this first analytical gel, they performed a second SDS-
PAGE gel in which electrophoresis was paused immediately the proteins entered the 
resolving gel not allowing them to separate in their entirety. This was a measure to 
get the conglomerate of proteins in the respective samples before they got separated 
so that a differential protein determination via tandem mass spectrometry analysis 
could be done. We postulated that proteins identified in the test construct and absent 
in the control construct should be potential interaction partners to Par14/Par17 and 
proteins found from both constructs were considered to be unspecific binders. 
 
 
Fig 3.15 More proteins pulled-down with Par17QRStrep-GFP construct as compared to 
Par17QR-GFP construct 
Silver stain compatible with mass spectrometry of 2.5 mM desthiobiotin eluted pooled fractions 
F61-F72 (Par17+) and (Par17-) for constructs Par17QRStrep-GFP and Par17QR-GFP respec-
tively. 
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3.4.2 Identification of Par14/Par17 Affinity Purified Coupled with Mass Spec-
trometry Interactors 
After the silver-stained protein bands for fractions F61-F72 (Par17QRStrep-GFP) and 
F51-F67 (Par17QR-GFP) were cut off from the gel, they were processed for tandem 
mass spectrometry as described in Section 2.3.8. The identification of proteins was 
done with the Mascot search engine that supports MS/MS ions data and the incorpo-
ration of a probability-based scoring (Perkins et al., 1999). The principle behind prob-
ability-based scoring is justified by the fact that the observed match between the ex-
perimental data set and each sequence database entry is a chance event. This im-
plies that the best match is the match with the lowest probability (Perkins et al., 
1999). As a rule of thumb to determine the significance of a match between an ex-
perimental data set and a database entry, the probability of the observed event oc-
curring by chance should be less than one in twenty (p < 0.05).  
 
Besides, the probability for a good match is usually a very small number, which must 
be expressed in scientific notation. This can be a bane for the analyses of MS/MS 
identified proteins. To circumvent this, Perkins and co-workers reported the conven-
tion often used in sequence similarity searches and report a score that is 10Log10 (P), 
where P is the probability (Perkins et al., 1999). This implies that the best match is 
the one with the highest score and a significant match should have a score of the 
order 70. In the evaluation of the proteins revealed by the Mascot search engine, we 
adopted the convention that for a protein to be accepted as identified a score of an 
order α  22.5 and at least 2 or more peptides or a score α  70 and at least 1 peptide of 
the identified protein must be present. Table 3.1 shows Par14/Par17-associated 
identified proteins that met the conditions of the above convention. 
Table 3.1 Identification of Par14/Par17-associated proteins by affinity purification 
coupled with mass spectrometry (AP-MS) 
Proteins  Accession Score Peptides MW 
(kDa) 
Cellular 
Compartment 
 
Protein translation       
TARS  Threonyl tRNA 
synthetase 
IPI00910719 32.9 2 70.3 Cytoplasm  
HARS  Histidyl-tRNA 
synthetase 
IPI00909075 48.9  2 35.6 Cytoplasm  
EEF1A2  Eukaryotic translation 
elongation factor 1 
alpha 2 
IPI00556204 73.8 2 36.9 Cytoplasm, 
nucleus 
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RNA processing       
SFRS1  Splicing factor, argi-
nine/serine-rich 1 
IPI00218592 70.8  1 70.8 Nucleus, 
cytoplasm 
 
HNRNPA2B1  Heterogeneous nuc-
lear ribonucleoprotein 
A2/B1 
IPI00916517 87.0  2 34.2 Nucleus, 
cytoplasm 
 
Ribosome biogenesis       
NCL  Nucleolin IPI00444262 118.0  5 65.9 Nucleus, 
nucleolus 
 
NPM1  Nucleophosmin IPI00658013 29,8 1 28.4 Nucleus, 
nucleolus 
 
Cell adhesion & cytoskeleton       
EZR Ezrin IPI00872684 388.8 14 69.3 Cytoskeleton, 
plasma membrane 
ACTB Actin, beta IPI00894365 49.6 2 39.2 Cytoskeleton, 
cytoplasm 
LMNA  Lamin A/C IPI00655812 97.4 3 55.6 Cytoplasm, 
nucleus, plasma 
membrane 
SHROOM4  Shroom family mem-
ber 4 
IPI00845416 32.3 2 152.7 Cytoskeleton, 
Cytoplasm, nucleus 
SPTAN1  Spectrin SHD00871535 47.3 2 284.9 Cytoskeleton, 
cytoplasm 
Signal transduction       
CKB Creatine kinase, 
brain 
IPI00908811 53.8 2 38.7 Cytoplasm, 
mitochondrion 
YWHAE  14-3-3 protein epsilon IPI00000816 102.2 4 29.2 Cytoplasm, 
mitochondrion 
Metabolism        
GOT2 Aspartate 
aminotransferase 2 
(mitochondrial) 
IPI00910267 59.4 2 43 Mitochondrion  
TKT  Transketolase IPI00792641 104.8 3 58,9 Cytoplasm  
Annexin        
ANXA1  Annexin A1 IPI00549413 79.3 3 22.7 Plasma membrane, 
cytoplasm, nucleus  
ANXA2  Annexin A2 IPI00455315 114.0 4 38.6 Plasma membrane, 
cytoplasm, nucleus 
ANXA5 Annexin A5 IPI00872379 50.2 2 35.8 Plasma membrane, 
cytoplasm, nucleus 
Peptidyl prolyl isomerases       
PPIA  Cyclophilin B IPI00925411 36.6 2 13 Cytoplasm, nucleus  
PPIB  Cyclophilin A IPI00646304 58.3  2 23.7 endoplasmic 
reticulum 
Chaperone proteins       
HSP90AA1  Heat shock protein 
90kDa alpha, class A 
member 1 
IPI00784295 223.5 7 84.6 Cytoplasm  
HSP90AB1  Heat shock protein 
90kDa alpha, class B 
member 1 
IPI00414676 242.5  7 83.2 Cytoplasm  
HSPA4 Heat shock 70kDa 
protein 4 
IPI00002966 108.6  3 94.3 Cytoplasm, 
nucleus  
 
HSPA5  Heat shock 70kDa 
protein 5 
IPI00003362 252.0  6 72.4 endoplasmic 
reticulum, nucleus 
HSPA9  Heat shock 70kDa 
protein 9 
IPI00922694 50.1  2 69.9 Mitochondrion, 
cytoplasm 
Protein disulfide isomerases       
P4HB  Prolyl 4-hydroxylase, IPI00010796 103.3  2 57.1 endoplasmic 
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beta polypeptide reticulum,plasma 
membrane 
PDIA3  Protein disulfide iso-
merase family A, 
member 3 
IPI00025252 201.3  7 56.7 endoplasmic 
reticulum 
PDIA4  Protein disulfide iso-
merase family A, 
member 4 
IPI00009904 61.0  2 72.9 endoplasmic 
reticulum 
Unclassified        
PRDX1  Peroxiredoxin 1 IPI00640741 126.2 4 19 Cytoplasm, 
nuleus 
 
NCAPG2  Isoform 1 of Conden-
sin-2 complex subunit 
G2 
SHD00797030 31.0 2 130.9 Nucleus  
NOMO1 NOMO1;NOMO3 139 
kDa protein 
SHD00413732 44.2 2 139.3 Plasma membra-
ne 
 
 
The proteins on Table 3.1 that met our criteria for identification have been classified 
in various groups based on a functional property that they might share in common. 
Proteins involved in the translational apparatus, RNA-processing, ribosome biogene-
sis, cell adhesion and the cytoskeletal network, signal transduction, metabolism, 
chaperones and peptidyl-prolyl and protein disulfide isomerases were found. Cellular 
compartments and molecular masses of the identified proteins are also listed on Ta-
ble 3.1. The highest score of 388.8 is seen for EZR, a protein that is part of the cy-
toskeletal network. 
 
After identifying some potential interaction partners of Par14/Par17, it was mandatory 
to investigate the up- and down-regulation of some of these proteins in the case that 
Par14/Par17 was absent. 
3.5 Par14/Par17 Gene Knock-Down Experiments 
Two approaches of siRNA technology were used to knock-down Par14/Par17. We 
first used synthetic double-stranded siRNAs in a pool consisting of 4 siRNAs specific 
for Par14/Par17. After transfection, fixation and staining were done as described in 
Materials and Methods. Cells were visualised using an Olympus BX61 fluorescence 
microscope (Fig. 3.16A; first column; top and bottom rows). The second column de-
picted cells treated with scrambled siRNA with no known sequence homology to any 
human gene, and the third column represented cells that were not treated with any 
form of siRNA. Transfection was stopped for cells treated with Par14/Par17 specific 
siRNA pool and scrambled siRNA after 72 hrs (Fig. 3.16A).  
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Fig 3.16 Study of morphological changes and protein knock-down levels with siRNAs 
in a pool specific to Par14/Par17  
A) 4 Par14/Par17 siRNAs in a pool were transfected in HeLa cells for 72 hrs. A scrambled siRNA 
sequence with no homology to any human gene was co-transfected. Transfected cells where 
stained with DAPI and PI and observed under a fluorescence microscope in bright field. B) HeLa 
lysates were prepared for western blot analyses with Par14/Par17 siRNAs in a pool after 48, 72, 
and 96 hrs of transfection. 
 
For western blot analyses, lysates of HeLa cells were used after being treated with 
Par14/Par17 siRNAs in a pool and the scrambled siRNA. Lane 1 was the lysate of 
E. coli over-expressing Par17 and was used as a positive control for the α PPIase 
antiserum for the detection of Par14 or Par17 (Fig. 3.16B). This antibody was the un-
purified final bleeding of α PPIase. Lanes 2, 3, and 4 were from lysates obtained after 
the transfection with Par14/Par17 siRNAs for 48, 72, and 96 hours respectively. 
Lanes 5 – 7 and lanes 8 – 10 were lysates from the treatment with the scrambled 
siRNA for 48, 72, and 96 hrs and from untreated cells cultured also for 48, 72, and 96 
hrs respectively. Since we could not achieve an appreciable knock-down at the pro-
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tein level and no observable morphological changes of the cells could be appreici-
ated, we then moved to the second approach to the elicit knock-down. 
 
Our second strategy with siRNA technology was the use of shRNAs cloned in to a 
plasmid. Three Par14/Par17 shRNAs and one shRNA for luciferase were cloned by 
GenScript, USA into pRNTin-H1.2/Hygro and pRNATin-H1.3/Hygro/siFluc vectors 
respectively. After a 72-hour transfection with all three Par14/Par17 shRNAs and the 
luciferase shRNA, HeLa cells were fixed and stained with DAPI. Fluorescence micro-
scopic observations were performed as was the case with double-stranded synthetic 
siRNAs in a pool. shRNA-1, shRNA-2 and shRNA-3 are shown on the upper row 
from left to right respectively (Fig. 3.17A). Cells treated with siRNA-Luc are on the 
bottom row. 
 
HeLa lysates from shRNAs 1 - 3, siRNA-Luc, and that from untreated cells were used 
for western blot analyses. The lysates were prepared after 48, 72, and 96 hrs of 
transfection with the respective shRNAs (Fig. 3.17B). α PPIase (not affinity-purified) 
was used for detection of endogenous Par14/Par17 and rhPar14 was employed to 
verify the efficiency of the antibody. 
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Fig 3.17 Study of morphological changes, mRNA and protein knock-down levels with 
shRNAs specific to Par14/Par17 
A) 3 shRNAs specific to Par14/Par17 were cloned into pRNTin-H1.2/Hygro vector and trans-
fected in HeLa cells for 72 hrs. The shRNA for luciferase in pRNATin-H1.3/Hygro/siFluc vector 
was also transfected for 72 hrs. Both vectors coded for the reporter gene GFP that was used as a 
transfection indicator. The transfected cells were stained with DAPI and observed under a fluo-
rescence microscope. B) HeLa lysates were prepared for western blot analyses with Par14/Par17 
shRNAs and luciferase shRNA after 72 hrs of transfection. C) qRT-PCR was performed from 
HCT116 cells transfected with Par14/Par17 shRNAs and luciferase shRNA after 72 hrs of trans-
fection. The white column shows the % KD of Par14 and Par17 with shRNA-3, the gray columns 
display the % KD for shRNA-1 for both genes and the blue columns depicts the % KD for shRNA-
2 for both genes. The black columns stand for the % KD of the control shRNA-Luc in Par14 and 
Par17. For western blot and qRT-PCR analyses, lysates of untransfected cells were also used. 
 
To look at the mRNA levels of Par14/Par17 with the Par14/Par17 shRNAs used, we 
performed qRT-PCR experiments (Materials and Methods). Here, HCT116 cells 
were used instead of HeLa cells because they had higher transfection efficiencies of 
more than 60 % and this was not the case with HeLa cells where transfection effi-
ciencies stood at 30 %. For each shRNA, transfection was done for 72 hrs in tripli-
cates in 12-well plates and for the RNA isolated from each well duplicates of the 
crossing point (Ct) values were measured. The percentage knock-down was calcu-
lated as explained in Section 2.4 and as shown on Fig. 3.17C. The columns in white 
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represented the % KD of Par14/Par17 with the shRNA-3 construct. The gray and 
blue columns showed the % KD achieved by construchts shRNA-1 and shRNA-2 for 
Par14/Par17 respectively. The % KD for the shRNA-Luc is shown on the black col-
umns for Par14/Par17. The bars on the columns were a reflection of the standard 
deviations in the three independent experiments carried out with the respective 
shRNAs constructs. A 10 % KD is seen for Par14/Par17 when shRNA-2 was used. 
The other shRNA constructs achieved a knock-down of Par14/Par17 mRNA in a 
magnitude of α  2 %. 
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4.  Discussion 
4.1 Par14, Chromatin and DNA-Binding in vivo 
Given the enrichment of Par14 in the nucleus and its structural and sequence identity 
to HMGB and HMGN proteins, it was pivotal to investigate the sub-nuclear localisa-
tion of Par14 so that clues to its cellular function could be obtained. Two biochemical 
fractionations were performed that fractionated the nucleus. In the sub-nuclear frac-
tionation 1, we obtained fractions S3- (soluble nucleoplasmic proteins) and P3- 
(chromatin-nuclear matrix bound proteins). We saw a trend that the Par14 signal in 
the P3- was stronger than the signal in the S3- fraction. The use of MNase to release 
DNA-bound proteins was less effective as seen for fractions S3+ (solubilised nuclear 
proteins) and P3+ (solubilised chromatin-nuclear matrix bound proteins). The purity 
of the fractions was monitored with the use of marker proteins characterising these 
fractions. The indications showed that Par14 probably associated with chromatin-
nuclear matrix bound proteins and this paved the way for the next sub-nuclear frac-
tionation scheme. 
 
The sub-nuclear fractionation 2 was particular in being able to discriminate between 
chromatin and nuclear matrix proteins. We acknowledged strong Par14 signals (3- 
and 2-fold) in the S2+ and S2- chromatin fractions respectively as opposed to the 
signals that were seen in the S3+ and S3- nuclear matrix fractions. The chromatin 
fraction S2+, which was treated with DNase I, showed a stronger band signal for 
Par14 (1.4-fold) than the fraction S2-, which was not treated with the nuclease. This 
suggested that Par14 preferably bound to DNA on chromatin. DNase I treatment of 
nuclear matrix fraction S3+ showed no difference to the fraction S3- that  was not 
treated with the nuclease. Our results suggest that Par14 is a chromatin protein since 
it was enriched in the chromatin fractions than in the nuclear matrix fractions and was 
also released with DNA following DNase I treatment. 
 
Furthermore, we saw in the fractionation of nuclear and nucleic acid-binding proteins 
that Par14 was eluted with increasing salt concentrations from the fraction that was 
termed nucleic acid-binding. Par14 band signals could be seen for eluates E2 and E3 
that were eluted with 0.35 and 1 M NaCl. The manufacturers of the kit (Qiagen, Ger-
many) that was used to perform the fractionation procedure claimed that the proteins 
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contained in the nucleic acid-binding fraction are low-abundant nuclear proteins such 
as transcription factors. We validated our fractionation scheme (Fig 3.4B) by using 
nuclear matrix protein p84, a transcription factor that was detected in the eluate E1 
and E2 that was eluted with 0.1 and 0.35 M NaCl respectively. In DNA cellulose affin-
ity experiments, total cell extracts and recombinant Par14 were used to show that 
Par14 bound to DNA in vitro (Surmacz et al., 2002). 
 
To mention, ASCC2 was reported to interact with Par14/Par17 in a yeast two-hybrid 
assay (Stelzl et al., 2005) and it was found to be a member of a novel transcription 
co-activator complex (Jung et al., 2002). In the same yeast two-hybrid screen, poly-
comb group (PcG) protein EZH2 (Enhancer of Zeste homologue 2), a histone methyl-
transferase associated with transcriptional repression, was reported as an interactor 
to Par14/Par17. Fujiyama and colleagues demonstrated that nucleolin interacted with 
Par14 (Fujiyama et al., 2002; Fujiyama-Nakamura et al., 2009) and in our protein-
protein interaction studies (Section 3.4.2), we shortlisted nucleolin to be a potential 
interaction partner to Par14/Par17. In co-immunoprecipitation experiments, Rickards 
and co-authors confirmed nucleolin to be associated with chromatin-containing rRNA 
genes transcriped by RNA polymerase I and not with genes transcribed by RNA po-
lymerase II or III (Rickards et al., 2007). They proposed that the function of nucleolin 
is to permit the transcription of nucleolar chromatin by RNA polymerase I. Further-
more, nucleolin was reported as a nuclear protein with a histone chaperone function 
(Angelov et al., 2006). Its histone chaperone activity enhanced the activity of chroma-
tin remodelling machineries such as SWI/SNF and ACF. All these lines of evidence 
show Par14/Par17, more likely Par14, to interact with the aforementioned proteins 
that play a role in transcription. 
 
Other proline isomerases have also been shown to be associated with chromatin. 
The nuclear FKBP, SpFkbp39p from Schizosaccharomyces pombe was reported to 
be a histone chaperone regulating rDNA silencing and it influenced chromatin or-
ganisation both in vivo and in vitro (Kuzuhara and Horikoshi, 2004). Still in yeast, 
Fpr4, a member of the FKBPs in Saccharomyces cerevisiae was shown to bind the 
amino-terminal tail of histones H3 and H4 and catalyses the isomerisation of histone 
H3 proline P30 and P38 in vitro (Nelson et al., 2006). In the same work, they also 
showed that the abrogation of Fpr4 catalytic activity in vivo resulted in increasing lev-
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els of H3K36 methylation and delayed transcriptional induction kinetics of yeast-
specific genes. The work summarises proline isomerisation as a novel non-covalent 
histone modification that regulates transcription and provides evidence for crosstalk 
between histone lysine methylation and proline isomerisation. Above all, Pin1 and its 
orthologue Ess1, haven been demonstrated to modulate the C-terminal domain 
(CTD) of RNA polymerase II (Pol II) during the transcriptional cycle (Krishnamurthy et 
al., 2009; Xu and Manley, 2007). The CTD is the largest subunit of Pol II and con-
tains repeatedly the heptad sequence (Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7) that 
plays a key role in the transcription cycle, coordinating the exchange of transcription 
and RNA processing factors. CTD has a structurally flexible structure that undergoes 
conformational changes in the advent of serine phosphorylation and proline isomeri-
sation by Pin1/Ess1, which then have an effect on the transcription of genes. How-
ever, the role of Par14 in transcription remains to be proven experimentally. 
4.1.1 Par14 and Polytene Chromosomes 
It was experimentally difficult to establish an unequivocal association of Par14 with 
polytene chromosomes by indirect immunostainings. In an effort to circumvent the 
not so successful immunostainings of polytene chromosome squashes, we per-
formed a complementary experiment. Immunoblots were conducted using the nu-
clear extracts of Kc cells from Drosophila melanogaster, which per se embodies 
polytene chromosomes. A protein band of 14 kDa was detected when the α PPIase-
was used as opposed to the use of the preimmune antisera of α PPIase (Fig. 3.5C). 
14 kDa is the molecular weight for endogenous Par14 in both organisms. Neverthe-
less, Par14 was reported in immunofluorence studies to have apparently accumu-
lated around chromosomes during mitosis (Fujiyama-Nakamura et al., 2009). This 
line of evidence adds weight to our findings that Par14 is a chromatin and DNA-
binding protein. 
4.1.2 Chromatin Affinity Purification (ChAP) 
One of the questions to be addressed in the course of this thesis was the search 
DNA-binding motifs of Par14/Par17. We used sheared cellular lysates after the trans-
fection of HCT 116 cells with Par17QR-GFP and Par17QR-Strep-GFP constructs. 
The use of transfection to characterise DNA binding sites using formaldehyde cross-
linking has previously been reported (Wells and Farnham, 2002). Before this step, we 
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had to optimise the shearing conditions. We agreed on shearing the transfected cel-
lular lysates at 8 pulses for 15 sec with a 30 sec rest on ice between each pulse 
(Fig. 3.6). At this pulse rate, we could see DNA smears in the range of about 700 – 
800 bp. This was in line with shearing efficiency to obtain DNA fragments for subse-
quent use that should be in the range of 200 – 1500 bp. 4 and 12 pulses were also 
tried and smears were also in this range. In effect, any of the pulse rates tried could 
have been used. 
 
The sheared chromatin from both constructs were further processed and sub-cloned 
in the pCR®2.1-TOPO® vector and transformed in E. coli. Blue and white screening 
was used to discriminate between clones that contained DNA fragments. White 
clones will test positive and blue clones will not. We observed in Fig. 3.7A that there 
were far less white clones than in Fig. 3.7B. The presence of more clones from 
Pa17QR-Strep-GFP was an indication that more DNA was pulled-down with this 
construct than with the Par17QR-GFP construct. Minipreps were made for clones 
from the respective constructs. We performed restriction digestions with HindIII and 
XhoI in order to very the sizes of the inserts. After several attempts, we could not get 
successful digestions and this hindered the processing of the clones for sequencing. 
Following careful trouble-shooting, the entire experiment will be repeated. Par14 
shows sequence and structural similarity to HMGN and HMGB proteins and was 
shown by fluorescence titration and electromobility shift assays to bind to AT-rich 
DNA oligonucleotides (Surmacz et al., 2002). AT-rich sequences of DNA are sug-
gested to dictate nucleosome positioning and play a role in the initiation of transcrip-
tion (Mueller and Bayer, 2008). The basic domain of Par14, which is also embodied 
in Par17, has sequence similarity to the chromatin-unfolding domain (CHUD) in 
HMGN proteins. This basic domain was indispensible for high affinity DNA-binding. 
Moreover, Par17 was demonstrated to bind to DNA in vitro at physiological salt con-
centrations (Kessler et al., 2007). Based on these arguments and with the data pre-
sented here so far, it is of paramount interest to investigate the DNA-binding motifs of 
both proteins in vivo. 
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4.2 Transcriptional and Translational Regulation of Par14/Par17 across the Cell 
Cycle 
The data from our qRT-PCR analyses showed to a certain degree that Par17 was 
more up-regulated during the S and G2/M phases as compared to its isoform Par14 
(Fig. 3.9). Minimal fold changes were observed for the mRNA expression of Par14, 
Par17, and cycline B2 at G1. Par14 and Par17 showed a 2- and 3-fold increase in 
expression at the S phase respectively. 3 and 5-fold increments in the expression for 
Par14 and Par17 at the G2/M phase were observed respectively. The expression of 
cyclin B2 in the S-phase was 6-fold as compared to a 10-fold increase in expression 
during G2/M phase. Cyclin B2 is a marker protein for the G2/M phase (Tschop et al., 
2006). 
 
Western blot analyses investigating the expression of Par14 showed an up-regulation 
during the cell cycle (Fig. 3.10). The signal for Par14 at G0 was very faint and this 
was also reflected in the weak signal of α -actin in the same phase. We argue that this 
observation was a result of an unequal amount of protein that was loaded. The anti-
serum for α -actin was applied after stripping the same membrane on which the 
α PPIase was applied. α -actin was used for the normalisation of Par14 expression. 
The 2 and 3-fold transcriptional increase of Par14 in the S and G2/M phases 
(Fig. 3.9) corrolated with a 4-fold translational up-regulation of Par14 in these phases 
(Fig. 3.10). 
 
We saw ~ 5-fold increase in the translational expression of Par17 during the G1 
phase and ~ 4- and 5-folds increases at the S and G2/M phases respectively (Fig. 
3.11). The expressions of the 24 and 28 kDa species were almost constant through-
out G1, S and G2/M phases. The increase of Par17 protein expression is directly 
proportional to the transcriptional increase of its mRNA during the S and G2/M phas-
es of the cell cycle (Fig. 3.9). The occurrence of the 28 kDa species made us to in-
vestigate if the same scenario will occur when HFF cells were fractionated into cyto-
sol, nuclei and mitochondria. 
 
The nucleus is not the physiological compartment of Par17 but the mitochondria 
(Kessler et al., 2007). The observation of protein expression in the nuclear fraction 
can be justified by the fact that this fraction was impure and did not only contain nu-
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clear proteins but also contained cell debris and unbroken cells. This should explain 
the presence of Par17, which was seen in the nuclear fractions during G1 and G2/M 
phases. The expression of Par17 in the mitochondria during the G0 and G1 phases 
was approximately constant but an almost null expression was observed during the S 
and an almost constant expression in the G2/M phases in the mitochondria. We also 
saw the almost constant expression of the 28 kDa variant throughout the phases of 
the cell cycle in the cytosol, nuclei and mitochondria in a similar manner observed 
when unfractionated cellular lysates were used.  
 
At the time when our group was characterising Par17 as a novel isoform of Par14, 
they acknowledged the occurrence of the 28 kDa band in cellular lysates (Mueller et 
al., 2006). They purported a potential SUMOylation or ubiquitylation as possible post-
translational modifications. They argued this because of the 11 kDa difference in the 
molecular weights of endogenous Par17 and this putative modified varaint weighing 
28 kDa. Western blot analyses with antibodies for SUMO und ubiquitin failed to de-
tect this 28 kDa in cellular lysates. We observed this 28 kDa variant of Par17 in our 
cell cycle experiments. We also saw an increase in the transcriptional up-regulation 
of Par17 in the S and G2/M phases, which was proportional to the amount of the pro-
tein expressed in these phases when the cells were not fractionated into cytosol, nu-
cleus, and mitochondria. Upon cellular fractionation, we saw a tendential down-
regulation of Par17 in the S and G2/M phases in the mitochondria. The mitochon-
drion is the physiological compartment of Par17. Therefore, we can speculate that 
total Par17 mRNA is expressed as the sum of Par17 protein plus Par17 protein vari-
ant of 28 kDa. |𝑃𝑎𝑟17 𝑚𝑅𝑁𝐴| = |𝑃𝑎𝑟17 𝑃𝑟𝑜𝑡𝑒𝑖𝑛| + |𝑃𝑎𝑟17 𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑣𝑎𝑟𝑖𝑎𝑛𝑡 𝑜𝑓 28 𝑘𝐷𝑎| 
4.3 Protein-Protein Interactions of Par14/Par17 
A considerable body of caution should be exercised when analysing data obtained 
from affinity purification combine with mass spectrometry (AP-MS) experiments. One 
reason for this is the presence of false positive interactors and the absence of real 
interactors (false negatives). 
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4.3.1 Filtering out Spurious and Non-specific Interactors of Par14/Par17 
Table 3.1 shows chaperone proteins and α -actin that were identified. Ribosomal pro-
teins, tubulin, actin, and chaperones exhibit a relative high abundance in the cell 
(Gingras et al., 2007). Thus, they are often considered as false positives or promis-
cuous proteins. Moreover, chaperones and heat-shock proteins bind to unfolded pep-
tides, as it might be the case for misfolded bait proteins that are usually over-
expressed as compared to their endogenous counterparts (Berggard et al., 2007). 
Therefore, we excluded all the chaperone proteins identified. 
 
With reservation, the protein disulfide isomerases listed on Table 3.1 could be bio-
logical contaminants. We argue this because the physiological cellular localisation of 
Par14 is the cytosol and nucleus (Reimer et al., 2003; Surmacz et al., 2002) and 
Par17 has been shown to be predominantly targeted to the mitochondrial matrix and 
to a lesser extend to the cytoplasm (Kessler et al., 2007). Protein disulfide isom-
erases are enzymes present in the endoplasmic reticulum that catalyse the formation 
and breakage of disulfide bonds between cysteine residues within proteins as they 
fold (Gruber et al., 2006). Based on this sub-cellular localisation difference, it is pre-
sumable to say that they are non-physiological targets to Par14 or to Par17 and 
probably must have associated with them during cell lysis, hence, their identification. 
In addition, P4HA2 (prolyl 4-hydroxylase, alpha polypeptide II) has been found as a 
contaminant in an affinity purification combined with mass spectrometry experiment 
(Glatter et al., 2009). This gives more weight to our argument to exclude the protein 
disulfide isomerases from our list of potential interactors to Par14/Par17. The pepti-
dyl-prolyl isomerases PPIA and PPIB identified are potential biological false positives 
because they show chaperone-like activity and are abundantly present. In addition, 
PPIB is localised to the endoplasmic reticulum justifying them not to be physiological 
interactors to Par14 or Par17. 
A decoy database is incorporated into the Mascot search engine. A decoy (false) is 
used to test the null hypothesis. This will determine whether a peptide was not identi-
fied in mass spectrometry (Bianco et al., 2009). It is useful in filtering off incorrect 
identifications found in the target search and hence eliminating false positives. In do-
ing this, all the amino acids of the source sequence are shuffled by arranging them 
randomly or the protein sequence of the source database is simply reversed. In con-
sequence hereof, we elimated the following proteins from being potential 
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Par14/Par17 interactors as listed on Table 3.1: SPTAN1 (SHD00871535), NCAPG2 
(SHD00797030) and NOMO1 (SHD00413732). SDH stands for decoy shuffled pro-
teins and it is the identifier used to search for such proteins in IPI (Internation Protein 
Index) databases. However, SPTAN1 (spectrin) was identified in a yeast two-hybrid 
screen as an interaction partner to Par14/Par17 (Stelzl et al., 2005). Based on these 
two contracding findings, we are in quandary on how to deal with SPTAN1. 
 
The exclusion of biological-based false positives is not sufficient in shortlisting poten-
tial interactors of Par14/Par17 without looking at the possibility of the presence of 
technique-dependent contaminants. The proteins reported on Table 3.1 are only 
those, which agreed with our probability-based scoring model and where not present 
in the negative control. Moreover, since a differential protein determination was done, 
proteins identified in the pull-downs with the Par17QRStrep-GFP construct, and the 
Par17QR-GFP construct (negative control) were not considered (Table 4.1). These 
proteins were classified into two main groups. One group contained proteins of kera-
tin cytoskeletal origin. These proteins were considered to be technical contaminants. 
The other group embodied non-specific binders, which were believed to have proba-
bly interacted with the Strep-Tactin affinity column.  
Table 4.1 Proteins identified in both Par17-tagged and non-tagged Par17 
Protein Accession Scores Peptides MW (kDa) 
Technical contaminants         
Keratin, type II cytoskeletal 1 IPI00220327 591.0  12 66.0 
Keratin, type I cytoskeletal 10 IPI00009865 436.1  12 58.8 
Keratin, type I cytoskeletal 9 IPI00019359 406.0  11 62.0 
Keratin, type II cytoskeletal 2 epidermal IPI00021304 257.4  7 65.8 
Non-specific binders         
Fructose-bisphosphate aldolase A IPI00465439 117.8  3 39.4 
cDNA FLJ53060, moderately similar to PPIA IPI00910407 64.1 2 14.0 
Histone H4 IPI00453473 115.5  3 11.4 
PA2G4 41 kDa protein IPI00794875 107.4  3 41.2 
SET translocation IPI00917753 109.4  2 31.0 
The differential protein determination approach applied herein had also been suc-
cessfully used in an integrated workflow for charting the human interaction proteome 
that gave insights into the PP2A system (Glatter et al., 2009). Glatter and co-workers 
excluded potential binders to GFP or to the modified streptavidin column in their tan-
dem affinity purification experiments (SH-tag consisting of a streptavidin-binding pep-
tide and hemagglutinin epitope). Protein IDs were filtered against a contaminant da-
tabase obtained from a total of eight independent SH-eGFP control purifications ana-
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lysed by 16 LC-MS/MS experiments and mapped to non-redundant entrez gene IDs 
(Glatter et al., 2009). Inspecting their supplementary table 2, which contains a list of 
contaminant proteins observed in SH-eGFP control purifications, we took into ac-
count the following proteins: ACTB (IPI00021439), EEF1A2 (IPI00014424), HSPA9 
(IPI00007765) and NCAPG2. We double-checked this with our data and we found 
corresponding proteins or proteins that were highly similar for them. ACTB corre-
sponded to our protein IPI00894365 described as highly similar to cytoplasmic actin. 
EEF1A2 matched to our IPI00556204 defined as eukaryotic elongation translation 
factor 1 alpha 2 and HSPA9 fitted to our IPI00922694 termed as highly similar mito-
chondrial Stress-70 protein. NCAPG2 was the same found in our experiment and in 
the data of Glatter and co-workers. NCAPG2 is for the second time herein mentioned 
as a potential false positive. In this vain, we excluded ACTB, EEF1A2, HSPA9, and 
NCAPG2 from our list of potential interaction partners of Par14/Par17. We speculate 
that they are either abundantly present or sticky proteins, which most likely interacted 
with the Strep-Tactin column (Gravel and Narang, 2005). 
4.3.2 Par14/Par17 Interactors 
After the exclusion of possible false interactors of Par14/Par17 as described in Sec-
tion 4.3.1, we were left with 17 proteins that could be possible physiological interac-
tors to both parvulins proteins (Fig. 4.1). We will not deal with all of these proteins 
since their validation is still pending if indeed they are bona fide interacting partners 
of Par14/Par17. We will make mention of a few that suggest Par14/Par17 involve-
ment in the cytoskeletal network. 
 
The high score of 388.8 for EZR seen in our affinity purification and mass spectro-
metric analyses suggests a possible interaction with Par14/Par17. This implied that 
the probability that the 14 identified peptides for EZR occurring by chance was less 
than one in twenty; p < 0.05 (Perkins et al., 1999). EZR was first isolated and identi-
fied as a protein located under the plasma membrane of chicken intestinal microvilli 
(Bretscher et al., 2002). Moreover, EZR has also been shown to be mostly associ-
ated with various membrane and cytoskeletal components such as CD44, EPB50 
and of F-actin (Bretscher et al., 1997). The ERM (ezrin, radixin, and merlin) domain is 
common to both ERZ and protein 4.1 (EPB41). EPB41 was reported in a high-
throughput co-immunoprecipitation and mass spectrometry screen to interact with 
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Par14/Par17 (Ewing et al., 2007). This 97 kDa protein, which is essential for normal 
cell shape and integrity, provides connections between the cytoskeleton and the 
plasma membrane in erythrocytes, but also plays an important role in a variety of 
functions in many tissues/organs, including the bone marrow, cerebellum, lungs, tes-
tes and thymus (Taylor-Harris et al., 2005). EPB41 and EZR belong to the protein 4.1 
superfamily. All the members of the protein 4.1 superfamily contain the ERM domain 
at the N-terminus (Diakowski et al., 2006). Following the line of thinking that EPB41 
is an interactor to Par14/Par17 and we have reported in this study a potential interac-
tion between EZR and Par14/Par17, it is intriguing to purport that the ERM domain 
might serve as a binding site for Par14/Par17 and thus justifying the herein observed 
interactions. Others have also reported that the ERM domain is responsible for the 
binding of EPB41 to other proteins such as glycophorin C (Gascard and Cohen, 
1994; Hemmings et al., 1996), protein p55 (Manno et al., 2005; Marfatia et al., 1994) 
and calmodulin (Nunomura et al., 2000). 
 
 
Fig 4.1 Protein-protein interactions of Par14/Par17 
Map of Par14/Par17 depicting its physical association with affinity-purified proteins detected 
by tandem mass spectrometry. The hexagonal node in red, Par14/Par17 served as the bait 
protein and the ellipse nodes in blue were the captured prey proteins. GOT2 as a node in 
the yellow hexagon was identified as a prey protein, which interacted with Par14/Par17 in 
this study and has been shown to interact with MPG and EPB41 (Ewing et al., 2007). The 
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diamond node in orange are prey proteins found in this study and have been previously 
found in a GST-Pull-down screen (Fujiyama-Nakamura et al., 2009). The edges in blue 
depict the link between the nodes of the bait and prey proteins. The line between two 
nodes is described as an edge. The visualisation was done using the software Cytoscape-
v2.6.3 (Cline et al., 2007). 
 
In this study, we showed that cDNA FLJ55705 highly similar to threonyl-tRNA syn-
thetase (IPI00910719, TARS), and cDNA FLJ59476 highly similar to histidyl-tRNA 
synthetase (IPI00909075, HARS) co-purified with Par14/Par17 (Table 3.1 and 
Fig. 4.1). In the light of this, the binding of EPB41 to eIF3-p44 suggested an interac-
tion between the cytoskeletal network and the translation apparatus (Hou et al., 
2000). eIF3-p84 represents a subunit of the eukaryotic translation initiation factor 3 
(elF3) complex (Block et al., 1998). The elF3 is a large translation initiation complex 
that contains at least 10 subunits. It plays an essential role in the binding of the initia-
tor methionyl-tRNA and mRNA to the 40S ribosomal subunit to form the 40S initiation 
complex (Hershey et al., 1996). Large body of evidences have pointed to the fact that 
EZR and EPB41 are cytoskeletal proteins with their roles in cell shape, adhesion, 
motility et cetera (Sylvain et al. 2009). The potential association of Par14/Par17 with 
EZR, EPB41, TARS, and HARS may suggest that Par14/Par17 acts as an anchor 
protein that links the cytoskeleton network to the translation apparatus. However, this 
suggestion stills remains to be validated. 
4.3.3 The Par14/Par17 Interactome 
We now have a list of 17 potential interaction partners of Par14/Par17 as revealed 
from our affinity purification coupled with mass spectrometric analysis. With this 
knowledge, we reasoned that it would be worthwhile to combine our data with all ex-
perimentally proven interactors of Par14/Par17. For this purpose, we used the pro-
tein-interaction IntAct-database (Aranda et al., 2010), iHOP (Information Hyperlinked 
over Proteins) database (Hoffmann and Valencia, 2004; Hoffmann and Valencia, 
2005) and the Entrez Gene database (Maglott et al., 2005) to identify previously re-
ported interactors of Par14/Par17. 
 
Fig. 4.2 shows all these reported interactions of Par14/Par17 with other proteins. 
MPG (N-methylpurine-DNA glycosylase) and EPB41 have been shown to interact 
with Par14/Par17 (Ewing et al., 2007). The white parallelogram nodes for HSPE1 
  Discussion 
 
 
 
    107
heat shock 10 kDa protein 1 (chaperonin 10), IARS (isoleucyl-tRNA synthetase), 
CACYBP (calcyclin binding protein), PSMA1 (proteasome macropain subunit, alpha 
type 1) and MIF (macrophage migration inhibitory factor) are interactors common 
both to MPG and EPB41 (Ewing et al., 2007). Ewing and co-workers also demon-
strated that Pin1 (white parallelogram) interacted with EPB41. Since Pin1 is a 
paralogue to Par14/Par17 (Mueller and Bayer, 2008), it was interesting to acknowl-
edge the fact that it also interacts with EPB41. In a yeast two-hybrid assay, Stelzl and 
co-authors reported that DNM1 (dynamin), EZH2 (enhancer of zeste homolog 2), 
ASCC2 (activating signal cointegrator 1 complex subunit 2), and SPTAN1 interacted 
with Par14/Par17 (Stelzl et al., 2005). FBL (fibrillarin), NPM1 (nucleophosmin) and 
NCL (nucleolin) were reported in a GST-Pull-down study to be interactors of Par14 
(Fujiyama-Nakamura et al., 2009). We also identified NPM1 and NCL in this study. 
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Fig 4.2 The Par14/Par17 interactome map  
The network involves 408 proteins (nodes) linked via 480 interactions (edges). The line 
between two nodes is described as an edge. Par14/Par17 is the node in the red hexagon. 
Ellipse blue nodes are prey interactors to Par14/Par17 found in this study and pink di-
amond nodes are bait proteins that directly interacted with Par14/Par17 in a yeast two-
hybrid system (Stelzl et al., 2005). Nodes in the green hexagon are proteins that co-
immunoprecipitated with Par14/Par17 (Ewing et al., 2007). GOT2 as a node in the yellow 
hexagon was identified as a prey protein, which interacted with Par14/Par17, MPG and 
EPB41 indicating an interesting interaction complex. The white parallelogram nodes are 
proteins, which interacted with both MPG and EPB41. Other prey interactors are depicted 
as roundrect nodes in light green. The visualisations were done using the software Cytos-
cape-v2.6.3 (Cline et al., 2007). 
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Table 4.2 Par14/Par17 interactors independently identified by other methods and 
found in this study. 
Common interactors identified in one or more approaches are represented as shaded blocks in 
light yellow, pale and sky blue respectively. 
Bait Prey Method of Detection Reference 
    
Par14/Par17 NCL AP-MS This study 
Par14 NCL GST-Pull-Down Fujiyama et al. (2002; 2009) 
Par14/Par17 NPM1 AP-MS This study 
Par14 NPM1 GST-Pull-Down Fujiyama et al. (2002; 2009) 
Par14/Par17 YWHAE AP-MS This study 
Par14 YWHAE GST-Pull-Down and Co-IP Doctoral Thesis Tatiana Rei-
mer 
Par14/Par17 GOT2 AP-MS This study 
EPB41 Par14/Par17 Co-IP-MS Ewing et al. (2007) 
MPG Par14/Par17 Co-IP-MS Ewing et al. (2007) 
 
From the interactome map of Par14/Par17 (Fig. 4.2 and Table 4.2), three sub-
networks can be deduced. One of them is the ASCC2, POLA2 polymerase (DNA di-
rected, alpha 2 70kD subunit), EZH2 and Par14/Par17 network. NCL, NPM1, and 
Par14 also show reciprocal interactions. We also acknowledge a Par14/Par17-
EPB41-GOT2-MPG network. 
4.3.4 Par14/Par17 Sub-Interactome Networks 
4.3.4.1 The ASCC2-POLA2-EZH2-Par14/Par17 Network 
As a bait protein, ASCC2 interacted with the prey protein POLA2 in a yeast two-
hybrid screen (Stelzl et al., 2005). In the same study, EZH2 as a bait served to catch 
the prey protein POLA2. Noteworthy was the fact that these two bait proteins ASCC2 
and EZH2 captured Par14/Par17 as a prey in the said study (Stelzl et al., 2005). The 
mutual interaction between Par14/Par17 with ASCC2 and EZH2 and the interaction 
of POLA2 to ASCC2 and EZH2 lead to the speculation that Par14, Par17, or both 
could as well have interacted with POLA2 within the framework of a complex. 
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Fig 4.3 The ASCC2-POLA2-EZH2-Par14/Par17 network 
 
ASCC2 was shown to be part of a novel transcriptional co-activator complex (Jung et 
al., 2002). Histone-lysine N-methyltransferase EZH2 is a member of the Polycomb-
group (PcG) family and members form multimeric protein complexes, which are in-
volved in maintaining the transcriptional repressive state of genes over successive 
cell generations (van, V and Otte, 1999). Evidence has also been provided that 
POLA2 is required for the initiation of SV40 DNA replication in vitro and was sug-
gested to play a similar role in cellular DNA replication (Collins et al., 1993; Weinberg 
et al., 1990). Up to now, nothing is known if Par17 is a nuclear protein but its isoform 
Par14 has been reported to be located in the nucleus (Surmacz et al., 2002). How-
ever, both of them are reported to bind DNA (Kessler et al., 2007; Surmacz et al., 
2002). ASCC2, EZH2, and POLA2 are nuclear proteins and this warrants the specu-
lation that in this scenario Par14 could have been the interactor instead of Par17. 
Nevertheless, experimental data will be mandatory to validate this assertion.  
4.3.4.2 The NCL-NPM1-Par14 Network 
In our affinity purification followed by mass spectrometry experiments, we observed 
that NCL and NPM1 associated with Par14/Par17 (Table 4.2). Comprehensive pro-
teomic-scale analyses with the aid of LC/MS/MS showed that Par14 is an interactor 
to both NCL and NPM1 (Fujiyama et al., 2002; Fujiyama-Nakamura et al., 2009). In 
the same study, they also reported that Par14 was localised to the nucleolus. Fur-
thermore, NCL and NPM1 were shown in a yeast-two-hybrid screen to interact with 
each other (Li et al., 1996).  
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Fig 4.4 The NCL-NPM1-Par14 network 
 
NCL is a nucleolar phosphoprotein involved in the regulation of cell proliferation, cy-
tokenesis, replication, embryogenesis, and nucleogenesis (Jordan, 1987; Srivastava 
and Pollard, 1999). NCL is expressed on the cell surface and has been demonstrated 
to associate with actin cytoskeleton (Hovanessian et al., 2000). NMP1 on its part is 
also a nucleolar phosphoprotein constantly shuttling between the nucleolus and the 
cytoplasm (Borer et al., 1989). The main function of NPM1 is in ribosome biogenesis. 
NMP1 associated with large RNA-ribonucleoprotein complexes containing nucleolin, 
fibrillarin, and several ribosomal proteins (Pinol-Roma, 1999). Based on the lines of 
evidence presented above and the nucleolar localisation of NCL and NPM1, it is ac-
ceptable to speculate they are interactors to Par14 and not Par17. 
4.3.4.3 The Par14/Par17-EPB41-GOT2-MPG Network 
We showed in this work that mitochondrial GOT2 possibly associated with 
Par14/Par17. Co-immunoprecipitation coupled with high-throughput mass spec-
trometry revealed that GOT2 interacted with EPB41 and MPG (Ewing et al., 2007). In 
the same high-throughput analysis, EPB41 and MPG were observed to have inter-
acted with Par14/Par17 respectively. This cross-interaction between EPB41 and 
MPG each interacting with Par14/Par17 and GOT2 respectively and the association 
of Par14/Par17 and GOT2 proposes a large body of evidence that EPB41, MPG, 
GOT2 and Par14/Par17 display a socio-affinity (physical proximity). This proposition 
should be assimilated with a pinch of salt. We say this because GOT2 plays a role in 
amino acid metabolism and the urea and tricarboxylic acid cycles. Berggard and co-
authors mentioned that metabolic enzymes could be a source of contaminating pro-
  Discussion 
 
 
 
    112
teins in protein-protein interaction studies because they are often present in large 
amounts in the cell (Berggard et al., 2007). This might also imply that GOT2 is a po-
tential false positive that has been observed in these two independent approaches. 
 
 
Fig 4.5 The Par14/Par17-EPB41-GOT2-MPG network 
 
N-methylpurine DNA glycosylase (MPG) is an initiator glycosylase in base excision 
repair (BER) and it is the principal mechanism by which mammalian cells repair alky-
lation damage in DNA (Krokan et al., 2000). BER appears to be the predominant 
DNA repair system in the mitochondria (Fishel et al., 2003; Harrison et al., 2007). 
MPG is a glycosylase that cleaves the N-glycosylic bond between the deoxyribose 
sugar moiety and the DNA base that is damaged but does not nick the DNA back-
bone (Fishel et al., 2003). Repair of mitochondrial DNA (mtDNA) is crucial because it 
suffers more damage than nuclear DNA after treatment with oxidative or alkylating 
agents (Fishel et al., 2003). In addition to being subjected to more damage, the muta-
tion rate is also 5 – 10 times higher in mtDNA (Fishel et al., 2003). We now know that 
GOT2 and MPG are of mitochondrial origin. Kessler and co-workers demonstrated 
that Par17 is targeted to the mitochondrial matrix (Kessler et al., 2007). Our current 
knowledge does not allow us to assign EPB41 as a mitochondrial protein. However, 
with the lines of arguments herein presented, we could presume that the interactions 
of GOT2, MPG, EPB41, if true, within the framework of a complex was with Par17 
and not Par14.  
 
We have gone to a certain length in analysing some of the possible interaction part-
ners of Par14/Par17 identified in this work. We also explored the Par14/Par17 inte-
ractome und its embodied sub-networks. Now, we will look at a common thread that 
some members of the Par14/Par17 interactome share in common. 
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4.3.5 Par14/Par17 Interactors and the Lysine Acetylome 
The lysine acetylome describes the conglomerate of proteins in the cell that have 
been acetylated on one or more lysine residues. In a high-resolution mass spec-
trometry approach, Choudhary and co-workers reported 3600 lysine acetylation sites 
on 1750 proteins and quantified acetylation changes in response to the deacetylase 
inhibitors suberoylanilide hydroxamic and MS-275 (Choudhary et al., 2009). 
Par14/Par17 was reported in the mentioned approach to be acetylated on lysine K32 
and K57 with respect to Par14 and Par17 respectively. The acetylation site (_AQGPK 
(ac) GGGNAVK_) is four amino acids less in front of the NMR resolved catalytic 
(PPIase) domain structure (Sekerina et al., 2000; Terada et al., 2001) of 
Par14/Par17. The PPIase domain is characterised by four-stranded α -sheets and 
three α -helices and it has been reported that acetylation sites were frequently located 
in regions with ordered secondary structure (Kim et al., 2006). 
 
 
Fig 4.6 Venn diagram of Par14/Par17 interactors and the lysine acetylome 
Showing 16 proteins (point of intersection) found in our affinity purification coupled with 
mass spectrometry studies and from the yeast-two hybrid screen and co-
immunoprecipitation experiments of Stelzl and colleagues (Stelzl et al., 2005) and Ewing 
and co-authors (Ewing et al., 2007) respectively. These 16 proteins were also found to be 
acetylated in the study of Choudhary and co-workers (Choudhary et al., 2009). A) 1750 
acetylated proteins found in the Choudhary study B) 23 Par14/Par17 interactors found in 
this study and in previously reported data. The list of the 17 proteins is found on Supple-
mentary Table 2.  
 
Looking at the Par14/Par17 interactome in a nutshell, 16 of its interacting proteins 
are acetylated (13 of them from Fig. 4.1), DMN1 and SPTAN1 from the two-hybrid-
screen of (Stelzl et al., 2005) and EPB41 from the co-immunoprecipitation studies of 
(Ewing et al., 2007). No reported acetylation of MPG is known to our knowledge but a 
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similar repair protein UDG (Uracil-DNA glycosylase) was reported to be acetylated 
(Choudhary et al., 2009). For this reason, we added MPG to the list on the Supple-
mentary Table 2. The acetylation of lysines can create new docking sites for pro-
tein–protein interactions, for example via recognition by the bromo-domain containing 
proteins (Spange et al., 2009). Moreover, a striking feature of lysine acetylation is 
that it tends to occur in large macromolecular complexes involved in diverse cellular 
processes, such as chromatin remodelling, cell cycle, splicing, nuclear transport, and 
actin nucleation (Choudhary et al., 2009). Based on this line of argument, we can 
speculate that Par14/Par17 and its acetylated interactors might exist as a complex 
with bromo-domain-containing proteins in the cell. However, experimental evidence 
will be paramount to prove this claim.  
 
The search of interaction partners of Par14/Par17 were followed by knock-down ex-
periments. The aim behind these knock-down trials was to verify any phenotypic 
changes like morphological aberrations in cells in the advent of the absence of 
Par14/Par17. Moreover, it was intended to check if the potential physiological part-
ners found in this study might be up- or down-regulated in the case of a Par14/Par17 
knock-down. This was to be verified by DNA microarray analyses. 
4.4 Par14/Par17 Gene Knock-Down Experiments 
To elicit knock-down, we first used double-stranded Par14/Par17 siRNAs in a pool. 
As it can be seen on Fig. 3.16A. HeLa cells treated with Par14/Par17 siRNAs looked 
the same as cells treated with scrambled siRNA with no known homology to any hu-
man gene. This was also the case when untreated HeLa cells were compared. The 
treatment with scrambled siRNA and non-treatment served as negative controls. We 
next checked the level of knock-down at the protein level by performing western 
blots. Transfections with these siRNAs were done for 48, 72, 96 hrs, and still no ap-
preciable reduction of Par14/Par17 could be recorded when compared with the con-
trols samples (Fig. 3.16B). 
 
After seeing no morphological abnormalities and no reduction at the protein levels in 
cells treated with Par14/Par17 double-stranded siRNAs, we employed plasmid-based 
siRNA technology as a second strategy. Nevertheless, we had similar observations 
that we experienced with the synthetic double-stranded Par14/Par17 siRNAs. 
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Fig. 3.17A revealed minor or no morphological changes in HeLa cells treated with 
shRNA-1-3 and cells treated with shRNA-Luc that served as negative control. How-
ever, what struck our attention was the presence of granule-like structures in both 
treated and untreated HeLa cells. The protein expression of Par14/Pa417 did not 
suffer any changes when comparing the experimental samples with the control sam-
ples (Fig. 3.17B). 
 
After observing no knock-down at the protein level with the use of two different 
strategies of siRNA technology, we aimed at looking at the efficiency of knock-down 
at the mRNA level. We used qRT-PCR and the calculation of percentage knock-
down has been elucidated in Section 3.5. We observed a 10 % KD for shRNA-2 
(Fig. 3.17C). This was the only knock-down worth mentioning when comparing the 
knock-down seen with shRNA-1 and shRNA-3. The knock-down with shRNA-Luc for 
Par14 and Par17 approached null and two respectively. siRNA-Luc was used as a  
negative control and no knock-down was to be expected. A knock-down of 10 % is 
not enough to evaluate the effects of the absence of a gene. Follow-up experiments 
of at least ≥ 80 % gene knock-down are usually recommended. A more than 80 % 
knock-down of Par14 mRNA and protein has been reported (Fujiyama-Nakamura et 
al., 2009). The authors demonstrated that Par14 knock-down decelerated the proc-
essing of pre-rRNAs to 18S and 28S rRNAs and had a diminishing effect on cell 
growth. 
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5.  Conclusion 
Using different biochemical fractionation schemes, we showed that Par14 is 3 and 2-
fold enriched in chromatin fractions (S2+/S2-) than in nuclear matrix fractions 
(S2+/S2-) respectively. The binding of Par14 to DNA in vivo was investigated. By 
means of the fractionation of nucleic-acid binding proteins and their elution with in-
creasing salt concentrations from a phospho-cellulose column, we demonstrated that 
Par14 bound to DNA in the nucleus. We went further to search for the DNA-binding 
motifs of Par14 and Par17. For this purpose, we used a Par17QR-Strep-GFP and 
Par17QR-GFP construct, the latter serving as a negative control. A substaintial 
amount of DNA fragments were pulled-down with the Par17QR-Strep-GFP construct 
than with the control construct but we did not determine the sequences of the in-
serted DNA fragments. 
 
We also investigated the transcriptional and translational regulation of Par14/Par17 in 
synchronised HFF cells. With the use of qRT-PCR, we acknowledged a 3- and 5-fold 
increase in the mRNA of Par17 during the S and G2/M phases in correlation with a 
tendential 4- and 3-fold up-regulation of the Par17 protein in these phases as seen in 
western blot experiments and in subsequent dentitiometric analyses. There was the 
occurrence of a 28 kDa variant of Par17 in both unfractionated and fractionated cellu-
lar lysates in G0, G1, S and G2/M phases of the cell cycle. We hypothesise that the 
amount of mRNA expressed is mirrored by the sum of Par17 and the 28 kDa variant 
post-transcriptionally expressed. As for Par14, there was a 2- and 3-fold increase of 
Par14 mRNA in the S and G2/M phases of the cell cycle. This transcriptional up-
regulation of Par14 was reciprocated by a 4-fold translational up-regulation in the S 
and G2/M phases when unfractionated cellular lysates were used. 
 
Our protein-protein interaction studies using affinity purification combined with mass 
spectrometry revealed 17 potential interaction partners to Par14/Par17. Some of 
these proteins are involved in translation, RNA processing, ribosome biogenesis, cell 
adhesion, signal transduction and metabolism. GOT2 and EZR were of interest. 
GOT2 was reported to interact with Par14/Pa17 in a co-immunoprecipitation study 
(Ewing et al., 2007). EZR had a score of 388.8 with 14 of its peptides found and it 
shares a common homology domain ERM with EPB41. EPB41 was found to interact 
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with Par14/Par17 in a co-immunoprecipitation combined with mass spectrometry 
high-througput experiment (Ewing et al., 2007). NCL and NMP1 previously reported 
to interact with Par14 (Fujiyama et al., 2002; Fujiyama-Nakamura et al., 2009) were 
also found in our AP-MS screens. Besides, we reported the interaction of YWHAE 
and Par14/Par17. This same interaction had been demonstrated in GST-Pull-downs 
and Co-IP studies (Doctoral thesis of Tatiana Reimer). 
 
The use of double-stranded siRNAs and shRNAs did not invoke the knock-down of 
Par14/Pa17 either at the mRNA or protein levels. We observed only a 10 % knock-
down at the transcriptional level when shRNA-2 was used in HCT116 cells. 
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6.  Future Perspectives 
We suggest that the ChAP experiment used to search for DNA-binding motifs for 
Par14/Par17 to be repeated after a thorough trouble shooting analysis. As a com-
plementary experiment, not only Par17QR-Strep-GFP construct but also a Par14-
Strep-GFP construct should be used in order to achieve a clean discrimination of the 
DNA-binding motifs for both proteins. In this light, nuclear and mitochondrial extracts 
should be used for Par14 and Par17 respectively.  
 
The fractionation of the cellular lysates from the phases of the cell cycle into cytosol 
and nucleus was absent for Par14. The expression of Par14 after cellular fractiona-
tion will be interesting to investigate if it is also up-regulated when cellular lysates 
were used. Moreover, the identification and charaterisation of the 28 kDa variant of 
Par17 that was present in all the phases of the cell cycle will be mandatory. 
 
The 17 potential interaction partners to Par14/Par17 need to be validated by other 
techniques. EZR and GOT2 are favourites for reasons mentioned in Section 5. 
Based on the fact that we used a tagging approach, EZR-Strep-GFP or 
GOT2 Strep GFP constructs could be used for affinity purification and mass spec-
trometry experiments. If we find Par17 or Par14 in the pull-down data, this will add 
credit to their physiological interaction. Co-immunoprecipitation (Co-IP) is another 
method to verify the protein-protein interactions. The antibodies for EZR or GOT2 
could be employed in Co-IP experiments and the eluates should be probed in west-
ern blotting with antibodies specific to both Par14/Par17 (α PPIase) or to Par17 
(α Par17-Ext). If we find their respective signals in the eluates, this will give additional 
evidence that their interaction to Par14/Par17 was bona fide. 
 
We could also use spectrometric approaches to validate our protein-protein interac-
tion data. The prerequisite is that the two interacting proteins should exhibit a differ-
ence relative to the free individual proteins in any spectrometer (for instance, the fluo-
rescence intensity, wave length maximum or polarisation, fluorescence resonance 
energy transfer efficiency, circular dichroism, or NMR chemical shift or intensity) 
(Berggard et al., 2007). Confocal microscopy (Miyashita, 2004) and surface plasmon 
resonance (Huber and Mueller, 2006) techniques have been reported in the verifica-
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tion of protein-protein interaction data. Protein-protein interactions have also been 
validated with the use of isothermal titration calirometry (Liang, 2008; Velazquez-
Campoy et al., 2004). Nevertheless, after the validation of these interactions, distin-
guishing the interaction partners that belong only to Par14 and to Par17 must be ad-
dressed. We propose that mitochondrial lysate obtained after transfection with 
Par17QR-Strep-GFP construct should be used to find Par17 interactors. The same 
should also be done with nuclear lysates obtained after transfection with Par14-
Strep-GFP construct to search for Par14 interactors. 
 
Knock-down of Par14/Par17 is still a prerequisite to characterise any associated 
phenotypic changes. We have ordered three stealth siRNAs (Invitrogen, Germany) to 
perform new RNAi experiments. Stealth siRNAs are double-stranded siRNAs se-
quences with a chemical modification that enhances specificity and stability and thus, 
the half-lives of the siRNA in vitro and in vivo could be extended. Two of the stealth 
siRNA sequences have been successfully used by Fujiyama and colleagues in Par14 
knock-down studies (Fujiyama-Nakamura et al., 2009) and the sequence of the third 
stealth siRNA correspond to that with shRNA-2 since it was the only shRNA that 
showed a reasonable but not enough 10 % KD at the mRNA level. We hope that this 
time an unequivocal knock-down of Par14/Par17 can be achieved. With a 
Par14/Par17 knock-down, whole genome microarray analyses can be conducted to 
determine which genes are up- and down-regulated in the absence of Par14/Par17. 
The transcriptional status of genes whose gene products we identified to be potential 
interactors to Par14/Par17 will be worthwhile to verify. If any changes are observed, 
this will serve as another source of validation of our protein-protein interaction data. 
The generation of a stable transfection line in DT40 cells in which both Par14/Par17 
alleles have been knocked-out by means of Cre-Lox recombination will be an alterna-
tive to carry out the planned experiments in the advent of the absence of 
Par14/Par17. 
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8.  Appendix 
Supplementary Table 1 List of all Par14/Par17 interactors identified by AP-MS with the 
exclusion of the technical contamitants and non-specifc binders as listed on Table 4.1 
Protein Symbol/Name Accession 
No 
Scores Peptides MW 
[kDa] 
ACTB cDNA FLJ52842  IPI00894365 49.6 2 39.2 
ACTN4 Alpha-actinin-4 IPI00013808 31.9 1 104.8 
ANXA1 Annexin A1 IPI00549413 79.3 3 22.7 
ANXA2 Annexin A2 IPI00455315 114.0 4 38.6 
ANXA5 Uncharacterized protein ANXA5 (Fragment) IPI00872379 50.2 2 35.8 
cDNA FLJ55692, GOT2, mitochondrial IPI00910267 59.4 2 43.0 
cDNA FLJ55705, highly similar to TARS IPI00910719 32.9 2 70.3 
cDNA FLJ59476, HARS IPI00909075 48.9 2 35.6 
CKB Creatine kinase, brain IPI00908811 53.8 2 38.7 
EEF1A2 Eukaryotic translation elongation factor 1 
alpha 2 
IPI00556204 73.8 2 36.9 
Ezrin (EZR) 69 kDa protein IPI00872684 388.8 14 69.3 
HNRNPA2B1 34 kDa protein IPI00916517 87.0 2 34.2 
HSP90AA1 Isoform 1 of Heat shock protein HSP 90-
alpha 
IPI00784295 223.5 7 84.6 
HSP90AB1 Heat shock protein HSP 90-beta IPI00414676 242.5 7 83.2 
HSPA4 Heat shock 70 kDa protein 4 IPI00002966 108.6 3 94.3 
HSPA5 HSPA5 protein IPI00003362 252.0 6 72.4 
HSPA9 cDNA FLJ51903, highly similar to Stress-70 
protein 
IPI00922694 50.1 2 69.9 
HSPA9 cDNA FLJ51903, mitochondrial IPI00922694 50.1 2 69.9 
LMNA Rhabdomyosarcoma antigen MU-RMS-40.12 IPI00655812 97.4 3 55.6 
NCAPG2 Isoform 1 of Condensin-2 complex subunit 
G2  
SHD00797030 31.0 2 130.9 
NCL Nucleolin IPI00444262 118.0 5 65.9 
NOMO1;NOMO3 139 kDa protein SHD00413732 44.2 2 139.3 
NPFFR2 Isoform 3 of Neuropeptide FF receptor 2 SHD00221214 28.6 1 49.0 
NPM1 nucleophosmin  IPI00658013 29.8 1 28.4 
P4HB Protein disulfide-isomerase precursor IPI00010796 103.3 2 57.1 
PDIA3 Protein disulfide-isomerase A3 precursor IPI00025252 201.3 7 56.7 
PDIA4 Protein disulfide-isomerase A4 precursor IPI00009904 61.0 2 72.9 
Peroxiredoxin 1 PRDX1 19 kDa protein  IPI00640741 126.2 4 19.0 
PPIA 13 kDa protein IPI00925411 36.6 2 13.0 
PPIB peptidylprolyl isomerase B precursor IPI00646304 58.3 2 23.7 
SFRS1 Isoform ASF-3 of Splicing factor, argi-
nine/serine-rich 1 
IPI00218592 70.8 1 22.4 
SHROOM4 Isoform 2 of Protein Shroom4  IPI00845416 32.3 2 152.7 
SPTAN1, Spectrin SHD00871535 284.9 2 47.3 
TLK2 Isoform 2 of Serine/threonine-protein kinase 
tousled-like 2 
SHD00337659 21.9 1 85.4 
Transketolase TKT Putative uncharacterized protein IPI00792641 104.8 3 58.9 
YWHAE 14-3-3 protein epsilon IPI00000816 102.2 4 29.2 
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Supplementary Table 2 List of potential Par14/Par17  
interactors that were reported to be acetylated by Choudary  
and co-workers. * stands for the inclusion of MPG, a DNA-repair  
protein that was not acetylated but its counterpart UDG  
(Uracil-DNA glycosylase) was reported to be acetylated in the  
same study 
Protein Symbol Acetylated Reference 
Protein translation   
HARS Yes Chouhdary et al. (2009) 
TARS Yes Chouhdary et al. (2009) 
DNA repair     
MPG No* 
 RNA processing     
HNRNPA2B1 Yes Chouhdary et al. (2009) 
SFRS1 Yes Chouhdary et al. (2009) 
Ribosome biogenesis   
NCL Yes Chouhdary et al. (2009) 
NPM1 Yes Chouhdary et al. (2009) 
Cell adhesion & cytoskeleton   
EZR Yes Chouhdary et al. (2009) 
LMNA Yes Chouhdary et al. (2009) 
SPTAN1 Yes Chouhdary et al. (2009) 
EPB41 Yes Chouhdary et al. (2009) 
DMN1 Yes Chouhdary et al. (2009) 
Par14/Par17 Yes Chouhdary et al. (2009) 
Signal transduction   
YWHAE Yes Chouhdary et al. (2009) 
Metabolism     
GOT2 Yes Chouhdary et al. (2009) 
TKT Yes Chouhdary et al. (2009) 
Annexin     
ANXA1 Yes Chouhdary et al. (2009) 
ANXA5 Yes Chouhdary et al. (2009) 
Unclassified     
PRDX1 Yes Chouhdary et al. (2009) 
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Supplementary Fig 1 Par14/Par17 mRNA displaying all the siRNA and shRNA se-
quences used in this study. In red are the sequences of the newly ordered siRNAs as 
mentioned in Section 6. 
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